#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Reduced Parietal Alpha Power and Psychotic Symptoms: Test-Retest Reliability of Resting-State Magnetoencephalography in Schizophrenia and Healthy Controls
#Text=Background:
#Text=Despite increased reporting of resting-state magnetoencephalography (MEG), reliability of those measures remains scarce and predominately reported in healthy controls (HC).
1-1	0-7	Reduced	_	
1-2	8-16	Parietal	_	
1-3	17-22	Alpha	_	
1-4	23-28	Power	_	
1-5	29-32	and	_	
1-6	33-42	Psychotic	_	
1-7	43-51	Symptoms	_	
1-8	51-52	:	_	
1-9	53-64	Test-Retest	_	
1-10	65-76	Reliability	_	
1-11	77-79	of	_	
1-12	80-93	Resting-State	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	
1-13	94-116	Magnetoencephalography	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography	
1-14	117-119	in	_	
1-15	120-133	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
1-16	134-137	and	_	
1-17	138-145	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
1-18	146-154	Controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[1]	
1-19	155-165	Background	_	
1-20	165-166	:	_	
1-21	167-174	Despite	_	
1-22	175-184	increased	_	
1-23	185-194	reporting	_	
1-24	195-197	of	_	
1-25	198-211	resting-state	_	
1-26	212-234	magnetoencephalography	_	
1-27	235-236	(	_	
1-28	236-239	MEG	_	
1-29	239-240	)	_	
1-30	240-241	,	_	
1-31	242-253	reliability	_	
1-32	254-256	of	_	
1-33	257-262	those	_	
1-34	263-271	measures	_	
1-35	272-279	remains	_	
1-36	280-286	scarce	_	
1-37	287-290	and	_	
1-38	291-304	predominately	_	
1-39	305-313	reported	_	
1-40	314-316	in	_	
1-41	317-324	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
1-42	325-333	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[2]	
1-43	334-335	(	_	
1-44	335-337	HC	_	
1-45	337-338	)	_	
1-46	338-339	.	_	

#Text=As such, there is limited knowledge on MEG resting-state reliability in schizophrenia (SZ).
2-1	340-342	As	_	
2-2	343-347	such	_	
2-3	347-348	,	_	
2-4	349-354	there	_	
2-5	355-357	is	_	
2-6	358-365	limited	_	
2-7	366-375	knowledge	_	
2-8	376-378	on	_	
2-9	379-382	MEG	_	
2-10	383-396	resting-state	_	
2-11	397-408	reliability	_	
2-12	409-411	in	_	
2-13	412-425	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
2-14	426-427	(	_	
2-15	427-429	SZ	_	
2-16	429-430	)	_	
2-17	430-431	.	_	

#Text=Methods:
#Text=To address test-retest reliability in psychosis, a reproducibility study of 26 participants (13-SZ, 13-HC) was performed.
3-1	432-439	Methods	_	
3-2	439-440	:	_	
3-3	441-443	To	_	
3-4	444-451	address	_	
3-5	452-463	test-retest	_	
3-6	464-475	reliability	_	
3-7	476-478	in	_	
3-8	479-488	psychosis	_	
3-9	488-489	,	_	
3-10	490-491	a	_	
3-11	492-507	reproducibility	_	
3-12	508-513	study	_	
3-13	514-516	of	_	
3-14	517-519	26	_	
3-15	520-532	participants	_	
3-16	533-534	(	_	
3-17	534-536	13	_	
3-18	536-537	-	_	
3-19	537-539	SZ	_	
3-20	539-540	,	_	
3-21	541-543	13	_	
3-22	543-544	-	_	
3-23	544-546	HC	_	
3-24	546-547	)	_	
3-25	548-551	was	_	
3-26	552-561	performed	_	
3-27	561-562	.	_	

#Text=We collected eyes open and eyes closed resting-state data during 4 separate instances (2 Visits, 2 runs per visit) to estimate spectral power reliability (power, normalized power, alpha reactivity) across one hour and one week.
4-1	563-565	We	_	
4-2	566-575	collected	_	
4-3	576-580	eyes	_	
4-4	581-585	open	_	
4-5	586-589	and	_	
4-6	590-594	eyes	_	
4-7	595-601	closed	_	
4-8	602-615	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]	
4-9	616-620	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[3]	
4-10	621-627	during	_	
4-11	628-629	4	_	
4-12	630-638	separate	_	
4-13	639-648	instances	_	
4-14	649-650	(	_	
4-15	650-651	2	_	
4-16	652-658	Visits	_	
4-17	658-659	,	_	
4-18	660-661	2	_	
4-19	662-666	runs	_	
4-20	667-670	per	_	
4-21	671-676	visit	_	
4-22	676-677	)	_	
4-23	678-680	to	_	
4-24	681-689	estimate	_	
4-25	690-698	spectral	_	
4-26	699-704	power	_	
4-27	705-716	reliability	_	
4-28	717-718	(	_	
4-29	718-723	power	_	
4-30	723-724	,	_	
4-31	725-735	normalized	_	
4-32	736-741	power	_	
4-33	741-742	,	_	
4-34	743-748	alpha	_	
4-35	749-759	reactivity	_	
4-36	759-760	)	_	
4-37	761-767	across	_	
4-38	768-771	one	_	
4-39	772-776	hour	_	
4-40	777-780	and	_	
4-41	781-784	one	_	
4-42	785-789	week	_	
4-43	789-790	.	_	

#Text=Intraclass correlation coefficients (ICCs) were calculated.
5-1	791-801	Intraclass	_	
5-2	802-813	correlation	_	
5-3	814-826	coefficients	_	
5-4	827-828	(	_	
5-5	828-832	ICCs	_	
5-6	832-833	)	_	
5-7	834-838	were	_	
5-8	839-849	calculated	_	
5-9	849-850	.	_	

#Text=For source modeling, we applied an anatomically constrained linear estimation inverse model known as dynamic statistical parametric mapping (MNE dSPM) and source-based connectivity using the weighted phase lag index.
6-1	851-854	For	_	
6-2	855-861	source	_	
6-3	862-870	modeling	_	
6-4	870-871	,	_	
6-5	872-874	we	_	
6-6	875-882	applied	_	
6-7	883-885	an	_	
6-8	886-898	anatomically	_	
6-9	899-910	constrained	_	
6-10	911-917	linear	_	
6-11	918-928	estimation	_	
6-12	929-936	inverse	_	
6-13	937-942	model	_	
6-14	943-948	known	_	
6-15	949-951	as	_	
6-16	952-959	dynamic	_	
6-17	960-971	statistical	_	
6-18	972-982	parametric	_	
6-19	983-990	mapping	_	
6-20	991-992	(	_	
6-21	992-995	MNE	_	
6-22	996-1000	dSPM	_	
6-23	1000-1001	)	_	
6-24	1002-1005	and	_	
6-25	1006-1018	source-based	_	
6-26	1019-1031	connectivity	_	
6-27	1032-1037	using	_	
6-28	1038-1041	the	_	
6-29	1042-1050	weighted	_	
6-30	1051-1056	phase	_	
6-31	1057-1060	lag	_	
6-32	1061-1066	index	_	
6-33	1066-1067	.	_	

#Text=Results:
#Text=Across one week there was excellent test-retest reliability in global spectral measures in theta-gamma bands (HC ICCAvg=0.87, SZ ICCAvg=0.87), regional spectral measures in all bands (HC ICCAvg=0.86, SZ ICCAvg=0.80), and parietal alpha measures (HC ICCAvg=0.90, SZ ICCAvg=0.84).
7-1	1068-1075	Results	_	
7-2	1075-1076	:	_	
7-3	1077-1083	Across	_	
7-4	1084-1087	one	_	
7-5	1088-1092	week	_	
7-6	1093-1098	there	_	
7-7	1099-1102	was	_	
7-8	1103-1112	excellent	_	
7-9	1113-1124	test-retest	_	
7-10	1125-1136	reliability	_	
7-11	1137-1139	in	_	
7-12	1140-1146	global	_	
7-13	1147-1155	spectral	_	
7-14	1156-1164	measures	_	
7-15	1165-1167	in	_	
7-16	1168-1179	theta-gamma	_	
7-17	1180-1185	bands	_	
7-18	1186-1187	(	_	
7-19	1187-1189	HC	_	
7-20	1190-1196	ICCAvg	_	
7-21	1196-1197	=	_	
7-22	1197-1201	0.87	_	
7-23	1201-1202	,	_	
7-24	1203-1205	SZ	_	
7-25	1206-1212	ICCAvg	_	
7-26	1212-1213	=	_	
7-27	1213-1217	0.87	_	
7-28	1217-1218	)	_	
7-29	1218-1219	,	_	
7-30	1220-1228	regional	_	
7-31	1229-1237	spectral	_	
7-32	1238-1246	measures	_	
7-33	1247-1249	in	_	
7-34	1250-1253	all	_	
7-35	1254-1259	bands	_	
7-36	1260-1261	(	_	
7-37	1261-1263	HC	_	
7-38	1264-1270	ICCAvg	_	
7-39	1270-1271	=	_	
7-40	1271-1275	0.86	_	
7-41	1275-1276	,	_	
7-42	1277-1279	SZ	_	
7-43	1280-1286	ICCAvg	_	
7-44	1286-1287	=	_	
7-45	1287-1291	0.80	_	
7-46	1291-1292	)	_	
7-47	1292-1293	,	_	
7-48	1294-1297	and	_	
7-49	1298-1306	parietal	_	
7-50	1307-1312	alpha	_	
7-51	1313-1321	measures	_	
7-52	1322-1323	(	_	
7-53	1323-1325	HC	_	
7-54	1326-1332	ICCAvg	_	
7-55	1332-1333	=	_	
7-56	1333-1337	0.90	_	
7-57	1337-1338	,	_	
7-58	1339-1341	SZ	_	
7-59	1342-1348	ICCAvg	_	
7-60	1348-1349	=	_	
7-61	1349-1353	0.84	_	
7-62	1353-1354	)	_	
7-63	1354-1355	.	_	

#Text=Conversely, functional connectivity had poor reliability, as did source spectral power across one hour for SZ.
8-1	1356-1366	Conversely	_	
8-2	1366-1367	,	_	
8-3	1368-1378	functional	_	
8-4	1379-1391	connectivity	_	
8-5	1392-1395	had	_	
8-6	1396-1400	poor	_	
8-7	1401-1412	reliability	_	
8-8	1412-1413	,	_	
8-9	1414-1416	as	_	
8-10	1417-1420	did	_	
8-11	1421-1427	source	_	
8-12	1428-1436	spectral	_	
8-13	1437-1442	power	_	
8-14	1443-1449	across	_	
8-15	1450-1453	one	_	
8-16	1454-1458	hour	_	
8-17	1459-1462	for	_	
8-18	1463-1465	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
8-19	1465-1466	.	_	

#Text=Relative to HC, SZ also had reduced parietal alpha normalized power during eyes closed only, reduced alpha reactivity, and an association between higher PANSS positive scores and lower parietal alpha power.
9-1	1467-1475	Relative	_	
9-2	1476-1478	to	_	
9-3	1479-1481	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
9-4	1481-1482	,	_	
9-5	1483-1485	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
9-6	1486-1490	also	_	
9-7	1491-1494	had	_	
9-8	1495-1502	reduced	_	
9-9	1503-1511	parietal	_	
9-10	1512-1517	alpha	_	
9-11	1518-1528	normalized	_	
9-12	1529-1534	power	_	
9-13	1535-1541	during	_	
9-14	1542-1546	eyes	_	
9-15	1547-1553	closed	_	
9-16	1554-1558	only	_	
9-17	1558-1559	,	_	
9-18	1560-1567	reduced	_	
9-19	1568-1573	alpha	_	
9-20	1574-1584	reactivity	_	
9-21	1584-1585	,	_	
9-22	1586-1589	and	_	
9-23	1590-1592	an	_	
9-24	1593-1604	association	_	
9-25	1605-1612	between	_	
9-26	1613-1619	higher	_	
9-27	1620-1625	PANSS	_	
9-28	1626-1634	positive	_	
9-29	1635-1641	scores	_	
9-30	1642-1645	and	_	
9-31	1646-1651	lower	_	
9-32	1652-1660	parietal	_	
9-33	1661-1666	alpha	_	
9-34	1667-1672	power	_	
9-35	1672-1673	.	_	

#Text=Conclusions:
#Text=There was excellent to good test-retest reliability in most MEG spectral measures with a few exceptions in the schizophrenia patient group.
10-1	1674-1685	Conclusions	_	
10-2	1685-1686	:	_	
10-3	1687-1692	There	_	
10-4	1693-1696	was	_	
10-5	1697-1706	excellent	_	
10-6	1707-1709	to	_	
10-7	1710-1714	good	_	
10-8	1715-1726	test-retest	_	
10-9	1727-1738	reliability	_	
10-10	1739-1741	in	_	
10-11	1742-1746	most	_	
10-12	1747-1750	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography	
10-13	1751-1759	spectral	_	
10-14	1760-1768	measures	_	
10-15	1769-1773	with	_	
10-16	1774-1775	a	_	
10-17	1776-1779	few	_	
10-18	1780-1790	exceptions	_	
10-19	1791-1793	in	_	
10-20	1794-1797	the	_	
10-21	1798-1811	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
10-22	1812-1819	patient	_	
10-23	1820-1825	group	_	
10-24	1825-1826	.	_	

#Text=Overall, these findings encourage the use of resting-state MEG while emphasizing the importance of determining reliability in clinical populations.
11-1	1827-1834	Overall	_	
11-2	1834-1835	,	_	
11-3	1836-1841	these	_	
11-4	1842-1850	findings	_	
11-5	1851-1860	encourage	_	
11-6	1861-1864	the	_	
11-7	1865-1868	use	_	
11-8	1869-1871	of	_	
11-9	1872-1885	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[4]	
11-10	1886-1889	MEG	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[4]|http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography[5]	
11-11	1890-1895	while	_	
11-12	1896-1907	emphasizing	_	
11-13	1908-1911	the	_	
11-14	1912-1922	importance	_	
11-15	1923-1925	of	_	
11-16	1926-1937	determining	_	
11-17	1938-1949	reliability	_	
11-18	1950-1952	in	_	
11-19	1953-1961	clinical	_	
11-20	1962-1973	populations	_	
11-21	1973-1974	.	_	

#Text=Introduction
#Text=Spontaneous neural oscillations during a resting-state have been used to study abnormal neurophysiology in a variety of clinical disorders.
12-1	1975-1987	Introduction	_	
12-2	1988-1999	Spontaneous	_	
12-3	2000-2006	neural	_	
12-4	2007-2019	oscillations	_	
12-5	2020-2026	during	_	
12-6	2027-2028	a	_	
12-7	2029-2042	resting-state	_	
12-8	2043-2047	have	_	
12-9	2048-2052	been	_	
12-10	2053-2057	used	_	
12-11	2058-2060	to	_	
12-12	2061-2066	study	_	
12-13	2067-2075	abnormal	_	
12-14	2076-2091	neurophysiology	_	
12-15	2092-2094	in	_	
12-16	2095-2096	a	_	
12-17	2097-2104	variety	_	
12-18	2105-2107	of	_	
12-19	2108-2116	clinical	_	
12-20	2117-2126	disorders	_	
12-21	2126-2127	.	_	

#Text=MEG spectral power measures have been informative in schizophrenia and Alzheimer’s disease, while MEG functional connectivity has revealed patient abnormalities in schizophrenia, mild cognitive impairment, and depression.
13-1	2128-2131	MEG	_	
13-2	2132-2140	spectral	_	
13-3	2141-2146	power	_	
13-4	2147-2155	measures	_	
13-5	2156-2160	have	_	
13-6	2161-2165	been	_	
13-7	2166-2177	informative	_	
13-8	2178-2180	in	_	
13-9	2181-2194	schizophrenia	_	
13-10	2195-2198	and	_	
13-11	2199-2208	Alzheimer	_	
13-12	2208-2209	’	_	
13-13	2209-2210	s	_	
13-14	2211-2218	disease	_	
13-15	2218-2219	,	_	
13-16	2220-2225	while	_	
13-17	2226-2229	MEG	_	
13-18	2230-2240	functional	_	
13-19	2241-2253	connectivity	_	
13-20	2254-2257	has	_	
13-21	2258-2266	revealed	_	
13-22	2267-2274	patient	_	
13-23	2275-2288	abnormalities	_	
13-24	2289-2291	in	_	
13-25	2292-2305	schizophrenia	_	
13-26	2305-2306	,	_	
13-27	2307-2311	mild	_	
13-28	2312-2321	cognitive	_	
13-29	2322-2332	impairment	_	
13-30	2332-2333	,	_	
13-31	2334-2337	and	_	
13-32	2338-2348	depression	_	
13-33	2348-2349	.	_	

#Text=Assessing MEG-derived neural oscillations in clinical populations has the potential to yield biomarkers for early detection and diagnosis; therefore, demonstrating the reliability of MEG resting-state spectral power and functional connectivity in patients is critical.
14-1	2350-2359	Assessing	_	
14-2	2360-2371	MEG-derived	_	
14-3	2372-2378	neural	_	
14-4	2379-2391	oscillations	_	
14-5	2392-2394	in	_	
14-6	2395-2403	clinical	_	
14-7	2404-2415	populations	_	
14-8	2416-2419	has	_	
14-9	2420-2423	the	_	
14-10	2424-2433	potential	_	
14-11	2434-2436	to	_	
14-12	2437-2442	yield	_	
14-13	2443-2453	biomarkers	_	
14-14	2454-2457	for	_	
14-15	2458-2463	early	_	
14-16	2464-2473	detection	_	
14-17	2474-2477	and	_	
14-18	2478-2487	diagnosis	_	
14-19	2487-2488	;	_	
14-20	2489-2498	therefore	_	
14-21	2498-2499	,	_	
14-22	2500-2513	demonstrating	_	
14-23	2514-2517	the	_	
14-24	2518-2529	reliability	_	
14-25	2530-2532	of	_	
14-26	2533-2536	MEG	_	
14-27	2537-2550	resting-state	_	
14-28	2551-2559	spectral	_	
14-29	2560-2565	power	_	
14-30	2566-2569	and	_	
14-31	2570-2580	functional	_	
14-32	2581-2593	connectivity	_	
14-33	2594-2596	in	_	
14-34	2597-2605	patients	_	
14-35	2606-2608	is	_	
14-36	2609-2617	critical	_	
14-37	2617-2618	.	_	

#Text=In HC, MEG spectral power in sensor and source space has good reliability in the theta, alpha, and beta bands (ICCs>0.6) over a 7 day test-retest interval, with lower reliability in delta and gamma bands in an eyes open resting-state.
15-1	2619-2621	In	_	
15-2	2622-2624	HC	_	
15-3	2624-2625	,	_	
15-4	2626-2629	MEG	_	
15-5	2630-2638	spectral	_	
15-6	2639-2644	power	_	
15-7	2645-2647	in	_	
15-8	2648-2654	sensor	_	
15-9	2655-2658	and	_	
15-10	2659-2665	source	_	
15-11	2666-2671	space	_	
15-12	2672-2675	has	_	
15-13	2676-2680	good	_	
15-14	2681-2692	reliability	_	
15-15	2693-2695	in	_	
15-16	2696-2699	the	_	
15-17	2700-2705	theta	_	
15-18	2705-2706	,	_	
15-19	2707-2712	alpha	_	
15-20	2712-2713	,	_	
15-21	2714-2717	and	_	
15-22	2718-2722	beta	_	
15-23	2723-2728	bands	_	
15-24	2729-2730	(	_	
15-25	2730-2734	ICCs	_	
15-26	2734-2735	>	_	
15-27	2735-2738	0.6	_	
15-28	2738-2739	)	_	
15-29	2740-2744	over	_	
15-30	2745-2746	a	_	
15-31	2747-2748	7	_	
15-32	2749-2752	day	_	
15-33	2753-2764	test-retest	_	
15-34	2765-2773	interval	_	
15-35	2773-2774	,	_	
15-36	2775-2779	with	_	
15-37	2780-2785	lower	_	
15-38	2786-2797	reliability	_	
15-39	2798-2800	in	_	
15-40	2801-2806	delta	_	
15-41	2807-2810	and	_	
15-42	2811-2816	gamma	_	
15-43	2817-2822	bands	_	
15-44	2823-2825	in	_	
15-45	2826-2828	an	_	
15-46	2829-2833	eyes	_	
15-47	2834-2838	open	_	
15-48	2839-2852	resting-state	_	
15-49	2852-2853	.	_	

#Text=Reliability of MEG functional connectivity in HC has varied depending on connectivity measure, with good reliability of phase-locking values in alpha, beta, and gamma bands (ICCs>0.74) but poor reliability for phase-lag index across all frequencies (ICCs<0.1) over a 7 day test-retest interval.
16-1	2854-2865	Reliability	_	
16-2	2866-2868	of	_	
16-3	2869-2872	MEG	_	
16-4	2873-2883	functional	_	
16-5	2884-2896	connectivity	_	
16-6	2897-2899	in	_	
16-7	2900-2902	HC	_	
16-8	2903-2906	has	_	
16-9	2907-2913	varied	_	
16-10	2914-2923	depending	_	
16-11	2924-2926	on	_	
16-12	2927-2939	connectivity	_	
16-13	2940-2947	measure	_	
16-14	2947-2948	,	_	
16-15	2949-2953	with	_	
16-16	2954-2958	good	_	
16-17	2959-2970	reliability	_	
16-18	2971-2973	of	_	
16-19	2974-2987	phase-locking	_	
16-20	2988-2994	values	_	
16-21	2995-2997	in	_	
16-22	2998-3003	alpha	_	
16-23	3003-3004	,	_	
16-24	3005-3009	beta	_	
16-25	3009-3010	,	_	
16-26	3011-3014	and	_	
16-27	3015-3020	gamma	_	
16-28	3021-3026	bands	_	
16-29	3027-3028	(	_	
16-30	3028-3032	ICCs	_	
16-31	3032-3033	>	_	
16-32	3033-3037	0.74	_	
16-33	3037-3038	)	_	
16-34	3039-3042	but	_	
16-35	3043-3047	poor	_	
16-36	3048-3059	reliability	_	
16-37	3060-3063	for	_	
16-38	3064-3073	phase-lag	_	
16-39	3074-3079	index	_	
16-40	3080-3086	across	_	
16-41	3087-3090	all	_	
16-42	3091-3102	frequencies	_	
16-43	3103-3104	(	_	
16-44	3104-3108	ICCs	_	
16-45	3108-3109	<	_	
16-46	3109-3112	0.1	_	
16-47	3112-3113	)	_	
16-48	3114-3118	over	_	
16-49	3119-3120	a	_	
16-50	3121-3122	7	_	
16-51	3123-3126	day	_	
16-52	3127-3138	test-retest	_	
16-53	3139-3147	interval	_	
16-54	3147-3148	.	_	

#Text=Reliability still needs to be quantified for other dependent variables, analysis methods and patient populations; thus far, the reliability of resting-state oscillatory measures in patients with schizophrenia remains unknown.
17-1	3149-3160	Reliability	_	
17-2	3161-3166	still	_	
17-3	3167-3172	needs	_	
17-4	3173-3175	to	_	
17-5	3176-3178	be	_	
17-6	3179-3189	quantified	_	
17-7	3190-3193	for	_	
17-8	3194-3199	other	_	
17-9	3200-3209	dependent	_	
17-10	3210-3219	variables	_	
17-11	3219-3220	,	_	
17-12	3221-3229	analysis	_	
17-13	3230-3237	methods	_	
17-14	3238-3241	and	_	
17-15	3242-3249	patient	_	
17-16	3250-3261	populations	_	
17-17	3261-3262	;	_	
17-18	3263-3267	thus	_	
17-19	3268-3271	far	_	
17-20	3271-3272	,	_	
17-21	3273-3276	the	_	
17-22	3277-3288	reliability	_	
17-23	3289-3291	of	_	
17-24	3292-3305	resting-state	_	
17-25	3306-3317	oscillatory	_	
17-26	3318-3326	measures	_	
17-27	3327-3329	in	_	
17-28	3330-3338	patients	_	
17-29	3339-3343	with	_	
17-30	3344-3357	schizophrenia	_	
17-31	3358-3365	remains	_	
17-32	3366-3373	unknown	_	
17-33	3373-3374	.	_	

#Text=Schizophrenia has been conceptualized as a disorder of altered brain connectivity or “disconnectivity” based on disruptions in resting-state brain networks highlighting disorganization as a key process.
18-1	3375-3388	Schizophrenia	_	
18-2	3389-3392	has	_	
18-3	3393-3397	been	_	
18-4	3398-3412	conceptualized	_	
18-5	3413-3415	as	_	
18-6	3416-3417	a	_	
18-7	3418-3426	disorder	_	
18-8	3427-3429	of	_	
18-9	3430-3437	altered	_	
18-10	3438-3443	brain	_	
18-11	3444-3456	connectivity	_	
18-12	3457-3459	or	_	
18-13	3460-3461	“	_	
18-14	3461-3476	disconnectivity	_	
18-15	3476-3477	”	_	
18-16	3478-3483	based	_	
18-17	3484-3486	on	_	
18-18	3487-3498	disruptions	_	
18-19	3499-3501	in	_	
18-20	3502-3515	resting-state	_	
18-21	3516-3521	brain	_	
18-22	3522-3530	networks	_	
18-23	3531-3543	highlighting	_	
18-24	3544-3559	disorganization	_	
18-25	3560-3562	as	_	
18-26	3563-3564	a	_	
18-27	3565-3568	key	_	
18-28	3569-3576	process	_	
18-29	3576-3577	.	_	

#Text=There have been several MEG studies reporting disrupted neural oscillations and brain connectivity within either an eyes open (EO) or eyes closed (EC) resting-state in schizophrenia, for review refer to.
19-1	3578-3583	There	_	
19-2	3584-3588	have	_	
19-3	3589-3593	been	_	
19-4	3594-3601	several	_	
19-5	3602-3605	MEG	_	
19-6	3606-3613	studies	_	
19-7	3614-3623	reporting	_	
19-8	3624-3633	disrupted	_	
19-9	3634-3640	neural	_	
19-10	3641-3653	oscillations	_	
19-11	3654-3657	and	_	
19-12	3658-3663	brain	_	
19-13	3664-3676	connectivity	_	
19-14	3677-3683	within	_	
19-15	3684-3690	either	_	
19-16	3691-3693	an	_	
19-17	3694-3698	eyes	_	
19-18	3699-3703	open	_	
19-19	3704-3705	(	_	
19-20	3705-3707	EO	_	
19-21	3707-3708	)	_	
19-22	3709-3711	or	_	
19-23	3712-3716	eyes	_	
19-24	3717-3723	closed	_	
19-25	3724-3725	(	_	
19-26	3725-3727	EC	_	
19-27	3727-3728	)	_	
19-28	3729-3742	resting-state	_	
19-29	3743-3745	in	_	
19-30	3746-3759	schizophrenia	_	
19-31	3759-3760	,	_	
19-32	3761-3764	for	_	
19-33	3765-3771	review	_	
19-34	3772-3777	refer	_	
19-35	3778-3780	to	_	
19-36	3780-3781	.	_	

#Text=Study results indicate that patients had increased slow-wave oscillatory activity within delta and theta frequencies, decreased gamma oscillatory activity, and decreased alpha oscillatory activity in widespread regions during EC and EO resting-states, along with reduced alpha-band connectivity in left prefrontal cortex and right superior temporal cortex, with clinical correlates ranging from associations with positive symptoms to negative symptoms depending on frequency band and brain region.
20-1	3782-3787	Study	_	
20-2	3788-3795	results	_	
20-3	3796-3804	indicate	_	
20-4	3805-3809	that	_	
20-5	3810-3818	patients	_	
20-6	3819-3822	had	_	
20-7	3823-3832	increased	_	
20-8	3833-3842	slow-wave	_	
20-9	3843-3854	oscillatory	_	
20-10	3855-3863	activity	_	
20-11	3864-3870	within	_	
20-12	3871-3876	delta	_	
20-13	3877-3880	and	_	
20-14	3881-3886	theta	_	
20-15	3887-3898	frequencies	_	
20-16	3898-3899	,	_	
20-17	3900-3909	decreased	_	
20-18	3910-3915	gamma	_	
20-19	3916-3927	oscillatory	_	
20-20	3928-3936	activity	_	
20-21	3936-3937	,	_	
20-22	3938-3941	and	_	
20-23	3942-3951	decreased	_	
20-24	3952-3957	alpha	_	
20-25	3958-3969	oscillatory	_	
20-26	3970-3978	activity	_	
20-27	3979-3981	in	_	
20-28	3982-3992	widespread	_	
20-29	3993-4000	regions	_	
20-30	4001-4007	during	_	
20-31	4008-4010	EC	_	
20-32	4011-4014	and	_	
20-33	4015-4017	EO	_	
20-34	4018-4032	resting-states	_	
20-35	4032-4033	,	_	
20-36	4034-4039	along	_	
20-37	4040-4044	with	_	
20-38	4045-4052	reduced	_	
20-39	4053-4063	alpha-band	_	
20-40	4064-4076	connectivity	_	
20-41	4077-4079	in	_	
20-42	4080-4084	left	_	
20-43	4085-4095	prefrontal	_	
20-44	4096-4102	cortex	_	
20-45	4103-4106	and	_	
20-46	4107-4112	right	_	
20-47	4113-4121	superior	_	
20-48	4122-4130	temporal	_	
20-49	4131-4137	cortex	_	
20-50	4137-4138	,	_	
20-51	4139-4143	with	_	
20-52	4144-4152	clinical	_	
20-53	4153-4163	correlates	_	
20-54	4164-4171	ranging	_	
20-55	4172-4176	from	_	
20-56	4177-4189	associations	_	
20-57	4190-4194	with	_	
20-58	4195-4203	positive	_	
20-59	4204-4212	symptoms	_	
20-60	4213-4215	to	_	
20-61	4216-4224	negative	_	
20-62	4225-4233	symptoms	_	
20-63	4234-4243	depending	_	
20-64	4244-4246	on	_	
20-65	4247-4256	frequency	_	
20-66	4257-4261	band	_	
20-67	4262-4265	and	_	
20-68	4266-4271	brain	_	
20-69	4272-4278	region	_	
20-70	4278-4279	.	_	

#Text=Inconsistencies in cross-sectional literature may be attributed to variations in rest collected (EO vs EC), analysis method, measure used, and frequency band.
21-1	4280-4295	Inconsistencies	_	
21-2	4296-4298	in	_	
21-3	4299-4314	cross-sectional	_	
21-4	4315-4325	literature	_	
21-5	4326-4329	may	_	
21-6	4330-4332	be	_	
21-7	4333-4343	attributed	_	
21-8	4344-4346	to	_	
21-9	4347-4357	variations	_	
21-10	4358-4360	in	_	
21-11	4361-4365	rest	_	
21-12	4366-4375	collected	_	
21-13	4376-4377	(	_	
21-14	4377-4379	EO	_	
21-15	4380-4382	vs	_	
21-16	4383-4385	EC	_	
21-17	4385-4386	)	_	
21-18	4386-4387	,	_	
21-19	4388-4396	analysis	_	
21-20	4397-4403	method	_	
21-21	4403-4404	,	_	
21-22	4405-4412	measure	_	
21-23	4413-4417	used	_	
21-24	4417-4418	,	_	
21-25	4419-4422	and	_	
21-26	4423-4432	frequency	_	
21-27	4433-4437	band	_	
21-28	4437-4438	.	_	

#Text=Narrowing the field on potential biomarkers for schizophrenia will require the reproducibility and reliability of previous findings before embarking on longitudinal studies.
22-1	4439-4448	Narrowing	_	
22-2	4449-4452	the	_	
22-3	4453-4458	field	_	
22-4	4459-4461	on	_	
22-5	4462-4471	potential	_	
22-6	4472-4482	biomarkers	_	
22-7	4483-4486	for	_	
22-8	4487-4500	schizophrenia	_	
22-9	4501-4505	will	_	
22-10	4506-4513	require	_	
22-11	4514-4517	the	_	
22-12	4518-4533	reproducibility	_	
22-13	4534-4537	and	_	
22-14	4538-4549	reliability	_	
22-15	4550-4552	of	_	
22-16	4553-4561	previous	_	
22-17	4562-4570	findings	_	
22-18	4571-4577	before	_	
22-19	4578-4587	embarking	_	
22-20	4588-4590	on	_	
22-21	4591-4603	longitudinal	_	
22-22	4604-4611	studies	_	
22-23	4611-4612	.	_	

#Text=It is critical for MEG research to complete its own test-retest studies, as reliability may be influenced by modality, type of data (evoked vs. spontaneous), analysis method, and/or imaging site.
23-1	4613-4615	It	_	
23-2	4616-4618	is	_	
23-3	4619-4627	critical	_	
23-4	4628-4631	for	_	
23-5	4632-4635	MEG	_	
23-6	4636-4644	research	_	
23-7	4645-4647	to	_	
23-8	4648-4656	complete	_	
23-9	4657-4660	its	_	
23-10	4661-4664	own	_	
23-11	4665-4676	test-retest	_	
23-12	4677-4684	studies	_	
23-13	4684-4685	,	_	
23-14	4686-4688	as	_	
23-15	4689-4700	reliability	_	
23-16	4701-4704	may	_	
23-17	4705-4707	be	_	
23-18	4708-4718	influenced	_	
23-19	4719-4721	by	_	
23-20	4722-4730	modality	_	
23-21	4730-4731	,	_	
23-22	4732-4736	type	_	
23-23	4737-4739	of	_	
23-24	4740-4744	data	_	
23-25	4745-4746	(	_	
23-26	4746-4752	evoked	_	
23-27	4753-4755	vs	_	
23-28	4755-4756	.	_	
23-29	4757-4768	spontaneous	_	
23-30	4768-4769	)	_	
23-31	4769-4770	,	_	
23-32	4771-4779	analysis	_	
23-33	4780-4786	method	_	
23-34	4786-4787	,	_	
23-35	4788-4791	and	_	
23-36	4791-4792	/	_	
23-37	4792-4794	or	_	
23-38	4795-4802	imaging	_	
23-39	4803-4807	site	_	
23-40	4807-4808	.	_	

#Text=Despite the same temporal resolution capabilities for EEG and MEG, MEG provides a number of advantages.
24-1	4809-4816	Despite	_	
24-2	4817-4820	the	_	
24-3	4821-4825	same	_	
24-4	4826-4834	temporal	_	
24-5	4835-4845	resolution	_	
24-6	4846-4858	capabilities	_	
24-7	4859-4862	for	_	
24-8	4863-4866	EEG	_	
24-9	4867-4870	and	_	
24-10	4871-4874	MEG	_	
24-11	4874-4875	,	_	
24-12	4876-4879	MEG	_	
24-13	4880-4888	provides	_	
24-14	4889-4890	a	_	
24-15	4891-4897	number	_	
24-16	4898-4900	of	_	
24-17	4901-4911	advantages	_	
24-18	4911-4912	.	_	

#Text=For EEG, the poor conductivity of the skull creates a smearing effect such that the brain signals picked up by the electrodes are not necessarily from local generators.
25-1	4913-4916	For	_	
25-2	4917-4920	EEG	_	
25-3	4920-4921	,	_	
25-4	4922-4925	the	_	
25-5	4926-4930	poor	_	
25-6	4931-4943	conductivity	_	
25-7	4944-4946	of	_	
25-8	4947-4950	the	_	
25-9	4951-4956	skull	_	
25-10	4957-4964	creates	_	
25-11	4965-4966	a	_	
25-12	4967-4975	smearing	_	
25-13	4976-4982	effect	_	
25-14	4983-4987	such	_	
25-15	4988-4992	that	_	
25-16	4993-4996	the	_	
25-17	4997-5002	brain	_	
25-18	5003-5010	signals	_	
25-19	5011-5017	picked	_	
25-20	5018-5020	up	_	
25-21	5021-5023	by	_	
25-22	5024-5027	the	_	
25-23	5028-5038	electrodes	_	
25-24	5039-5042	are	_	
25-25	5043-5046	not	_	
25-26	5047-5058	necessarily	_	
25-27	5059-5063	from	_	
25-28	5064-5069	local	_	
25-29	5070-5080	generators	_	
25-30	5080-5081	.	_	

#Text=MEG offers a reference-free method for assessing electromagnetic signals which are not distorted by the differing conductivities of the scalp, skull, and brain, thereby allowing for improved spatial resolution and the application of simpler models for estimating sources of measured activity.
26-1	5082-5085	MEG	_	
26-2	5086-5092	offers	_	
26-3	5093-5094	a	_	
26-4	5095-5109	reference-free	_	
26-5	5110-5116	method	_	
26-6	5117-5120	for	_	
26-7	5121-5130	assessing	_	
26-8	5131-5146	electromagnetic	_	
26-9	5147-5154	signals	_	
26-10	5155-5160	which	_	
26-11	5161-5164	are	_	
26-12	5165-5168	not	_	
26-13	5169-5178	distorted	_	
26-14	5179-5181	by	_	
26-15	5182-5185	the	_	
26-16	5186-5195	differing	_	
26-17	5196-5210	conductivities	_	
26-18	5211-5213	of	_	
26-19	5214-5217	the	_	
26-20	5218-5223	scalp	_	
26-21	5223-5224	,	_	
26-22	5225-5230	skull	_	
26-23	5230-5231	,	_	
26-24	5232-5235	and	_	
26-25	5236-5241	brain	_	
26-26	5241-5242	,	_	
26-27	5243-5250	thereby	_	
26-28	5251-5259	allowing	_	
26-29	5260-5263	for	_	
26-30	5264-5272	improved	_	
26-31	5273-5280	spatial	_	
26-32	5281-5291	resolution	_	
26-33	5292-5295	and	_	
26-34	5296-5299	the	_	
26-35	5300-5311	application	_	
26-36	5312-5314	of	_	
26-37	5315-5322	simpler	_	
26-38	5323-5329	models	_	
26-39	5330-5333	for	_	
26-40	5334-5344	estimating	_	
26-41	5345-5352	sources	_	
26-42	5353-5355	of	_	
26-43	5356-5364	measured	_	
26-44	5365-5373	activity	_	
26-45	5373-5374	.	_	

#Text=The current study was designed to examine global and regional test-retest reliability of neuromagnetic oscillatory measures across sensor and source MEG data in EC and EO resting-states.
27-1	5375-5378	The	_	
27-2	5379-5386	current	_	
27-3	5387-5392	study	_	
27-4	5393-5396	was	_	
27-5	5397-5405	designed	_	
27-6	5406-5408	to	_	
27-7	5409-5416	examine	_	
27-8	5417-5423	global	_	
27-9	5424-5427	and	_	
27-10	5428-5436	regional	_	
27-11	5437-5448	test-retest	_	
27-12	5449-5460	reliability	_	
27-13	5461-5463	of	_	
27-14	5464-5477	neuromagnetic	_	
27-15	5478-5489	oscillatory	_	
27-16	5490-5498	measures	_	
27-17	5499-5505	across	_	
27-18	5506-5512	sensor	_	
27-19	5513-5516	and	_	
27-20	5517-5523	source	_	
27-21	5524-5527	MEG	_	
27-22	5528-5532	data	_	
27-23	5533-5535	in	_	
27-24	5536-5538	EC	_	
27-25	5539-5542	and	_	
27-26	5543-5545	EO	_	
27-27	5546-5560	resting-states	_	
27-28	5560-5561	.	_	

#Text=We collected resting-state data in 26 participants (13-SZ, 13-HC) during 2 visits to estimate reliability across one hour and one week in spectral power measures and functional connectivity.
28-1	5562-5564	We	_	
28-2	5565-5574	collected	_	
28-3	5575-5588	resting-state	_	
28-4	5589-5593	data	_	
28-5	5594-5596	in	_	
28-6	5597-5599	26	_	
28-7	5600-5612	participants	_	
28-8	5613-5614	(	_	
28-9	5614-5616	13	_	
28-10	5616-5617	-	_	
28-11	5617-5619	SZ	_	
28-12	5619-5620	,	_	
28-13	5621-5623	13	_	
28-14	5623-5624	-	_	
28-15	5624-5626	HC	_	
28-16	5626-5627	)	_	
28-17	5628-5634	during	_	
28-18	5635-5636	2	_	
28-19	5637-5643	visits	_	
28-20	5644-5646	to	_	
28-21	5647-5655	estimate	_	
28-22	5656-5667	reliability	_	
28-23	5668-5674	across	_	
28-24	5675-5678	one	_	
28-25	5679-5683	hour	_	
28-26	5684-5687	and	_	
28-27	5688-5691	one	_	
28-28	5692-5696	week	_	
28-29	5697-5699	in	_	
28-30	5700-5708	spectral	_	
28-31	5709-5714	power	_	
28-32	5715-5723	measures	_	
28-33	5724-5727	and	_	
28-34	5728-5738	functional	_	
28-35	5739-5751	connectivity	_	
28-36	5751-5752	.	_	

#Text=We hypothesized test-retest reliability would be moderately high in HC and lower in SZ.
29-1	5753-5755	We	_	
29-2	5756-5768	hypothesized	_	
29-3	5769-5780	test-retest	_	
29-4	5781-5792	reliability	_	
29-5	5793-5798	would	_	
29-6	5799-5801	be	_	
29-7	5802-5812	moderately	_	
29-8	5813-5817	high	_	
29-9	5818-5820	in	_	
29-10	5821-5823	HC	_	
29-11	5824-5827	and	_	
29-12	5828-5833	lower	_	
29-13	5834-5836	in	_	
29-14	5837-5839	SZ	_	
29-15	5839-5840	.	_	

#Text=Alpha oscillatory activity in the parietal region was also examined based on its well-defined physiological properties, that is, the known suppression of response amplitude to eye opening in the parietal-occipital regions.
30-1	5841-5846	Alpha	_	
30-2	5847-5858	oscillatory	_	
30-3	5859-5867	activity	_	
30-4	5868-5870	in	_	
30-5	5871-5874	the	_	
30-6	5875-5883	parietal	_	
30-7	5884-5890	region	_	
30-8	5891-5894	was	_	
30-9	5895-5899	also	_	
30-10	5900-5908	examined	_	
30-11	5909-5914	based	_	
30-12	5915-5917	on	_	
30-13	5918-5921	its	_	
30-14	5922-5934	well-defined	_	
30-15	5935-5948	physiological	_	
30-16	5949-5959	properties	_	
30-17	5959-5960	,	_	
30-18	5961-5965	that	_	
30-19	5966-5968	is	_	
30-20	5968-5969	,	_	
30-21	5970-5973	the	_	
30-22	5974-5979	known	_	
30-23	5980-5991	suppression	_	
30-24	5992-5994	of	_	
30-25	5995-6003	response	_	
30-26	6004-6013	amplitude	_	
30-27	6014-6016	to	_	
30-28	6017-6020	eye	_	
30-29	6021-6028	opening	_	
30-30	6029-6031	in	_	
30-31	6032-6035	the	_	
30-32	6036-6054	parietal-occipital	_	
30-33	6055-6062	regions	_	
30-34	6062-6063	.	_	

#Text=Given that we collected both EC and EO data, we directly examined alpha reactivity.
31-1	6064-6069	Given	_	
31-2	6070-6074	that	_	
31-3	6075-6077	we	_	
31-4	6078-6087	collected	_	
31-5	6088-6092	both	_	
31-6	6093-6095	EC	_	
31-7	6096-6099	and	_	
31-8	6100-6102	EO	_	
31-9	6103-6107	data	_	
31-10	6107-6108	,	_	
31-11	6109-6111	we	_	
31-12	6112-6120	directly	_	
31-13	6121-6129	examined	_	
31-14	6130-6135	alpha	_	
31-15	6136-6146	reactivity	_	
31-16	6146-6147	.	_	

#Text=We hypothesized resting-state alpha oscillatory activity would be decreased in SZ when compared to HC, similar to previous MEG studies, partially attributed to potential thalamic abnormalities and thalamic connectivity aberrations previously reported in SZ, and the thalamus’ role in generating oscillatory activity in the parietal-occipital regions.
32-1	6148-6150	We	_	
32-2	6151-6163	hypothesized	_	
32-3	6164-6177	resting-state	_	
32-4	6178-6183	alpha	_	
32-5	6184-6195	oscillatory	_	
32-6	6196-6204	activity	_	
32-7	6205-6210	would	_	
32-8	6211-6213	be	_	
32-9	6214-6223	decreased	_	
32-10	6224-6226	in	_	
32-11	6227-6229	SZ	_	
32-12	6230-6234	when	_	
32-13	6235-6243	compared	_	
32-14	6244-6246	to	_	
32-15	6247-6249	HC	_	
32-16	6249-6250	,	_	
32-17	6251-6258	similar	_	
32-18	6259-6261	to	_	
32-19	6262-6270	previous	_	
32-20	6271-6274	MEG	_	
32-21	6275-6282	studies	_	
32-22	6282-6283	,	_	
32-23	6284-6293	partially	_	
32-24	6294-6304	attributed	_	
32-25	6305-6307	to	_	
32-26	6308-6317	potential	_	
32-27	6318-6326	thalamic	_	
32-28	6327-6340	abnormalities	_	
32-29	6341-6344	and	_	
32-30	6345-6353	thalamic	_	
32-31	6354-6366	connectivity	_	
32-32	6367-6378	aberrations	_	
32-33	6379-6389	previously	_	
32-34	6390-6398	reported	_	
32-35	6399-6401	in	_	
32-36	6402-6404	SZ	_	
32-37	6404-6405	,	_	
32-38	6406-6409	and	_	
32-39	6410-6413	the	_	
32-40	6414-6422	thalamus	_	
32-41	6422-6423	’	_	
32-42	6424-6428	role	_	
32-43	6429-6431	in	_	
32-44	6432-6442	generating	_	
32-45	6443-6454	oscillatory	_	
32-46	6455-6463	activity	_	
32-47	6464-6466	in	_	
32-48	6467-6470	the	_	
32-49	6471-6489	parietal-occipital	_	
32-50	6490-6497	regions	_	
32-51	6497-6498	.	_	

#Text=Materials and Methods
#Text=Participants
#Text=The current study included 13 individuals diagnosed with schizophrenia (SZ) and 13 healthy controls (HC), age and gender matched, Table 1.
33-1	6499-6508	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[6]	
33-2	6509-6512	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[6]	
33-3	6513-6520	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[6]	
33-4	6521-6533	Participants	_	
33-5	6534-6537	The	_	
33-6	6538-6545	current	_	
33-7	6546-6551	study	_	
33-8	6552-6560	included	_	
33-9	6561-6563	13	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-10	6564-6575	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-11	6576-6585	diagnosed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-12	6586-6590	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-13	6591-6604	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[8]	
33-14	6605-6606	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[8]	
33-15	6606-6608	SZ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[8]	
33-16	6608-6609	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[8]	
33-17	6610-6613	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-18	6614-6616	13	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-19	6617-6624	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
33-20	6625-6633	controls	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
33-21	6634-6635	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
33-22	6635-6637	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
33-23	6637-6638	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]	
33-24	6638-6639	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-25	6640-6643	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-26	6644-6647	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-27	6648-6654	gender	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-28	6655-6662	matched	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-29	6662-6663	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-30	6664-6669	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-31	6670-6671	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	
33-32	6671-6672	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]	

#Text=Informed consent was obtained from all participants according to institutional guidelines.
34-1	6673-6681	Informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
34-2	6682-6689	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
34-3	6690-6693	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
34-4	6694-6702	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
34-5	6703-6707	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
34-6	6708-6711	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
34-7	6712-6724	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
34-8	6725-6734	according	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
34-9	6735-6737	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
34-10	6738-6751	institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
34-11	6752-6762	guidelines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
34-12	6762-6763	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=The study was approved by the University of New Mexico Health Sciences Center Human Research Review Committee.
35-1	6764-6767	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-2	6768-6773	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-3	6774-6777	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-4	6778-6786	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-5	6787-6789	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-6	6790-6793	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-7	6794-6804	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-8	6805-6807	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-9	6808-6811	New	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-10	6812-6818	Mexico	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-11	6819-6825	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-12	6826-6834	Sciences	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-13	6835-6841	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-14	6842-6847	Human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-15	6848-6856	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-16	6857-6863	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-17	6864-6873	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
35-18	6873-6874	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=All participants were within 21–49 years of age with no history of neurological disorder (e.g. epilepsy), no history of major head trauma (loss of consciousness >5 min), no current substance abuse diagnosis (excluding nicotine), no current dependence/abuse of PCP/amphetamine/cocaine within the past 12 months, and were not currently on mood stabilizers such as lithium or valproic acid.
36-1	6875-6878	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-2	6879-6891	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-3	6892-6896	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-4	6897-6903	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-5	6904-6906	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-6	6906-6907	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-7	6907-6909	49	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-8	6910-6915	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-9	6916-6918	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-10	6919-6922	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-11	6923-6927	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-12	6928-6930	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-13	6931-6938	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-14	6939-6941	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-15	6942-6954	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-16	6955-6963	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-17	6964-6965	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-18	6965-6968	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-19	6968-6969	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-20	6970-6978	epilepsy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-21	6978-6979	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-22	6979-6980	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-23	6981-6983	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-24	6984-6991	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-25	6992-6994	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-26	6995-7000	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-27	7001-7005	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-28	7006-7012	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-29	7013-7014	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-30	7014-7018	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-31	7019-7021	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-32	7022-7035	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-33	7036-7037	>	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-34	7037-7038	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-35	7039-7042	min	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-36	7042-7043	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-37	7043-7044	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-38	7045-7047	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-39	7048-7055	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-40	7056-7065	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-41	7066-7071	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-42	7072-7081	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-43	7082-7083	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-44	7083-7092	excluding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-45	7093-7101	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-46	7101-7102	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-47	7102-7103	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-48	7104-7106	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-49	7107-7114	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-50	7115-7125	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-51	7125-7126	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-52	7126-7131	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-53	7132-7134	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-54	7135-7138	PCP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-55	7138-7139	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-56	7139-7150	amphetamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-57	7150-7151	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-58	7151-7158	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-59	7159-7165	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-60	7166-7169	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-61	7170-7174	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-62	7175-7177	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-63	7178-7184	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-64	7184-7185	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-65	7186-7189	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-66	7190-7194	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-67	7195-7198	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-68	7199-7208	currently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-69	7209-7211	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-70	7212-7216	mood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-71	7217-7228	stabilizers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-72	7229-7233	such	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-73	7234-7236	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-74	7237-7244	lithium	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-75	7245-7247	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-76	7248-7256	valproic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-77	7257-7261	acid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
36-78	7261-7262	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	

#Text=HC had IQ scores within the normal range and no history of developmental delays or neurological or psychiatric disorders based on the Structured Clinical Interview for DSM-IV-Non-patient (SCIDNP).
37-1	7263-7265	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
37-2	7266-7269	had	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-3	7270-7272	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-4	7273-7279	scores	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-5	7280-7286	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-6	7287-7290	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-7	7291-7297	normal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-8	7298-7303	range	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-9	7304-7307	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-10	7308-7310	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-11	7311-7318	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-12	7319-7321	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-13	7322-7335	developmental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-14	7336-7342	delays	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-15	7343-7345	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-16	7346-7358	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-17	7359-7361	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-18	7362-7373	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-19	7374-7383	disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-20	7384-7389	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-21	7390-7392	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-22	7393-7396	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
37-23	7397-7407	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[13]	
37-24	7408-7416	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[13]	
37-25	7417-7426	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[13]	
37-26	7427-7430	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[13]	
37-27	7431-7449	DSM-IV-Non-patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[13]	
37-28	7450-7451	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[13]	
37-29	7451-7457	SCIDNP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[13]	
37-30	7457-7458	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[13]	
37-31	7458-7459	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=HCs also did not have a family history of a psychotic disorder in first-degree relatives or a history of more than 1 lifetime depressive episode.
38-1	7460-7463	HCs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-2	7464-7468	also	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-3	7469-7472	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-4	7473-7476	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-5	7477-7481	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-6	7482-7483	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-7	7484-7490	family	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-8	7491-7498	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-9	7499-7501	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-10	7502-7503	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-11	7504-7513	psychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-12	7514-7522	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-13	7523-7525	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-14	7526-7538	first-degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-15	7539-7548	relatives	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-16	7549-7551	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-17	7552-7553	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-18	7554-7561	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-19	7562-7564	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-20	7565-7569	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-21	7570-7574	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-22	7575-7576	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-23	7577-7585	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-24	7586-7596	depressive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-25	7597-7604	episode	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
38-26	7604-7605	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Participants with schizophrenia were confirmed to have a DSM-IV-TR diagnosis of schizophrenia with the Structured Clinical Interview for DSM-IV-Patient (SCID-IP) and retrospective clinical stability.
39-1	7606-7618	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]	
39-2	7619-7623	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]	
39-3	7624-7637	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[14]	
39-4	7638-7642	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
39-5	7643-7652	confirmed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
39-6	7653-7655	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
39-7	7656-7660	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
39-8	7661-7662	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
39-9	7663-7672	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
39-10	7673-7682	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
39-11	7683-7685	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
39-12	7686-7699	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[15]	
39-13	7700-7704	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
39-14	7705-7708	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
39-15	7709-7719	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[16]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[17]	
39-16	7720-7728	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[16]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[17]	
39-17	7729-7738	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[16]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[17]	
39-18	7739-7742	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[16]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[17]	
39-19	7743-7757	DSM-IV-Patient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[16]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[17]	
39-20	7758-7759	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[16]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[17]	
39-21	7759-7766	SCID-IP	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[16]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[17]	
39-22	7766-7767	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[16]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders[17]	
39-23	7768-7771	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
39-24	7772-7785	retrospective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
39-25	7786-7794	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
39-26	7795-7804	stability	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
39-27	7804-7805	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=Participants were not excluded for nicotine use, however, they were not allowed to smoke within 1 hour of the MEG session or be more than 5 hours from their previous cigarette to avoid confounds of acute nicotine exposure or withdrawal.
40-1	7806-7818	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-2	7819-7823	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-3	7824-7827	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-4	7828-7836	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-5	7837-7840	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-6	7841-7849	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-7	7850-7853	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-8	7853-7854	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-9	7855-7862	however	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-10	7862-7863	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-11	7864-7868	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-12	7869-7873	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-13	7874-7877	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-14	7878-7885	allowed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-15	7886-7888	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-16	7889-7894	smoke	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-17	7895-7901	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-18	7902-7903	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-19	7904-7908	hour	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-20	7909-7911	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-21	7912-7915	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-22	7916-7919	MEG	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-23	7920-7927	session	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-24	7928-7930	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-25	7931-7933	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-26	7934-7938	more	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-27	7939-7943	than	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-28	7944-7945	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-29	7946-7951	hours	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-30	7952-7956	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-31	7957-7962	their	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-32	7963-7971	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-33	7972-7981	cigarette	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-34	7982-7984	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-35	7985-7990	avoid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-36	7991-8000	confounds	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-37	8001-8003	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-38	8004-8009	acute	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-39	8010-8018	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-40	8019-8027	exposure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-41	8028-8030	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-42	8031-8041	withdrawal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
40-43	8041-8042	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	

#Text=The following assessments were collected in SZ participants and reported in Table 1: Wechsler Test of Adult Reading (WTAR), Standard and Predicted (premorbid) IQ, Positive and Negative Syndrome Scale (PANSS), antipsychotic medication dose information, and duration of illness.
41-1	8043-8046	The	_	
41-2	8047-8056	following	_	
41-3	8057-8068	assessments	_	
41-4	8069-8073	were	_	
41-5	8074-8083	collected	_	
41-6	8084-8086	in	_	
41-7	8087-8089	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
41-8	8090-8102	participants	_	
41-9	8103-8106	and	_	
41-10	8107-8115	reported	_	
41-11	8116-8118	in	_	
41-12	8119-8124	Table	_	
41-13	8125-8126	1	_	
41-14	8126-8127	:	_	
41-15	8128-8136	Wechsler	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[18]	
41-16	8137-8141	Test	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[18]	
41-17	8142-8144	of	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[18]	
41-18	8145-8150	Adult	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[18]	
41-19	8151-8158	Reading	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[18]	
41-20	8159-8160	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[18]	
41-21	8160-8164	WTAR	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[18]	
41-22	8164-8165	)	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[18]	
41-23	8165-8166	,	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[18]	
41-24	8167-8175	Standard	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[19]	
41-25	8176-8179	and	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[19]	
41-26	8180-8189	Predicted	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[19]	
41-27	8190-8191	(	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[19]	
41-28	8191-8200	premorbid	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[19]	
41-29	8200-8201	)	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[19]	
41-30	8202-8204	IQ	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[19]	
41-31	8204-8205	,	_	
41-32	8206-8214	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
41-33	8215-8218	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
41-34	8219-8227	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
41-35	8228-8236	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
41-36	8237-8242	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
41-37	8243-8244	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
41-38	8244-8249	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
41-39	8249-8250	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale[20]	
41-40	8250-8251	,	_	
41-41	8252-8265	antipsychotic	_	
41-42	8266-8276	medication	_	
41-43	8277-8281	dose	_	
41-44	8282-8293	information	_	
41-45	8293-8294	,	_	
41-46	8295-8298	and	_	
41-47	8299-8307	duration	_	
41-48	8308-8310	of	_	
41-49	8311-8318	illness	_	
41-50	8318-8319	.	_	

#Text=PANSS scores were determined for each visit.
42-1	8320-8325	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale	
42-2	8326-8332	scores	_	
42-3	8333-8337	were	_	
42-4	8338-8348	determined	_	
42-5	8349-8352	for	_	
42-6	8353-8357	each	_	
42-7	8358-8363	visit	_	
42-8	8363-8364	.	_	

#Text=Antipsychotic medication was converted to olanzapine equivalents for comparison between medication.
43-1	8365-8378	Antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[21]	
43-2	8379-8389	medication	http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[21]	
43-3	8390-8393	was	_	
43-4	8394-8403	converted	_	
43-5	8404-8406	to	_	
43-6	8407-8417	olanzapine	_	
43-7	8418-8429	equivalents	_	
43-8	8430-8433	for	_	
43-9	8434-8444	comparison	_	
43-10	8445-8452	between	_	
43-11	8453-8463	medication	_	
43-12	8463-8464	.	_	

#Text=Duration of illness was calculated by subtracting age at onset of psychotic symptoms from current age.
44-1	8465-8473	Duration	_	
44-2	8474-8476	of	_	
44-3	8477-8484	illness	_	
44-4	8485-8488	was	_	
44-5	8489-8499	calculated	_	
44-6	8500-8502	by	_	
44-7	8503-8514	subtracting	_	
44-8	8515-8518	age	_	
44-9	8519-8521	at	_	
44-10	8522-8527	onset	_	
44-11	8528-8530	of	_	
44-12	8531-8540	psychotic	_	
44-13	8541-8549	symptoms	_	
44-14	8550-8554	from	_	
44-15	8555-8562	current	_	
44-16	8563-8566	age	_	
44-17	8566-8567	.	_	

#Text=MEG Behavioral Tasks
#Text=All participants had two visits across 7 days [HC=7.54 days ±60 minutes, SZ=7.84 days ±51 minutes].
45-1	8568-8571	MEG	_	
45-2	8572-8582	Behavioral	_	
45-3	8583-8588	Tasks	_	
45-4	8589-8592	All	_	
45-5	8593-8605	participants	_	
45-6	8606-8609	had	_	
45-7	8610-8613	two	_	
45-8	8614-8620	visits	_	
45-9	8621-8627	across	_	
45-10	8628-8629	7	_	
45-11	8630-8634	days	_	
45-12	8635-8636	[	_	
45-13	8636-8638	HC	_	
45-14	8638-8639	=	_	
45-15	8639-8643	7.54	_	
45-16	8644-8648	days	_	
45-17	8649-8650	±	_	
45-18	8650-8652	60	_	
45-19	8653-8660	minutes	_	
45-20	8660-8661	,	_	
45-21	8662-8664	SZ	_	
45-22	8664-8665	=	_	
45-23	8665-8669	7.84	_	
45-24	8670-8674	days	_	
45-25	8675-8676	±	_	
45-26	8676-8678	51	_	
45-27	8679-8686	minutes	_	
45-28	8686-8687	]	_	
45-29	8687-8688	.	_	

#Text=Time of day between visits was matched to take into account circadian rhythm.
46-1	8689-8693	Time	_	
46-2	8694-8696	of	_	
46-3	8697-8700	day	_	
46-4	8701-8708	between	_	
46-5	8709-8715	visits	_	
46-6	8716-8719	was	_	
46-7	8720-8727	matched	_	
46-8	8728-8730	to	_	
46-9	8731-8735	take	_	
46-10	8736-8740	into	_	
46-11	8741-8748	account	_	
46-12	8749-8758	circadian	_	
46-13	8759-8765	rhythm	_	
46-14	8765-8766	.	_	

#Text=Each visit began with a 10-minute rest task (referred to as Rest10) and ended with a 4-minute rest task (referred to as Rest4), see Figure 1.
47-1	8767-8771	Each	_	
47-2	8772-8777	visit	_	
47-3	8778-8783	began	_	
47-4	8784-8788	with	_	
47-5	8789-8790	a	_	
47-6	8791-8793	10	_	
47-7	8793-8794	-	_	
47-8	8794-8800	minute	_	
47-9	8801-8805	rest	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[22]	
47-10	8806-8810	task	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[22]	
47-11	8811-8812	(	_	
47-12	8812-8820	referred	_	
47-13	8821-8823	to	_	
47-14	8824-8826	as	_	
47-15	8827-8833	Rest10	_	
47-16	8833-8834	)	_	
47-17	8835-8838	and	_	
47-18	8839-8844	ended	_	
47-19	8845-8849	with	_	
47-20	8850-8851	a	_	
47-21	8852-8853	4	_	
47-22	8853-8854	-	_	
47-23	8854-8860	minute	_	
47-24	8861-8865	rest	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[23]	
47-25	8866-8870	task	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[23]	
47-26	8871-8872	(	_	
47-27	8872-8880	referred	_	
47-28	8881-8883	to	_	
47-29	8884-8886	as	_	
47-30	8887-8892	Rest4	_	
47-31	8892-8893	)	_	
47-32	8893-8894	,	_	
47-33	8895-8898	see	_	
47-34	8899-8905	Figure	_	
47-35	8906-8907	1	_	
47-36	8907-8908	.	_	

#Text=No responses were required from the participant; however, participants were instructed to attend the instructions for prompts to close their eyes or fixate on a white cross.
48-1	8909-8911	No	_	
48-2	8912-8921	responses	_	
48-3	8922-8926	were	_	
48-4	8927-8935	required	_	
48-5	8936-8940	from	_	
48-6	8941-8944	the	_	
48-7	8945-8956	participant	_	
48-8	8956-8957	;	_	
48-9	8958-8965	however	_	
48-10	8965-8966	,	_	
48-11	8967-8979	participants	_	
48-12	8980-8984	were	_	
48-13	8985-8995	instructed	_	
48-14	8996-8998	to	_	
48-15	8999-9005	attend	_	
48-16	9006-9009	the	_	
48-17	9010-9022	instructions	_	
48-18	9023-9026	for	_	
48-19	9027-9034	prompts	_	
48-20	9035-9037	to	_	
48-21	9038-9043	close	_	
48-22	9044-9049	their	_	
48-23	9050-9054	eyes	_	
48-24	9055-9057	or	_	
48-25	9058-9064	fixate	_	
48-26	9065-9067	on	_	
48-27	9068-9069	a	_	
48-28	9070-9075	white	_	
48-29	9076-9081	cross	_	
48-30	9081-9082	.	_	

#Text=Each task alternated between EC and EO.
49-1	9083-9087	Each	_	
49-2	9088-9092	task	_	
49-3	9093-9103	alternated	_	
49-4	9104-9111	between	_	
49-5	9112-9114	EC	_	
49-6	9115-9118	and	_	
49-7	9119-9121	EO	_	
49-8	9121-9122	.	_	

#Text=In total, resting-state activity was recorded 4 separate times with 14 minutes of EO and 14 minutes of EC.
50-1	9123-9125	In	_	
50-2	9126-9131	total	_	
50-3	9131-9132	,	_	
50-4	9133-9146	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[24]	
50-5	9147-9155	activity	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[24]	
50-6	9156-9159	was	_	
50-7	9160-9168	recorded	_	
50-8	9169-9170	4	_	
50-9	9171-9179	separate	_	
50-10	9180-9185	times	_	
50-11	9186-9190	with	_	
50-12	9191-9193	14	_	
50-13	9194-9201	minutes	_	
50-14	9202-9204	of	_	
50-15	9205-9207	EO	_	
50-16	9208-9211	and	_	
50-17	9212-9214	14	_	
50-18	9215-9222	minutes	_	
50-19	9223-9225	of	_	
50-20	9226-9228	EC	_	
50-21	9228-9229	.	_	

#Text=MEG Data Acquisition
#Text=MEG data were collected in a magnetically shielded room (Vacuumschmelze – Ak3B) at the Mind Research Network in Albuquerque, New Mexico using a 306-channel whole-head MEG system (Elekta Neuromag) with a sampling rate of 1000 Hz and an antialiasing filter with a passband of 0.1–330 Hz.
51-1	9230-9233	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography[25]	
51-2	9234-9238	Data	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography[25]	
51-3	9239-9250	Acquisition	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography[25]	
51-4	9251-9254	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography	
51-5	9255-9259	data	_	
51-6	9260-9264	were	_	
51-7	9265-9274	collected	_	
51-8	9275-9277	in	_	
51-9	9278-9279	a	_	
51-10	9280-9292	magnetically	_	
51-11	9293-9301	shielded	_	
51-12	9302-9306	room	_	
51-13	9307-9308	(	_	
51-14	9308-9322	Vacuumschmelze	_	
51-15	9323-9324	–	_	
51-16	9325-9329	Ak3B	_	
51-17	9329-9330	)	_	
51-18	9331-9333	at	_	
51-19	9334-9337	the	_	
51-20	9338-9342	Mind	_	
51-21	9343-9351	Research	_	
51-22	9352-9359	Network	_	
51-23	9360-9362	in	_	
51-24	9363-9374	Albuquerque	_	
51-25	9374-9375	,	_	
51-26	9376-9379	New	_	
51-27	9380-9386	Mexico	_	
51-28	9387-9392	using	_	
51-29	9393-9394	a	_	
51-30	9395-9398	306	_	
51-31	9398-9399	-	_	
51-32	9399-9406	channel	_	
51-33	9407-9417	whole-head	_	
51-34	9418-9421	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography	
51-35	9422-9428	system	_	
51-36	9429-9430	(	_	
51-37	9430-9436	Elekta	_	
51-38	9437-9445	Neuromag	_	
51-39	9445-9446	)	_	
51-40	9447-9451	with	_	
51-41	9452-9453	a	_	
51-42	9454-9462	sampling	_	
51-43	9463-9467	rate	_	
51-44	9468-9470	of	_	
51-45	9471-9475	1000	_	
51-46	9476-9478	Hz	_	
51-47	9479-9482	and	_	
51-48	9483-9485	an	_	
51-49	9486-9498	antialiasing	_	
51-50	9499-9505	filter	_	
51-51	9506-9510	with	_	
51-52	9511-9512	a	_	
51-53	9513-9521	passband	_	
51-54	9522-9524	of	_	
51-55	9525-9528	0.1	_	
51-56	9528-9529	–	_	
51-57	9529-9532	330	_	
51-58	9533-9535	Hz	_	
51-59	9535-9536	.	_	

#Text=Prior to data acquisition, four electromagnetic coils were placed on the participant’s mastoid bone and upper forehead, along with electro-oculogram and electrocardiogram channels.
52-1	9537-9542	Prior	_	
52-2	9543-9545	to	_	
52-3	9546-9550	data	_	
52-4	9551-9562	acquisition	_	
52-5	9562-9563	,	_	
52-6	9564-9568	four	_	
52-7	9569-9584	electromagnetic	_	
52-8	9585-9590	coils	_	
52-9	9591-9595	were	_	
52-10	9596-9602	placed	_	
52-11	9603-9605	on	_	
52-12	9606-9609	the	_	
52-13	9610-9621	participant	_	
52-14	9621-9622	’	_	
52-15	9622-9623	s	_	
52-16	9624-9631	mastoid	_	
52-17	9632-9636	bone	_	
52-18	9637-9640	and	_	
52-19	9641-9646	upper	_	
52-20	9647-9655	forehead	_	
52-21	9655-9656	,	_	
52-22	9657-9662	along	_	
52-23	9663-9667	with	_	
52-24	9668-9685	electro-oculogram	_	
52-25	9686-9689	and	_	
52-26	9690-9707	electrocardiogram	_	
52-27	9708-9716	channels	_	
52-28	9716-9717	.	_	

#Text=The location of the coils were registered to the nasion and preauricular points using three-dimensional digitization equipment (Polhemus FastTrack).
53-1	9718-9721	The	_	
53-2	9722-9730	location	_	
53-3	9731-9733	of	_	
53-4	9734-9737	the	_	
53-5	9738-9743	coils	_	
53-6	9744-9748	were	_	
53-7	9749-9759	registered	_	
53-8	9760-9762	to	_	
53-9	9763-9766	the	_	
53-10	9767-9773	nasion	_	
53-11	9774-9777	and	_	
53-12	9778-9790	preauricular	_	
53-13	9791-9797	points	_	
53-14	9798-9803	using	_	
53-15	9804-9821	three-dimensional	_	
53-16	9822-9834	digitization	_	
53-17	9835-9844	equipment	_	
53-18	9845-9846	(	_	
53-19	9846-9854	Polhemus	_	
53-20	9855-9864	FastTrack	_	
53-21	9864-9865	)	_	
53-22	9865-9866	.	_	

#Text=Participants sat upright in the MEG during the task.
54-1	9867-9879	Participants	_	
54-2	9880-9883	sat	_	
54-3	9884-9891	upright	_	
54-4	9892-9894	in	_	
54-5	9895-9898	the	_	
54-6	9899-9902	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography	
54-7	9903-9909	during	_	
54-8	9910-9913	the	_	
54-9	9914-9918	task	_	
54-10	9918-9919	.	_	

#Text=Continuous Head Position Indicator (cHPI) monitoring allowed for motion correction.
55-1	9920-9930	Continuous	_	
55-2	9931-9935	Head	_	
55-3	9936-9944	Position	_	
55-4	9945-9954	Indicator	_	
55-5	9955-9956	(	_	
55-6	9956-9960	cHPI	_	
55-7	9960-9961	)	_	
55-8	9962-9972	monitoring	_	
55-9	9973-9980	allowed	_	
55-10	9981-9984	for	_	
55-11	9985-9991	motion	_	
55-12	9992-10002	correction	_	
55-13	10002-10003	.	_	

#Text=Head position was checked between visits.
56-1	10004-10008	Head	_	
56-2	10009-10017	position	_	
56-3	10018-10021	was	_	
56-4	10022-10029	checked	_	
56-5	10030-10037	between	_	
56-6	10038-10044	visits	_	
56-7	10044-10045	.	_	

#Text=For the Rest10 task, average Euclidean distance between visits was 4.62 mm for HC and 6.06 mm for SZ.
57-1	10046-10049	For	_	
57-2	10050-10053	the	_	
57-3	10054-10060	Rest10	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[26]	
57-4	10061-10065	task	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[26]	
57-5	10065-10066	,	_	
57-6	10067-10074	average	_	
57-7	10075-10084	Euclidean	_	
57-8	10085-10093	distance	_	
57-9	10094-10101	between	_	
57-10	10102-10108	visits	_	
57-11	10109-10112	was	_	
57-12	10113-10117	4.62	_	
57-13	10118-10120	mm	_	
57-14	10121-10124	for	_	
57-15	10125-10127	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
57-16	10128-10131	and	_	
57-17	10132-10136	6.06	_	
57-18	10137-10139	mm	_	
57-19	10140-10143	for	_	
57-20	10144-10146	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
57-21	10146-10147	.	_	

#Text=For the Rest4 task, the distance was 4.90 mm for HC and 6.12 mm for SZ.
58-1	10148-10151	For	_	
58-2	10152-10155	the	_	
58-3	10156-10161	Rest4	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[27]	
58-4	10162-10166	task	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[27]	
58-5	10166-10167	,	_	
58-6	10168-10171	the	_	
58-7	10172-10180	distance	_	
58-8	10181-10184	was	_	
58-9	10185-10189	4.90	_	
58-10	10190-10192	mm	_	
58-11	10193-10196	for	_	
58-12	10197-10199	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
58-13	10200-10203	and	_	
58-14	10204-10208	6.12	_	
58-15	10209-10211	mm	_	
58-16	10212-10215	for	_	
58-17	10216-10218	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
58-18	10218-10219	.	_	

#Text=Head position consistency was similar between HC and SZ (all p’s>0.31).
59-1	10220-10224	Head	_	
59-2	10225-10233	position	_	
59-3	10234-10245	consistency	_	
59-4	10246-10249	was	_	
59-5	10250-10257	similar	_	
59-6	10258-10265	between	_	
59-7	10266-10268	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
59-8	10269-10272	and	_	
59-9	10273-10275	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
59-10	10276-10277	(	_	
59-11	10277-10280	all	_	
59-12	10281-10282	p	_	
59-13	10282-10283	’	_	
59-14	10283-10284	s	_	
59-15	10284-10285	>	_	
59-16	10285-10289	0.31	_	
59-17	10289-10290	)	_	
59-18	10290-10291	.	_	

#Text=Structural MRI Data Acquisition
#Text=Structural MRIs were obtained for mapping source locations.
60-1	10292-10302	Structural	_	
60-2	10303-10306	MRI	_	
60-3	10307-10311	Data	_	
60-4	10312-10323	Acquisition	_	
60-5	10324-10334	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[28]	
60-6	10335-10339	MRIs	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[28]	
60-7	10340-10344	were	_	
60-8	10345-10353	obtained	_	
60-9	10354-10357	for	_	
60-10	10358-10365	mapping	_	
60-11	10366-10372	source	_	
60-12	10373-10382	locations	_	
60-13	10382-10383	.	_	

#Text=Sagittal T1-weighted anatomical MR images were obtained using a Siemens TIM Trio 3 Tesla MRI system with a 32-channel head coil.
61-1	10384-10392	Sagittal	_	
61-2	10393-10395	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[29]	
61-3	10395-10396	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[29]	
61-4	10396-10404	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[29]	
61-5	10405-10415	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[30]	
61-6	10416-10418	MR	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[30]	
61-7	10419-10425	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[30]	
61-8	10426-10430	were	_	
61-9	10431-10439	obtained	_	
61-10	10440-10445	using	_	
61-11	10446-10447	a	_	
61-12	10448-10455	Siemens	_	
61-13	10456-10459	TIM	_	
61-14	10460-10464	Trio	_	
61-15	10465-10466	3	_	
61-16	10467-10472	Tesla	_	
61-17	10473-10476	MRI	_	
61-18	10477-10483	system	_	
61-19	10484-10488	with	_	
61-20	10489-10490	a	_	
61-21	10491-10493	32	_	
61-22	10493-10494	-	_	
61-23	10494-10501	channel	_	
61-24	10502-10506	head	_	
61-25	10507-10511	coil	_	
61-26	10511-10512	.	_	

#Text=Parameters of the multiecho 3D MPRAGE sequence were: TR/TE/TI = 2530/1.64, 3.5, 5.36, 7.22, 9.08/1200 ms, flip angle = 7°, field of view (FOV) = 256 mm x 256 mm, matrix = 256 × 256, 1 mm thick slice, 192 slices, GRAPPA acceleration = 2.
62-1	10513-10523	Parameters	_	
62-2	10524-10526	of	_	
62-3	10527-10530	the	_	
62-4	10531-10540	multiecho	_	
62-5	10541-10543	3D	_	
62-6	10544-10550	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[31]	
62-7	10551-10559	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[31]	
62-8	10560-10564	were	_	
62-9	10564-10565	:	_	
62-10	10566-10568	TR	_	
62-11	10568-10569	/	_	
62-12	10569-10571	TE	_	
62-13	10571-10572	/	_	
62-14	10572-10574	TI	_	
62-15	10575-10576	=	_	
62-16	10577-10581	2530	_	
62-17	10581-10582	/	_	
62-18	10582-10586	1.64	_	
62-19	10586-10587	,	_	
62-20	10588-10591	3.5	_	
62-21	10591-10592	,	_	
62-22	10593-10597	5.36	_	
62-23	10597-10598	,	_	
62-24	10599-10603	7.22	_	
62-25	10603-10604	,	_	
62-26	10605-10609	9.08	_	
62-27	10609-10610	/	_	
62-28	10610-10614	1200	_	
62-29	10615-10617	ms	_	
62-30	10617-10618	,	_	
62-31	10619-10623	flip	_	
62-32	10624-10629	angle	_	
62-33	10630-10631	=	_	
62-34	10632-10633	7	_	
62-35	10633-10634	°	_	
62-36	10634-10635	,	_	
62-37	10636-10641	field	_	
62-38	10642-10644	of	_	
62-39	10645-10649	view	_	
62-40	10650-10651	(	_	
62-41	10651-10654	FOV	_	
62-42	10654-10655	)	_	
62-43	10656-10657	=	_	
62-44	10658-10661	256	_	
62-45	10662-10664	mm	_	
62-46	10665-10666	x	_	
62-47	10667-10670	256	_	
62-48	10671-10673	mm	_	
62-49	10673-10674	,	_	
62-50	10675-10681	matrix	_	
62-51	10682-10683	=	_	
62-52	10684-10687	256	_	
62-53	10688-10689	×	_	
62-54	10690-10693	256	_	
62-55	10693-10694	,	_	
62-56	10695-10696	1	_	
62-57	10697-10699	mm	_	
62-58	10700-10705	thick	_	
62-59	10706-10711	slice	_	
62-60	10711-10712	,	_	
62-61	10713-10716	192	_	
62-62	10717-10723	slices	_	
62-63	10723-10724	,	_	
62-64	10725-10731	GRAPPA	_	
62-65	10732-10744	acceleration	_	
62-66	10745-10746	=	_	
62-67	10747-10748	2	_	
62-68	10748-10749	.	_	

#Text=MEG Data Preprocessing
#Text=Raw MEG data were filtered for noise and corrected for head motion with the Neuromag Max-Filter 2.2 software using the temporal extension of signal space separation (t-SSS) method with movement compensation.
63-1	10750-10753	MEG	_	
63-2	10754-10758	Data	_	
63-3	10759-10772	Preprocessing	_	
63-4	10773-10776	Raw	_	
63-5	10777-10780	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography	
63-6	10781-10785	data	_	
63-7	10786-10790	were	_	
63-8	10791-10799	filtered	_	
63-9	10800-10803	for	_	
63-10	10804-10809	noise	_	
63-11	10810-10813	and	_	
63-12	10814-10823	corrected	_	
63-13	10824-10827	for	_	
63-14	10828-10832	head	_	
63-15	10833-10839	motion	_	
63-16	10840-10844	with	_	
63-17	10845-10848	the	_	
63-18	10849-10857	Neuromag	_	
63-19	10858-10868	Max-Filter	_	
63-20	10869-10872	2.2	_	
63-21	10873-10881	software	_	
63-22	10882-10887	using	_	
63-23	10888-10891	the	_	
63-24	10892-10900	temporal	_	
63-25	10901-10910	extension	_	
63-26	10911-10913	of	_	
63-27	10914-10920	signal	_	
63-28	10921-10926	space	_	
63-29	10927-10937	separation	_	
63-30	10938-10939	(	_	
63-31	10939-10944	t-SSS	_	
63-32	10944-10945	)	_	
63-33	10946-10952	method	_	
63-34	10953-10957	with	_	
63-35	10958-10966	movement	_	
63-36	10967-10979	compensation	_	
63-37	10979-10980	.	_	

#Text=MEG data from each subject’s Visit 2 was transformed to Visit 1 head position using Maxfilter 2.2 MaxMove option to ensure equivalent sensor locations between visits.
64-1	10981-10984	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography	
64-2	10985-10989	data	_	
64-3	10990-10994	from	_	
64-4	10995-10999	each	_	
64-5	11000-11007	subject	_	
64-6	11007-11008	’	_	
64-7	11008-11009	s	_	
64-8	11010-11015	Visit	_	
64-9	11016-11017	2	_	
64-10	11018-11021	was	_	
64-11	11022-11033	transformed	_	
64-12	11034-11036	to	_	
64-13	11037-11042	Visit	_	
64-14	11043-11044	1	_	
64-15	11045-11049	head	_	
64-16	11050-11058	position	_	
64-17	11059-11064	using	_	
64-18	11065-11074	Maxfilter	_	
64-19	11075-11078	2.2	_	
64-20	11079-11086	MaxMove	_	
64-21	11087-11093	option	_	
64-22	11094-11096	to	_	
64-23	11097-11103	ensure	_	
64-24	11104-11114	equivalent	_	
64-25	11115-11121	sensor	_	
64-26	11122-11131	locations	_	
64-27	11132-11139	between	_	
64-28	11140-11146	visits	_	
64-29	11146-11147	.	_	

#Text=No downsampling of the data was implemented at the preprocessing stage.
65-1	11148-11150	No	_	
65-2	11151-11163	downsampling	_	
65-3	11164-11166	of	_	
65-4	11167-11170	the	_	
65-5	11171-11175	data	_	
65-6	11176-11179	was	_	
65-7	11180-11191	implemented	_	
65-8	11192-11194	at	_	
65-9	11195-11198	the	_	
65-10	11199-11212	preprocessing	_	
65-11	11213-11218	stage	_	
65-12	11218-11219	.	_	

#Text=Heartbeat and eye-blink artifacts were automatically detected and removed using signal space projection (SSP) in MNE software.
66-1	11220-11229	Heartbeat	_	
66-2	11230-11233	and	_	
66-3	11234-11243	eye-blink	_	
66-4	11244-11253	artifacts	_	
66-5	11254-11258	were	_	
66-6	11259-11272	automatically	_	
66-7	11273-11281	detected	_	
66-8	11282-11285	and	_	
66-9	11286-11293	removed	_	
66-10	11294-11299	using	_	
66-11	11300-11306	signal	_	
66-12	11307-11312	space	_	
66-13	11313-11323	projection	_	
66-14	11324-11325	(	_	
66-15	11325-11328	SSP	_	
66-16	11328-11329	)	_	
66-17	11330-11332	in	_	
66-18	11333-11336	MNE	_	
66-19	11337-11345	software	_	
66-20	11345-11346	.	_	

#Text=The continuous data were segmented into artifact-free 2 second epochs.
67-1	11347-11350	The	_	
67-2	11351-11361	continuous	_	
67-3	11362-11366	data	_	
67-4	11367-11371	were	_	
67-5	11372-11381	segmented	_	
67-6	11382-11386	into	_	
67-7	11387-11400	artifact-free	_	
67-8	11401-11402	2	_	
67-9	11403-11409	second	_	
67-10	11410-11416	epochs	_	
67-11	11416-11417	.	_	

#Text=Epochs in which the magnetic field exceeded 5 pT were rejected.
68-1	11418-11424	Epochs	_	
68-2	11425-11427	in	_	
68-3	11428-11433	which	_	
68-4	11434-11437	the	_	
68-5	11438-11446	magnetic	_	
68-6	11447-11452	field	_	
68-7	11453-11461	exceeded	_	
68-8	11462-11463	5	_	
68-9	11464-11466	pT	_	
68-10	11467-11471	were	_	
68-11	11472-11480	rejected	_	
68-12	11480-11481	.	_	

#Text=HC had 2.4% and SZ had 4.6% of all epochs rejected.
69-1	11482-11484	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
69-2	11485-11488	had	_	
69-3	11489-11493	2.4%	_	
69-4	11494-11497	and	_	
69-5	11498-11500	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
69-6	11501-11504	had	_	
69-7	11505-11509	4.6%	_	
69-8	11510-11512	of	_	
69-9	11513-11516	all	_	
69-10	11517-11523	epochs	_	
69-11	11524-11532	rejected	_	
69-12	11532-11533	.	_	

#Text=The total number of epochs used for further analysis included 401 EC, 402 EO epochs in HC, and 393 EC, 403 EO epochs in SZ.
70-1	11534-11537	The	_	
70-2	11538-11543	total	_	
70-3	11544-11550	number	_	
70-4	11551-11553	of	_	
70-5	11554-11560	epochs	_	
70-6	11561-11565	used	_	
70-7	11566-11569	for	_	
70-8	11570-11577	further	_	
70-9	11578-11586	analysis	_	
70-10	11587-11595	included	_	
70-11	11596-11599	401	_	
70-12	11600-11602	EC	_	
70-13	11602-11603	,	_	
70-14	11604-11607	402	_	
70-15	11608-11610	EO	_	
70-16	11611-11617	epochs	_	
70-17	11618-11620	in	_	
70-18	11621-11623	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
70-19	11623-11624	,	_	
70-20	11625-11628	and	_	
70-21	11629-11632	393	_	
70-22	11633-11635	EC	_	
70-23	11635-11636	,	_	
70-24	11637-11640	403	_	
70-25	11641-11643	EO	_	
70-26	11644-11650	epochs	_	
70-27	11651-11653	in	_	
70-28	11654-11656	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	
70-29	11656-11657	.	_	

#Text=The number of closed/open epochs did not differ between groups (all p’s>0.25).
71-1	11658-11661	The	_	
71-2	11662-11668	number	_	
71-3	11669-11671	of	_	
71-4	11672-11678	closed	_	
71-5	11678-11679	/	_	
71-6	11679-11683	open	_	
71-7	11684-11690	epochs	_	
71-8	11691-11694	did	_	
71-9	11695-11698	not	_	
71-10	11699-11705	differ	_	
71-11	11706-11713	between	_	
71-12	11714-11720	groups	_	
71-13	11721-11722	(	_	
71-14	11722-11725	all	_	
71-15	11726-11727	p	_	
71-16	11727-11728	’	_	
71-17	11728-11729	s	_	
71-18	11729-11730	>	_	
71-19	11730-11734	0.25	_	
71-20	11734-11735	)	_	
71-21	11735-11736	.	_	

#Text=MEG Spectral Analyses
#Text=For sensor analysis, we applied the summary spectral measures described in to simplify multi-channel MEG spectral data.
72-1	11737-11740	MEG	_	
72-2	11741-11749	Spectral	_	
72-3	11750-11758	Analyses	_	
72-4	11759-11762	For	_	
72-5	11763-11769	sensor	_	
72-6	11770-11778	analysis	_	
72-7	11778-11779	,	_	
72-8	11780-11782	we	_	
72-9	11783-11790	applied	_	
72-10	11791-11794	the	_	
72-11	11795-11802	summary	_	
72-12	11803-11811	spectral	_	
72-13	11812-11820	measures	_	
72-14	11821-11830	described	_	
72-15	11831-11833	in	_	
72-16	11834-11836	to	_	
72-17	11837-11845	simplify	_	
72-18	11846-11859	multi-channel	_	
72-19	11860-11863	MEG	http://maven.renci.org/NeuroBridge/neurobridge#Magnetoencephalography	
72-20	11864-11872	spectral	_	
72-21	11873-11877	data	_	
72-22	11877-11878	.	_	

#Text=Using only planar gradiometers, the sensor array was divided into left and right equivalent regions, see Figure 2.
73-1	11879-11884	Using	_	
73-2	11885-11889	only	_	
73-3	11890-11896	planar	_	
73-4	11897-11909	gradiometers	_	
73-5	11909-11910	,	_	
73-6	11911-11914	the	_	
73-7	11915-11921	sensor	_	
73-8	11922-11927	array	_	
73-9	11928-11931	was	_	
73-10	11932-11939	divided	_	
73-11	11940-11944	into	_	
73-12	11945-11949	left	_	
73-13	11950-11953	and	_	
73-14	11954-11959	right	_	
73-15	11960-11970	equivalent	_	
73-16	11971-11978	regions	_	
73-17	11978-11979	,	_	
73-18	11980-11983	see	_	
73-19	11984-11990	Figure	_	
73-20	11991-11992	2	_	
73-21	11992-11993	.	_	

#Text=Spectral power was estimated using Matlab’s FFT function with a window size of 2048 for the following frequency bands: Delta (1–4 Hz), Theta (5–8 Hz), Alpha (9–13 Hz), Beta (14–29 Hz), and Gamma (31–58 Hz).
74-1	11994-12002	Spectral	_	
74-2	12003-12008	power	_	
74-3	12009-12012	was	_	
74-4	12013-12022	estimated	_	
74-5	12023-12028	using	_	
74-6	12029-12035	Matlab	_	
74-7	12035-12036	’	_	
74-8	12036-12037	s	_	
74-9	12038-12041	FFT	_	
74-10	12042-12050	function	_	
74-11	12051-12055	with	_	
74-12	12056-12057	a	_	
74-13	12058-12064	window	_	
74-14	12065-12069	size	_	
74-15	12070-12072	of	_	
74-16	12073-12077	2048	_	
74-17	12078-12081	for	_	
74-18	12082-12085	the	_	
74-19	12086-12095	following	_	
74-20	12096-12105	frequency	_	
74-21	12106-12111	bands	_	
74-22	12111-12112	:	_	
74-23	12113-12118	Delta	_	
74-24	12119-12120	(	_	
74-25	12120-12121	1	_	
74-26	12121-12122	–	_	
74-27	12122-12123	4	_	
74-28	12124-12126	Hz	_	
74-29	12126-12127	)	_	
74-30	12127-12128	,	_	
74-31	12129-12134	Theta	_	
74-32	12135-12136	(	_	
74-33	12136-12137	5	_	
74-34	12137-12138	–	_	
74-35	12138-12139	8	_	
74-36	12140-12142	Hz	_	
74-37	12142-12143	)	_	
74-38	12143-12144	,	_	
74-39	12145-12150	Alpha	_	
74-40	12151-12152	(	_	
74-41	12152-12153	9	_	
74-42	12153-12154	–	_	
74-43	12154-12156	13	_	
74-44	12157-12159	Hz	_	
74-45	12159-12160	)	_	
74-46	12160-12161	,	_	
74-47	12162-12166	Beta	_	
74-48	12167-12168	(	_	
74-49	12168-12170	14	_	
74-50	12170-12171	–	_	
74-51	12171-12173	29	_	
74-52	12174-12176	Hz	_	
74-53	12176-12177	)	_	
74-54	12177-12178	,	_	
74-55	12179-12182	and	_	
74-56	12183-12188	Gamma	_	
74-57	12189-12190	(	_	
74-58	12190-12192	31	_	
74-59	12192-12193	–	_	
74-60	12193-12195	58	_	
74-61	12196-12198	Hz	_	
74-62	12198-12199	)	_	
74-63	12199-12200	.	_	

#Text=Spectral measures included: power, normalized power, half-power, Shannon Spectral Entropy (SSE), and alpha reactivity.
75-1	12201-12209	Spectral	_	
75-2	12210-12218	measures	_	
75-3	12219-12227	included	_	
75-4	12227-12228	:	_	
75-5	12229-12234	power	_	
75-6	12234-12235	,	_	
75-7	12236-12246	normalized	_	
75-8	12247-12252	power	_	
75-9	12252-12253	,	_	
75-10	12254-12264	half-power	_	
75-11	12264-12265	,	_	
75-12	12266-12273	Shannon	_	
75-13	12274-12282	Spectral	_	
75-14	12283-12290	Entropy	_	
75-15	12291-12292	(	_	
75-16	12292-12295	SSE	_	
75-17	12295-12296	)	_	
75-18	12296-12297	,	_	
75-19	12298-12301	and	_	
75-20	12302-12307	alpha	_	
75-21	12308-12318	reactivity	_	
75-22	12318-12319	.	_	

#Text=Normalized power was obtained by dividing the power within the frequency band by total 1–50 Hz power.
76-1	12320-12330	Normalized	_	
76-2	12331-12336	power	_	
76-3	12337-12340	was	_	
76-4	12341-12349	obtained	_	
76-5	12350-12352	by	_	
76-6	12353-12361	dividing	_	
76-7	12362-12365	the	_	
76-8	12366-12371	power	_	
76-9	12372-12378	within	_	
76-10	12379-12382	the	_	
76-11	12383-12392	frequency	_	
76-12	12393-12397	band	_	
76-13	12398-12400	by	_	
76-14	12401-12406	total	_	
76-15	12407-12408	1	_	
76-16	12408-12409	–	_	
76-17	12409-12411	50	_	
76-18	12412-12414	Hz	_	
76-19	12415-12420	power	_	
76-20	12420-12421	.	_	

#Text=Half power was defined as the midpoint frequency where half of the power is below/above for the 1–50 Hz range and indicates overall spectral power shifts from low to high frequencies.
77-1	12422-12426	Half	_	
77-2	12427-12432	power	_	
77-3	12433-12436	was	_	
77-4	12437-12444	defined	_	
77-5	12445-12447	as	_	
77-6	12448-12451	the	_	
77-7	12452-12460	midpoint	_	
77-8	12461-12470	frequency	_	
77-9	12471-12476	where	_	
77-10	12477-12481	half	_	
77-11	12482-12484	of	_	
77-12	12485-12488	the	_	
77-13	12489-12494	power	_	
77-14	12495-12497	is	_	
77-15	12498-12503	below	_	
77-16	12503-12504	/	_	
77-17	12504-12509	above	_	
77-18	12510-12513	for	_	
77-19	12514-12517	the	_	
77-20	12518-12519	1	_	
77-21	12519-12520	–	_	
77-22	12520-12522	50	_	
77-23	12523-12525	Hz	_	
77-24	12526-12531	range	_	
77-25	12532-12535	and	_	
77-26	12536-12545	indicates	_	
77-27	12546-12553	overall	_	
77-28	12554-12562	spectral	_	
77-29	12563-12568	power	_	
77-30	12569-12575	shifts	_	
77-31	12576-12580	from	_	
77-32	12581-12584	low	_	
77-33	12585-12587	to	_	
77-34	12588-12592	high	_	
77-35	12593-12604	frequencies	_	
77-36	12604-12605	.	_	

#Text=Alpha reactivity was calculated using normalized spectral power values with the following: (EC-EO)/EO.
78-1	12606-12611	Alpha	_	
78-2	12612-12622	reactivity	_	
78-3	12623-12626	was	_	
78-4	12627-12637	calculated	_	
78-5	12638-12643	using	_	
78-6	12644-12654	normalized	_	
78-7	12655-12663	spectral	_	
78-8	12664-12669	power	_	
78-9	12670-12676	values	_	
78-10	12677-12681	with	_	
78-11	12682-12685	the	_	
78-12	12686-12695	following	_	
78-13	12695-12696	:	_	
78-14	12697-12698	(	_	
78-15	12698-12703	EC-EO	_	
78-16	12703-12704	)	_	
78-17	12704-12705	/	_	
78-18	12705-12707	EO	_	
78-19	12707-12708	.	_	

#Text=Global measures were the average of all regions and gradiometers.
79-1	12709-12715	Global	_	
79-2	12716-12724	measures	_	
79-3	12725-12729	were	_	
79-4	12730-12733	the	_	
79-5	12734-12741	average	_	
79-6	12742-12744	of	_	
79-7	12745-12748	all	_	
79-8	12749-12756	regions	_	
79-9	12757-12760	and	_	
79-10	12761-12773	gradiometers	_	
79-11	12773-12774	.	_	

#Text=For source analysis, the cortical surface of each participant was reconstructed from T1-weighted MRI files using FreeSurfer with a repeatedly subdivided octahedron as the spatial subsampling method, creating 4,098 locations per hemisphere with a source space of 4.9 mm.
80-1	12775-12778	For	_	
80-2	12779-12785	source	_	
80-3	12786-12794	analysis	_	
80-4	12794-12795	,	_	
80-5	12796-12799	the	_	
80-6	12800-12808	cortical	_	
80-7	12809-12816	surface	_	
80-8	12817-12819	of	_	
80-9	12820-12824	each	_	
80-10	12825-12836	participant	_	
80-11	12837-12840	was	_	
80-12	12841-12854	reconstructed	_	
80-13	12855-12859	from	_	
80-14	12860-12862	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[32]	
80-15	12862-12863	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[32]	
80-16	12863-12871	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[32]	
80-17	12872-12875	MRI	_	
80-18	12876-12881	files	_	
80-19	12882-12887	using	_	
80-20	12888-12898	FreeSurfer	_	
80-21	12899-12903	with	_	
80-22	12904-12905	a	_	
80-23	12906-12916	repeatedly	_	
80-24	12917-12927	subdivided	_	
80-25	12928-12938	octahedron	_	
80-26	12939-12941	as	_	
80-27	12942-12945	the	_	
80-28	12946-12953	spatial	_	
80-29	12954-12965	subsampling	_	
80-30	12966-12972	method	_	
80-31	12972-12973	,	_	
80-32	12974-12982	creating	_	
80-33	12983-12988	4,098	_	
80-34	12989-12998	locations	_	
80-35	12999-13002	per	_	
80-36	13003-13013	hemisphere	_	
80-37	13014-13018	with	_	
80-38	13019-13020	a	_	
80-39	13021-13027	source	_	
80-40	13028-13033	space	_	
80-41	13034-13036	of	_	
80-42	13037-13040	4.9	_	
80-43	13041-13043	mm	_	
80-44	13043-13044	.	_	

#Text=Source analysis was performed with MNE software using an anatomically constrained linear estimation inverse model known as dynamic statistical parametric mapping (dSPM).
81-1	13045-13051	Source	_	
81-2	13052-13060	analysis	_	
81-3	13061-13064	was	_	
81-4	13065-13074	performed	_	
81-5	13075-13079	with	_	
81-6	13080-13083	MNE	_	
81-7	13084-13092	software	_	
81-8	13093-13098	using	_	
81-9	13099-13101	an	_	
81-10	13102-13114	anatomically	_	
81-11	13115-13126	constrained	_	
81-12	13127-13133	linear	_	
81-13	13134-13144	estimation	_	
81-14	13145-13152	inverse	_	
81-15	13153-13158	model	_	
81-16	13159-13164	known	_	
81-17	13165-13167	as	_	
81-18	13168-13175	dynamic	_	
81-19	13176-13187	statistical	_	
81-20	13188-13198	parametric	_	
81-21	13199-13206	mapping	_	
81-22	13207-13208	(	_	
81-23	13208-13212	dSPM	_	
81-24	13212-13213	)	_	
81-25	13213-13214	.	_	

#Text=The regularization parameter corresponded with a signal-to-noise ratio of 3.
82-1	13215-13218	The	_	
82-2	13219-13233	regularization	_	
82-3	13234-13243	parameter	_	
82-4	13244-13256	corresponded	_	
82-5	13257-13261	with	_	
82-6	13262-13263	a	_	
82-7	13264-13279	signal-to-noise	_	
82-8	13280-13285	ratio	_	
82-9	13286-13288	of	_	
82-10	13289-13290	3	_	
82-11	13290-13291	.	_	

#Text=Source orientation had a loose constraint of 0.2.
83-1	13292-13298	Source	_	
83-2	13299-13310	orientation	_	
83-3	13311-13314	had	_	
83-4	13315-13316	a	_	
83-5	13317-13322	loose	_	
83-6	13323-13333	constraint	_	
83-7	13334-13336	of	_	
83-8	13337-13340	0.2	_	
83-9	13340-13341	.	_	

#Text=The forward solution was calculated with a single layer (inner skull) boundary element method.
84-1	13342-13345	The	_	
84-2	13346-13353	forward	_	
84-3	13354-13362	solution	_	
84-4	13363-13366	was	_	
84-5	13367-13377	calculated	_	
84-6	13378-13382	with	_	
84-7	13383-13384	a	_	
84-8	13385-13391	single	_	
84-9	13392-13397	layer	_	
84-10	13398-13399	(	_	
84-11	13399-13404	inner	_	
84-12	13405-13410	skull	_	
84-13	13410-13411	)	_	
84-14	13412-13420	boundary	_	
84-15	13421-13428	element	_	
84-16	13429-13435	method	_	
84-17	13435-13436	.	_	

#Text=The dSPM inverse model identified where the estimated current at each cortical surface vertex differed significantly from baseline noise (empty room data).
85-1	13437-13440	The	_	
85-2	13441-13445	dSPM	_	
85-3	13446-13453	inverse	_	
85-4	13454-13459	model	_	
85-5	13460-13470	identified	_	
85-6	13471-13476	where	_	
85-7	13477-13480	the	_	
85-8	13481-13490	estimated	_	
85-9	13491-13498	current	_	
85-10	13499-13501	at	_	
85-11	13502-13506	each	_	
85-12	13507-13515	cortical	_	
85-13	13516-13523	surface	_	
85-14	13524-13530	vertex	_	
85-15	13531-13539	differed	_	
85-16	13540-13553	significantly	_	
85-17	13554-13558	from	_	
85-18	13559-13567	baseline	_	
85-19	13568-13573	noise	_	
85-20	13574-13575	(	_	
85-21	13575-13580	empty	_	
85-22	13581-13585	room	_	
85-23	13586-13590	data	_	
85-24	13590-13591	)	_	
85-25	13591-13592	.	_	

#Text=Power spectral density (PSD) measures were computed from epochs using a multi-taper method with Discrete Prolate Spheroidal Sequence (DPSS) windows for each frequency band and region, using 7 tapers at 4 Hz and regions of interest based on the FreeSurfer DKT atlas.
86-1	13593-13598	Power	_	
86-2	13599-13607	spectral	_	
86-3	13608-13615	density	_	
86-4	13616-13617	(	_	
86-5	13617-13620	PSD	_	
86-6	13620-13621	)	_	
86-7	13622-13630	measures	_	
86-8	13631-13635	were	_	
86-9	13636-13644	computed	_	
86-10	13645-13649	from	_	
86-11	13650-13656	epochs	_	
86-12	13657-13662	using	_	
86-13	13663-13664	a	_	
86-14	13665-13676	multi-taper	_	
86-15	13677-13683	method	_	
86-16	13684-13688	with	_	
86-17	13689-13697	Discrete	_	
86-18	13698-13705	Prolate	_	
86-19	13706-13716	Spheroidal	_	
86-20	13717-13725	Sequence	_	
86-21	13726-13727	(	_	
86-22	13727-13731	DPSS	_	
86-23	13731-13732	)	_	
86-24	13733-13740	windows	_	
86-25	13741-13744	for	_	
86-26	13745-13749	each	_	
86-27	13750-13759	frequency	_	
86-28	13760-13764	band	_	
86-29	13765-13768	and	_	
86-30	13769-13775	region	_	
86-31	13775-13776	,	_	
86-32	13777-13782	using	_	
86-33	13783-13784	7	_	
86-34	13785-13791	tapers	_	
86-35	13792-13794	at	_	
86-36	13795-13796	4	_	
86-37	13797-13799	Hz	_	
86-38	13800-13803	and	_	
86-39	13804-13811	regions	_	
86-40	13812-13814	of	_	
86-41	13815-13823	interest	_	
86-42	13824-13829	based	_	
86-43	13830-13832	on	_	
86-44	13833-13836	the	_	
86-45	13837-13847	FreeSurfer	_	
86-46	13848-13851	DKT	_	
86-47	13852-13857	atlas	_	
86-48	13857-13858	.	_	

#Text=PSD represents the average spectral power derived from each voxel time series for each regional label.
87-1	13859-13862	PSD	_	
87-2	13863-13873	represents	_	
87-3	13874-13877	the	_	
87-4	13878-13885	average	_	
87-5	13886-13894	spectral	_	
87-6	13895-13900	power	_	
87-7	13901-13908	derived	_	
87-8	13909-13913	from	_	
87-9	13914-13918	each	_	
87-10	13919-13924	voxel	_	
87-11	13925-13929	time	_	
87-12	13930-13936	series	_	
87-13	13937-13940	for	_	
87-14	13941-13945	each	_	
87-15	13946-13954	regional	_	
87-16	13955-13960	label	_	
87-17	13960-13961	.	_	

#Text=Global measures were data from all regional labels averaged.
88-1	13962-13968	Global	_	
88-2	13969-13977	measures	_	
88-3	13978-13982	were	_	
88-4	13983-13987	data	_	
88-5	13988-13992	from	_	
88-6	13993-13996	all	_	
88-7	13997-14005	regional	_	
88-8	14006-14012	labels	_	
88-9	14013-14021	averaged	_	
88-10	14021-14022	.	_	

#Text=Normalized power was obtained by dividing the power within frequency band by the total 1–58 Hz power.
89-1	14023-14033	Normalized	_	
89-2	14034-14039	power	_	
89-3	14040-14043	was	_	
89-4	14044-14052	obtained	_	
89-5	14053-14055	by	_	
89-6	14056-14064	dividing	_	
89-7	14065-14068	the	_	
89-8	14069-14074	power	_	
89-9	14075-14081	within	_	
89-10	14082-14091	frequency	_	
89-11	14092-14096	band	_	
89-12	14097-14099	by	_	
89-13	14100-14103	the	_	
89-14	14104-14109	total	_	
89-15	14110-14111	1	_	
89-16	14111-14112	–	_	
89-17	14112-14114	58	_	
89-18	14115-14117	Hz	_	
89-19	14118-14123	power	_	
89-20	14123-14124	.	_	

#Text=Functional network connectivity was estimated using a debiased estimator of the squared weighted phase lag index (wPLI-debiased).
90-1	14125-14135	Functional	_	
90-2	14136-14143	network	_	
90-3	14144-14156	connectivity	_	
90-4	14157-14160	was	_	
90-5	14161-14170	estimated	_	
90-6	14171-14176	using	_	
90-7	14177-14178	a	_	
90-8	14179-14187	debiased	_	
90-9	14188-14197	estimator	_	
90-10	14198-14200	of	_	
90-11	14201-14204	the	_	
90-12	14205-14212	squared	_	
90-13	14213-14221	weighted	_	
90-14	14222-14227	phase	_	
90-15	14228-14231	lag	_	
90-16	14232-14237	index	_	
90-17	14238-14239	(	_	
90-18	14239-14252	wPLI-debiased	_	
90-19	14252-14253	)	_	
90-20	14253-14254	.	_	

#Text=The FNC measure, wPLI-debiased, detects true changes in phase-synchronization, while reducing the influence of common noise sources, changes in phase of coherency, and avoids spuriously increases by volume-conduction.
91-1	14255-14258	The	_	
91-2	14259-14262	FNC	_	
91-3	14263-14270	measure	_	
91-4	14270-14271	,	_	
91-5	14272-14285	wPLI-debiased	_	
91-6	14285-14286	,	_	
91-7	14287-14294	detects	_	
91-8	14295-14299	true	_	
91-9	14300-14307	changes	_	
91-10	14308-14310	in	_	
91-11	14311-14332	phase-synchronization	_	
91-12	14332-14333	,	_	
91-13	14334-14339	while	_	
91-14	14340-14348	reducing	_	
91-15	14349-14352	the	_	
91-16	14353-14362	influence	_	
91-17	14363-14365	of	_	
91-18	14366-14372	common	_	
91-19	14373-14378	noise	_	
91-20	14379-14386	sources	_	
91-21	14386-14387	,	_	
91-22	14388-14395	changes	_	
91-23	14396-14398	in	_	
91-24	14399-14404	phase	_	
91-25	14405-14407	of	_	
91-26	14408-14417	coherency	_	
91-27	14417-14418	,	_	
91-28	14419-14422	and	_	
91-29	14423-14429	avoids	_	
91-30	14430-14440	spuriously	_	
91-31	14441-14450	increases	_	
91-32	14451-14453	by	_	
91-33	14454-14471	volume-conduction	_	
91-34	14471-14472	.	_	

#Text=It estimates the extent of observed phase leads and lags by the magnitude of the imaginary component of the cross-spectrum.
92-1	14473-14475	It	_	
92-2	14476-14485	estimates	_	
92-3	14486-14489	the	_	
92-4	14490-14496	extent	_	
92-5	14497-14499	of	_	
92-6	14500-14508	observed	_	
92-7	14509-14514	phase	_	
92-8	14515-14520	leads	_	
92-9	14521-14524	and	_	
92-10	14525-14529	lags	_	
92-11	14530-14532	by	_	
92-12	14533-14536	the	_	
92-13	14537-14546	magnitude	_	
92-14	14547-14549	of	_	
92-15	14550-14553	the	_	
92-16	14554-14563	imaginary	_	
92-17	14564-14573	component	_	
92-18	14574-14576	of	_	
92-19	14577-14580	the	_	
92-20	14581-14595	cross-spectrum	_	
92-21	14595-14596	.	_	

#Text=All data were exported to MATLAB (2018a, MathWorks) and run through custom scripts.
93-1	14597-14600	All	_	
93-2	14601-14605	data	_	
93-3	14606-14610	were	_	
93-4	14611-14619	exported	_	
93-5	14620-14622	to	_	
93-6	14623-14629	MATLAB	_	
93-7	14630-14631	(	_	
93-8	14631-14636	2018a	_	
93-9	14636-14637	,	_	
93-10	14638-14647	MathWorks	_	
93-11	14647-14648	)	_	
93-12	14649-14652	and	_	
93-13	14653-14656	run	_	
93-14	14657-14664	through	_	
93-15	14665-14671	custom	_	
93-16	14672-14679	scripts	_	
93-17	14679-14680	.	_	

#Text=Intraclass Correlation (ICC)
#Text=ICC estimates and their 95% confidence intervals were calculated in SPSS to assess the between and within-subject variability using a two-way mixed effects model with absolute agreement, single measurement criteria, also known as ICC (3,1) model.
94-1	14681-14691	Intraclass	_	
94-2	14692-14703	Correlation	_	
94-3	14704-14705	(	_	
94-4	14705-14708	ICC	_	
94-5	14708-14709	)	_	
94-6	14710-14713	ICC	_	
94-7	14714-14723	estimates	_	
94-8	14724-14727	and	_	
94-9	14728-14733	their	_	
94-10	14734-14737	95%	_	
94-11	14738-14748	confidence	_	
94-12	14749-14758	intervals	_	
94-13	14759-14763	were	_	
94-14	14764-14774	calculated	_	
94-15	14775-14777	in	_	
94-16	14778-14782	SPSS	_	
94-17	14783-14785	to	_	
94-18	14786-14792	assess	_	
94-19	14793-14796	the	_	
94-20	14797-14804	between	_	
94-21	14805-14808	and	_	
94-22	14809-14823	within-subject	_	
94-23	14824-14835	variability	_	
94-24	14836-14841	using	_	
94-25	14842-14843	a	_	
94-26	14844-14851	two-way	_	
94-27	14852-14857	mixed	_	
94-28	14858-14865	effects	_	
94-29	14866-14871	model	_	
94-30	14872-14876	with	_	
94-31	14877-14885	absolute	_	
94-32	14886-14895	agreement	_	
94-33	14895-14896	,	_	
94-34	14897-14903	single	_	
94-35	14904-14915	measurement	_	
94-36	14916-14924	criteria	_	
94-37	14924-14925	,	_	
94-38	14926-14930	also	_	
94-39	14931-14936	known	_	
94-40	14937-14939	as	_	
94-41	14940-14943	ICC	_	
94-42	14944-14945	(	_	
94-43	14945-14948	3,1	_	
94-44	14948-14949	)	_	
94-45	14950-14955	model	_	
94-46	14955-14956	.	_	

#Text=ICCs were calculated for multiple rest iterations: for each visit (across one hour), for each task (across one week) and for all runs.
95-1	14957-14961	ICCs	_	
95-2	14962-14966	were	_	
95-3	14967-14977	calculated	_	
95-4	14978-14981	for	_	
95-5	14982-14990	multiple	_	
95-6	14991-14995	rest	_	
95-7	14996-15006	iterations	_	
95-8	15006-15007	:	_	
95-9	15008-15011	for	_	
95-10	15012-15016	each	_	
95-11	15017-15022	visit	_	
95-12	15023-15024	(	_	
95-13	15024-15030	across	_	
95-14	15031-15034	one	_	
95-15	15035-15039	hour	_	
95-16	15039-15040	)	_	
95-17	15040-15041	,	_	
95-18	15042-15045	for	_	
95-19	15046-15050	each	_	
95-20	15051-15055	task	_	
95-21	15056-15057	(	_	
95-22	15057-15063	across	_	
95-23	15064-15067	one	_	
95-24	15068-15072	week	_	
95-25	15072-15073	)	_	
95-26	15074-15077	and	_	
95-27	15078-15081	for	_	
95-28	15082-15085	all	_	
95-29	15086-15090	runs	_	
95-30	15090-15091	.	_	

#Text=ICCs ranged from 0 to 1 (negative values scored as zero) with higher values indicating better reliability.
96-1	15092-15096	ICCs	_	
96-2	15097-15103	ranged	_	
96-3	15104-15108	from	_	
96-4	15109-15110	0	_	
96-5	15111-15113	to	_	
96-6	15114-15115	1	_	
96-7	15116-15117	(	_	
96-8	15117-15125	negative	_	
96-9	15126-15132	values	_	
96-10	15133-15139	scored	_	
96-11	15140-15142	as	_	
96-12	15143-15147	zero	_	
96-13	15147-15148	)	_	
96-14	15149-15153	with	_	
96-15	15154-15160	higher	_	
96-16	15161-15167	values	_	
96-17	15168-15178	indicating	_	
96-18	15179-15185	better	_	
96-19	15186-15197	reliability	_	
96-20	15197-15198	.	_	

#Text=Following the guidelines of we defined ICCs as: excellent reliability >0.75, good reliability 0.75–0.60, fair reliability 0.59–0.40, and poor reliability <0.40.
97-1	15199-15208	Following	_	
97-2	15209-15212	the	_	
97-3	15213-15223	guidelines	_	
97-4	15224-15226	of	_	
97-5	15227-15229	we	_	
97-6	15230-15237	defined	_	
97-7	15238-15242	ICCs	_	
97-8	15243-15245	as	_	
97-9	15245-15246	:	_	
97-10	15247-15256	excellent	_	
97-11	15257-15268	reliability	_	
97-12	15269-15270	>	_	
97-13	15270-15274	0.75	_	
97-14	15274-15275	,	_	
97-15	15276-15280	good	_	
97-16	15281-15292	reliability	_	
97-17	15293-15297	0.75	_	
97-18	15297-15298	–	_	
97-19	15298-15302	0.60	_	
97-20	15302-15303	,	_	
97-21	15304-15308	fair	_	
97-22	15309-15320	reliability	_	
97-23	15321-15325	0.59	_	
97-24	15325-15326	–	_	
97-25	15326-15330	0.40	_	
97-26	15330-15331	,	_	
97-27	15332-15335	and	_	
97-28	15336-15340	poor	_	
97-29	15341-15352	reliability	_	
97-30	15353-15354	<	_	
97-31	15354-15358	0.40	_	
97-32	15358-15359	.	_	

#Text=Statistical Analysis
#Text=All statistics were performed using SPSS (version 25 for Macintosh).
98-1	15360-15371	Statistical	_	
98-2	15372-15380	Analysis	_	
98-3	15381-15384	All	_	
98-4	15385-15395	statistics	_	
98-5	15396-15400	were	_	
98-6	15401-15410	performed	_	
98-7	15411-15416	using	_	
98-8	15417-15421	SPSS	_	
98-9	15422-15423	(	_	
98-10	15423-15430	version	_	
98-11	15431-15433	25	_	
98-12	15434-15437	for	_	
98-13	15438-15447	Macintosh	_	
98-14	15447-15448	)	_	
98-15	15448-15449	.	_	

#Text=Mixed Effect Repeated Measures-Analysis of Variance (RM-ANOVAs) had statistical thresholds set at p<0.05.
99-1	15450-15455	Mixed	_	
99-2	15456-15462	Effect	_	
99-3	15463-15471	Repeated	_	
99-4	15472-15489	Measures-Analysis	_	
99-5	15490-15492	of	_	
99-6	15493-15501	Variance	_	
99-7	15502-15503	(	_	
99-8	15503-15512	RM-ANOVAs	_	
99-9	15512-15513	)	_	
99-10	15514-15517	had	_	
99-11	15518-15529	statistical	_	
99-12	15530-15540	thresholds	_	
99-13	15541-15544	set	_	
99-14	15545-15547	at	_	
99-15	15548-15549	p	_	
99-16	15549-15550	<	_	
99-17	15550-15554	0.05	_	
99-18	15554-15555	.	_	

#Text=Greenhouse-Geisser corrections were made for sphericity violations.
100-1	15556-15574	Greenhouse-Geisser	_	
100-2	15575-15586	corrections	_	
100-3	15587-15591	were	_	
100-4	15592-15596	made	_	
100-5	15597-15600	for	_	
100-6	15601-15611	sphericity	_	
100-7	15612-15622	violations	_	
100-8	15622-15623	.	_	

#Text=The between-subject factor was Group (HC,SZ), within-subject factors included Hemisphere (Left, Right), Resting-State (EO, EC), and/or Region [Superior Parietal (SupPar), Inferior Parietal (InfPar), Precuneus] depending on measure explored.
101-1	15624-15627	The	_	
101-2	15628-15643	between-subject	_	
101-3	15644-15650	factor	_	
101-4	15651-15654	was	_	
101-5	15655-15660	Group	_	
101-6	15661-15662	(	_	
101-7	15662-15664	HC	_	
101-8	15664-15665	,	_	
101-9	15665-15667	SZ	_	
101-10	15667-15668	)	_	
101-11	15668-15669	,	_	
101-12	15670-15684	within-subject	_	
101-13	15685-15692	factors	_	
101-14	15693-15701	included	_	
101-15	15702-15712	Hemisphere	_	
101-16	15713-15714	(	_	
101-17	15714-15718	Left	_	
101-18	15718-15719	,	_	
101-19	15720-15725	Right	_	
101-20	15725-15726	)	_	
101-21	15726-15727	,	_	
101-22	15728-15741	Resting-State	_	
101-23	15742-15743	(	_	
101-24	15743-15745	EO	_	
101-25	15745-15746	,	_	
101-26	15747-15749	EC	_	
101-27	15749-15750	)	_	
101-28	15750-15751	,	_	
101-29	15752-15755	and	_	
101-30	15755-15756	/	_	
101-31	15756-15758	or	_	
101-32	15759-15765	Region	_	
101-33	15766-15767	[	_	
101-34	15767-15775	Superior	_	
101-35	15776-15784	Parietal	_	
101-36	15785-15786	(	_	
101-37	15786-15792	SupPar	_	
101-38	15792-15793	)	_	
101-39	15793-15794	,	_	
101-40	15795-15803	Inferior	_	
101-41	15804-15812	Parietal	_	
101-42	15813-15814	(	_	
101-43	15814-15820	InfPar	_	
101-44	15820-15821	)	_	
101-45	15821-15822	,	_	
101-46	15823-15832	Precuneus	_	
101-47	15832-15833	]	_	
101-48	15834-15843	depending	_	
101-49	15844-15846	on	_	
101-50	15847-15854	measure	_	
101-51	15855-15863	explored	_	
101-52	15863-15864	.	_	

#Text=Significant interactions were followed-up with separate one-way ANOVAs, or t-tests on the factors of interest with familywise multiple comparisons correction using false discovery rate (FDR) correction with q=0.05.
102-1	15865-15876	Significant	_	
102-2	15877-15889	interactions	_	
102-3	15890-15894	were	_	
102-4	15895-15906	followed-up	_	
102-5	15907-15911	with	_	
102-6	15912-15920	separate	_	
102-7	15921-15928	one-way	_	
102-8	15929-15935	ANOVAs	_	
102-9	15935-15936	,	_	
102-10	15937-15939	or	_	
102-11	15940-15947	t-tests	_	
102-12	15948-15950	on	_	
102-13	15951-15954	the	_	
102-14	15955-15962	factors	_	
102-15	15963-15965	of	_	
102-16	15966-15974	interest	_	
102-17	15975-15979	with	_	
102-18	15980-15990	familywise	_	
102-19	15991-15999	multiple	_	
102-20	16000-16011	comparisons	_	
102-21	16012-16022	correction	_	
102-22	16023-16028	using	_	
102-23	16029-16034	false	_	
102-24	16035-16044	discovery	_	
102-25	16045-16049	rate	_	
102-26	16050-16051	(	_	
102-27	16051-16054	FDR	_	
102-28	16054-16055	)	_	
102-29	16056-16066	correction	_	
102-30	16067-16071	with	_	
102-31	16072-16073	q	_	
102-32	16073-16074	=	_	
102-33	16074-16078	0.05	_	
102-34	16078-16079	.	_	

#Text=Results
#Text=Reliability of Global Spectral Measures
#Text=Global MEG spectral measures had good to excellent test-retest reliability in each frequency band, resting-state and participant group at the sensor and source level, Figure 3 and supplementary Table S1.
103-1	16080-16087	Results	_	
103-2	16088-16099	Reliability	_	
103-3	16100-16102	of	_	
103-4	16103-16109	Global	_	
103-5	16110-16118	Spectral	_	
103-6	16119-16127	Measures	_	
103-7	16128-16134	Global	_	
103-8	16135-16138	MEG	_	
103-9	16139-16147	spectral	_	
103-10	16148-16156	measures	_	
103-11	16157-16160	had	_	
103-12	16161-16165	good	_	
103-13	16166-16168	to	_	
103-14	16169-16178	excellent	_	
103-15	16179-16190	test-retest	_	
103-16	16191-16202	reliability	_	
103-17	16203-16205	in	_	
103-18	16206-16210	each	_	
103-19	16211-16220	frequency	_	
103-20	16221-16225	band	_	
103-21	16225-16226	,	_	
103-22	16227-16240	resting-state	_	
103-23	16241-16244	and	_	
103-24	16245-16256	participant	_	
103-25	16257-16262	group	_	
103-26	16263-16265	at	_	
103-27	16266-16269	the	_	
103-28	16270-16276	sensor	_	
103-29	16277-16280	and	_	
103-30	16281-16287	source	_	
103-31	16288-16293	level	_	
103-32	16293-16294	,	_	
103-33	16295-16301	Figure	_	
103-34	16302-16303	3	_	
103-35	16304-16307	and	_	
103-36	16308-16321	supplementary	_	
103-37	16322-16327	Table	_	
103-38	16328-16330	S1	_	
103-39	16330-16331	.	_	

#Text=To summarize the group means reported in Figure 3, per condition group averages are reported below for descriptive purposes.
104-1	16332-16334	To	_	
104-2	16335-16344	summarize	_	
104-3	16345-16348	the	_	
104-4	16349-16354	group	_	
104-5	16355-16360	means	_	
104-6	16361-16369	reported	_	
104-7	16370-16372	in	_	
104-8	16373-16379	Figure	_	
104-9	16380-16381	3	_	
104-10	16381-16382	,	_	
104-11	16383-16386	per	_	
104-12	16387-16396	condition	_	
104-13	16397-16402	group	_	
104-14	16403-16411	averages	_	
104-15	16412-16415	are	_	
104-16	16416-16424	reported	_	
104-17	16425-16430	below	_	
104-18	16431-16434	for	_	
104-19	16435-16446	descriptive	_	
104-20	16447-16455	purposes	_	
104-21	16455-16456	.	_	

#Text=HC had excellent reliability across one hour in all frequency bands (ICCAvg=0.89) and across one week in theta-gamma bands (ICCAvg=0.87) with the exception of good reliability in delta band across one week (ICCAvg=0.67).
105-1	16457-16459	HC	_	
105-2	16460-16463	had	_	
105-3	16464-16473	excellent	_	
105-4	16474-16485	reliability	_	
105-5	16486-16492	across	_	
105-6	16493-16496	one	_	
105-7	16497-16501	hour	_	
105-8	16502-16504	in	_	
105-9	16505-16508	all	_	
105-10	16509-16518	frequency	_	
105-11	16519-16524	bands	_	
105-12	16525-16526	(	_	
105-13	16526-16532	ICCAvg	_	
105-14	16532-16533	=	_	
105-15	16533-16537	0.89	_	
105-16	16537-16538	)	_	
105-17	16539-16542	and	_	
105-18	16543-16549	across	_	
105-19	16550-16553	one	_	
105-20	16554-16558	week	_	
105-21	16559-16561	in	_	
105-22	16562-16573	theta-gamma	_	
105-23	16574-16579	bands	_	
105-24	16580-16581	(	_	
105-25	16581-16587	ICCAvg	_	
105-26	16587-16588	=	_	
105-27	16588-16592	0.87	_	
105-28	16592-16593	)	_	
105-29	16594-16598	with	_	
105-30	16599-16602	the	_	
105-31	16603-16612	exception	_	
105-32	16613-16615	of	_	
105-33	16616-16620	good	_	
105-34	16621-16632	reliability	_	
105-35	16633-16635	in	_	
105-36	16636-16641	delta	_	
105-37	16642-16646	band	_	
105-38	16647-16653	across	_	
105-39	16654-16657	one	_	
105-40	16658-16662	week	_	
105-41	16663-16664	(	_	
105-42	16664-16670	ICCAvg	_	
105-43	16670-16671	=	_	
105-44	16671-16675	0.67	_	
105-45	16675-16676	)	_	
105-46	16676-16677	.	_	

#Text=SZ also had excellent reliability across one hour (ICCAvg=0.88) and across one week (ICCAvg=0.87) in theta-gamma bands, with exceptions of good reliability in delta band across one hour (Source ICCAvg=0.69) and across one week (ICCAvg=0.74).
106-1	16678-16680	SZ	_	
106-2	16681-16685	also	_	
106-3	16686-16689	had	_	
106-4	16690-16699	excellent	_	
106-5	16700-16711	reliability	_	
106-6	16712-16718	across	_	
106-7	16719-16722	one	_	
106-8	16723-16727	hour	_	
106-9	16728-16729	(	_	
106-10	16729-16735	ICCAvg	_	
106-11	16735-16736	=	_	
106-12	16736-16740	0.88	_	
106-13	16740-16741	)	_	
106-14	16742-16745	and	_	
106-15	16746-16752	across	_	
106-16	16753-16756	one	_	
106-17	16757-16761	week	_	
106-18	16762-16763	(	_	
106-19	16763-16769	ICCAvg	_	
106-20	16769-16770	=	_	
106-21	16770-16774	0.87	_	
106-22	16774-16775	)	_	
106-23	16776-16778	in	_	
106-24	16779-16790	theta-gamma	_	
106-25	16791-16796	bands	_	
106-26	16796-16797	,	_	
106-27	16798-16802	with	_	
106-28	16803-16813	exceptions	_	
106-29	16814-16816	of	_	
106-30	16817-16821	good	_	
106-31	16822-16833	reliability	_	
106-32	16834-16836	in	_	
106-33	16837-16842	delta	_	
106-34	16843-16847	band	_	
106-35	16848-16854	across	_	
106-36	16855-16858	one	_	
106-37	16859-16863	hour	_	
106-38	16864-16865	(	_	
106-39	16865-16871	Source	_	
106-40	16872-16878	ICCAvg	_	
106-41	16878-16879	=	_	
106-42	16879-16883	0.69	_	
106-43	16883-16884	)	_	
106-44	16885-16888	and	_	
106-45	16889-16895	across	_	
106-46	16896-16899	one	_	
106-47	16900-16904	week	_	
106-48	16905-16906	(	_	
106-49	16906-16912	ICCAvg	_	
106-50	16912-16913	=	_	
106-51	16913-16917	0.74	_	
106-52	16917-16918	)	_	
106-53	16918-16919	.	_	

#Text=Both resting-states had similar reliability levels in HC (Closed ICCAvg=0.86, Open ICCAvg=0.87); however, for SZ the EC average was higher than EO average group mean (Closed ICCAvg=0.89, Open ICCAvg=0.83).
107-1	16920-16924	Both	_	
107-2	16925-16939	resting-states	_	
107-3	16940-16943	had	_	
107-4	16944-16951	similar	_	
107-5	16952-16963	reliability	_	
107-6	16964-16970	levels	_	
107-7	16971-16973	in	_	
107-8	16974-16976	HC	_	
107-9	16977-16978	(	_	
107-10	16978-16984	Closed	_	
107-11	16985-16991	ICCAvg	_	
107-12	16991-16992	=	_	
107-13	16992-16996	0.86	_	
107-14	16996-16997	,	_	
107-15	16998-17002	Open	_	
107-16	17003-17009	ICCAvg	_	
107-17	17009-17010	=	_	
107-18	17010-17014	0.87	_	
107-19	17014-17015	)	_	
107-20	17015-17016	;	_	
107-21	17017-17024	however	_	
107-22	17024-17025	,	_	
107-23	17026-17029	for	_	
107-24	17030-17032	SZ	_	
107-25	17033-17036	the	_	
107-26	17037-17039	EC	_	
107-27	17040-17047	average	_	
107-28	17048-17051	was	_	
107-29	17052-17058	higher	_	
107-30	17059-17063	than	_	
107-31	17064-17066	EO	_	
107-32	17067-17074	average	_	
107-33	17075-17080	group	_	
107-34	17081-17085	mean	_	
107-35	17086-17087	(	_	
107-36	17087-17093	Closed	_	
107-37	17094-17100	ICCAvg	_	
107-38	17100-17101	=	_	
107-39	17101-17105	0.89	_	
107-40	17105-17106	,	_	
107-41	17107-17111	Open	_	
107-42	17112-17118	ICCAvg	_	
107-43	17118-17119	=	_	
107-44	17119-17123	0.83	_	
107-45	17123-17124	)	_	
107-46	17124-17125	.	_	

#Text=Between condition group averages were not tested further.
108-1	17126-17133	Between	_	
108-2	17134-17143	condition	_	
108-3	17144-17149	group	_	
108-4	17150-17158	averages	_	
108-5	17159-17163	were	_	
108-6	17164-17167	not	_	
108-7	17168-17174	tested	_	
108-8	17175-17182	further	_	
108-9	17182-17183	.	_	

#Text=Reliability of Regional Spectral Measures
#Text=Regional ICC estimates from the Rest10 task were calculated for normalized power across one week, Figure 4.
109-1	17184-17195	Reliability	_	
109-2	17196-17198	of	_	
109-3	17199-17207	Regional	_	
109-4	17208-17216	Spectral	_	
109-5	17217-17225	Measures	_	
109-6	17226-17234	Regional	_	
109-7	17235-17238	ICC	_	
109-8	17239-17248	estimates	_	
109-9	17249-17253	from	_	
109-10	17254-17257	the	_	
109-11	17258-17264	Rest10	_	
109-12	17265-17269	task	_	
109-13	17270-17274	were	_	
109-14	17275-17285	calculated	_	
109-15	17286-17289	for	_	
109-16	17290-17300	normalized	_	
109-17	17301-17306	power	_	
109-18	17307-17313	across	_	
109-19	17314-17317	one	_	
109-20	17318-17322	week	_	
109-21	17322-17323	,	_	
109-22	17324-17330	Figure	_	
109-23	17331-17332	4	_	
109-24	17332-17333	.	_	

#Text=HC had excellent Rest10 task reliability across a week in most sensor regions and bands (ICCAvg=0.86), with an exception of delta, right orbital region during EC (ICC=0.46).
110-1	17334-17336	HC	_	
110-2	17337-17340	had	_	
110-3	17341-17350	excellent	_	
110-4	17351-17357	Rest10	_	
110-5	17358-17362	task	_	
110-6	17363-17374	reliability	_	
110-7	17375-17381	across	_	
110-8	17382-17383	a	_	
110-9	17384-17388	week	_	
110-10	17389-17391	in	_	
110-11	17392-17396	most	_	
110-12	17397-17403	sensor	_	
110-13	17404-17411	regions	_	
110-14	17412-17415	and	_	
110-15	17416-17421	bands	_	
110-16	17422-17423	(	_	
110-17	17423-17429	ICCAvg	_	
110-18	17429-17430	=	_	
110-19	17430-17434	0.86	_	
110-20	17434-17435	)	_	
110-21	17435-17436	,	_	
110-22	17437-17441	with	_	
110-23	17442-17444	an	_	
110-24	17445-17454	exception	_	
110-25	17455-17457	of	_	
110-26	17458-17463	delta	_	
110-27	17463-17464	,	_	
110-28	17465-17470	right	_	
110-29	17471-17478	orbital	_	
110-30	17479-17485	region	_	
110-31	17486-17492	during	_	
110-32	17493-17495	EC	_	
110-33	17496-17497	(	_	
110-34	17497-17500	ICC	_	
110-35	17500-17501	=	_	
110-36	17501-17505	0.46	_	
110-37	17505-17506	)	_	
110-38	17506-17507	.	_	

#Text=SZ had excellent Rest10 task reliability in many bands and regions (ICCAvg=0.80), with the lowest reliability in delta and theta bands during EO (delta ICCAvg=0.73, theta ICCAvg=0.69) and lower reliability than HC in several regions.
111-1	17508-17510	SZ	_	
111-2	17511-17514	had	_	
111-3	17515-17524	excellent	_	
111-4	17525-17531	Rest10	_	
111-5	17532-17536	task	_	
111-6	17537-17548	reliability	_	
111-7	17549-17551	in	_	
111-8	17552-17556	many	_	
111-9	17557-17562	bands	_	
111-10	17563-17566	and	_	
111-11	17567-17574	regions	_	
111-12	17575-17576	(	_	
111-13	17576-17582	ICCAvg	_	
111-14	17582-17583	=	_	
111-15	17583-17587	0.80	_	
111-16	17587-17588	)	_	
111-17	17588-17589	,	_	
111-18	17590-17594	with	_	
111-19	17595-17598	the	_	
111-20	17599-17605	lowest	_	
111-21	17606-17617	reliability	_	
111-22	17618-17620	in	_	
111-23	17621-17626	delta	_	
111-24	17627-17630	and	_	
111-25	17631-17636	theta	_	
111-26	17637-17642	bands	_	
111-27	17643-17649	during	_	
111-28	17650-17652	EO	_	
111-29	17653-17654	(	_	
111-30	17654-17659	delta	_	
111-31	17660-17666	ICCAvg	_	
111-32	17666-17667	=	_	
111-33	17667-17671	0.73	_	
111-34	17671-17672	,	_	
111-35	17673-17678	theta	_	
111-36	17679-17685	ICCAvg	_	
111-37	17685-17686	=	_	
111-38	17686-17690	0.69	_	
111-39	17690-17691	)	_	
111-40	17692-17695	and	_	
111-41	17696-17701	lower	_	
111-42	17702-17713	reliability	_	
111-43	17714-17718	than	_	
111-44	17719-17721	HC	_	
111-45	17722-17724	in	_	
111-46	17725-17732	several	_	
111-47	17733-17740	regions	_	
111-48	17740-17741	.	_	

#Text=Parietal region ICC estimates within the alpha frequency band are shown in Figure 5 and supplementary Table S2.
112-1	17742-17750	Parietal	_	
112-2	17751-17757	region	_	
112-3	17758-17761	ICC	_	
112-4	17762-17771	estimates	_	
112-5	17772-17778	within	_	
112-6	17779-17782	the	_	
112-7	17783-17788	alpha	_	
112-8	17789-17798	frequency	_	
112-9	17799-17803	band	_	
112-10	17804-17807	are	_	
112-11	17808-17813	shown	_	
112-12	17814-17816	in	_	
112-13	17817-17823	Figure	_	
112-14	17824-17825	5	_	
112-15	17826-17829	and	_	
112-16	17830-17843	supplementary	_	
112-17	17844-17849	Table	_	
112-18	17850-17852	S2	_	
112-19	17852-17853	.	_	

#Text=HC had excellent reliability for the parietal alpha spectral measures (power, normalized power, half power, SSE) across one hour (ICCAvg=0.93) and across one week (ICCAvg=0.90) with the exception of good reliability in alpha reactivity (ICCAvg=0.67).
113-1	17854-17856	HC	_	
113-2	17857-17860	had	_	
113-3	17861-17870	excellent	_	
113-4	17871-17882	reliability	_	
113-5	17883-17886	for	_	
113-6	17887-17890	the	_	
113-7	17891-17899	parietal	_	
113-8	17900-17905	alpha	_	
113-9	17906-17914	spectral	_	
113-10	17915-17923	measures	_	
113-11	17924-17925	(	_	
113-12	17925-17930	power	_	
113-13	17930-17931	,	_	
113-14	17932-17942	normalized	_	
113-15	17943-17948	power	_	
113-16	17948-17949	,	_	
113-17	17950-17954	half	_	
113-18	17955-17960	power	_	
113-19	17960-17961	,	_	
113-20	17962-17965	SSE	_	
113-21	17965-17966	)	_	
113-22	17967-17973	across	_	
113-23	17974-17977	one	_	
113-24	17978-17982	hour	_	
113-25	17983-17984	(	_	
113-26	17984-17990	ICCAvg	_	
113-27	17990-17991	=	_	
113-28	17991-17995	0.93	_	
113-29	17995-17996	)	_	
113-30	17997-18000	and	_	
113-31	18001-18007	across	_	
113-32	18008-18011	one	_	
113-33	18012-18016	week	_	
113-34	18017-18018	(	_	
113-35	18018-18024	ICCAvg	_	
113-36	18024-18025	=	_	
113-37	18025-18029	0.90	_	
113-38	18029-18030	)	_	
113-39	18031-18035	with	_	
113-40	18036-18039	the	_	
113-41	18040-18049	exception	_	
113-42	18050-18052	of	_	
113-43	18053-18057	good	_	
113-44	18058-18069	reliability	_	
113-45	18070-18072	in	_	
113-46	18073-18078	alpha	_	
113-47	18079-18089	reactivity	_	
113-48	18090-18091	(	_	
113-49	18091-18097	ICCAvg	_	
113-50	18097-18098	=	_	
113-51	18098-18102	0.67	_	
113-52	18102-18103	)	_	
113-53	18103-18104	.	_	

#Text=SZ had excellent reliability for most parietal alpha measures across one hour (ICCAvg=0.80) and across one week (ICCAvg=0.84), with the exceptions of good reliability of alpha reactivity (ICCAvg=0.64) and poor reliability in source power across one hour (ICCAvg=0.05).
114-1	18105-18107	SZ	_	
114-2	18108-18111	had	_	
114-3	18112-18121	excellent	_	
114-4	18122-18133	reliability	_	
114-5	18134-18137	for	_	
114-6	18138-18142	most	_	
114-7	18143-18151	parietal	_	
114-8	18152-18157	alpha	_	
114-9	18158-18166	measures	_	
114-10	18167-18173	across	_	
114-11	18174-18177	one	_	
114-12	18178-18182	hour	_	
114-13	18183-18184	(	_	
114-14	18184-18190	ICCAvg	_	
114-15	18190-18191	=	_	
114-16	18191-18195	0.80	_	
114-17	18195-18196	)	_	
114-18	18197-18200	and	_	
114-19	18201-18207	across	_	
114-20	18208-18211	one	_	
114-21	18212-18216	week	_	
114-22	18217-18218	(	_	
114-23	18218-18224	ICCAvg	_	
114-24	18224-18225	=	_	
114-25	18225-18229	0.84	_	
114-26	18229-18230	)	_	
114-27	18230-18231	,	_	
114-28	18232-18236	with	_	
114-29	18237-18240	the	_	
114-30	18241-18251	exceptions	_	
114-31	18252-18254	of	_	
114-32	18255-18259	good	_	
114-33	18260-18271	reliability	_	
114-34	18272-18274	of	_	
114-35	18275-18280	alpha	_	
114-36	18281-18291	reactivity	_	
114-37	18292-18293	(	_	
114-38	18293-18299	ICCAvg	_	
114-39	18299-18300	=	_	
114-40	18300-18304	0.64	_	
114-41	18304-18305	)	_	
114-42	18306-18309	and	_	
114-43	18310-18314	poor	_	
114-44	18315-18326	reliability	_	
114-45	18327-18329	in	_	
114-46	18330-18336	source	_	
114-47	18337-18342	power	_	
114-48	18343-18349	across	_	
114-49	18350-18353	one	_	
114-50	18354-18358	hour	_	
114-51	18359-18360	(	_	
114-52	18360-18366	ICCAvg	_	
114-53	18366-18367	=	_	
114-54	18367-18371	0.05	_	
114-55	18371-18372	)	_	
114-56	18372-18373	.	_	

#Text=Both resting-states had similar reliability levels in HC (Closed ICCAvg=0.92 vs.
115-1	18374-18378	Both	_	
115-2	18379-18393	resting-states	_	
115-3	18394-18397	had	_	
115-4	18398-18405	similar	_	
115-5	18406-18417	reliability	_	
115-6	18418-18424	levels	_	
115-7	18425-18427	in	_	
115-8	18428-18430	HC	_	
115-9	18431-18432	(	_	
115-10	18432-18438	Closed	_	
115-11	18439-18445	ICCAvg	_	
115-12	18445-18446	=	_	
115-13	18446-18450	0.92	_	
115-14	18451-18453	vs	_	
115-15	18453-18454	.	_	

#Text=Open ICCAvg=0.90) and SZ (Closed ICCAvg=0.82 vs.
116-1	18455-18459	Open	_	
116-2	18460-18466	ICCAvg	_	
116-3	18466-18467	=	_	
116-4	18467-18471	0.90	_	
116-5	18471-18472	)	_	
116-6	18473-18476	and	_	
116-7	18477-18479	SZ	_	
116-8	18480-18481	(	_	
116-9	18481-18487	Closed	_	
116-10	18488-18494	ICCAvg	_	
116-11	18494-18495	=	_	
116-12	18495-18499	0.82	_	
116-13	18500-18502	vs	_	
116-14	18502-18503	.	_	

#Text=Open ICCAvg=0.82).
117-1	18504-18508	Open	_	
117-2	18509-18515	ICCAvg	_	
117-3	18515-18516	=	_	
117-4	18516-18520	0.82	_	
117-5	18520-18521	)	_	
117-6	18521-18522	.	_	

#Text=Source ICCs were generally lower than sensor ICCs.
118-1	18523-18529	Source	_	
118-2	18530-18534	ICCs	_	
118-3	18535-18539	were	_	
118-4	18540-18549	generally	_	
118-5	18550-18555	lower	_	
118-6	18556-18560	than	_	
118-7	18561-18567	sensor	_	
118-8	18568-18572	ICCs	_	
118-9	18572-18573	.	_	

#Text=Group Differences in Parietal Alpha Measures
#Text=At the sensor level, in the EC state only, SZ had reduced parietal normalized power [Figure 6A–6B; State x Group interaction: F(1,24)=7.73, p=.012; Group effect at EC: F(1,24)=6.39, p=.018], reduced absolute power [data not shown; State x Group interaction: F(1,24)=7.37, p=.010; Group effect at EC: F(1,24)=6.39, p=.018] and reduced alpha reactivity [Figure 6C; Group effect: F(1,24)=6.16, p=.020].
119-1	18574-18579	Group	_	
119-2	18580-18591	Differences	_	
119-3	18592-18594	in	_	
119-4	18595-18603	Parietal	_	
119-5	18604-18609	Alpha	_	
119-6	18610-18618	Measures	_	
119-7	18619-18621	At	_	
119-8	18622-18625	the	_	
119-9	18626-18632	sensor	_	
119-10	18633-18638	level	_	
119-11	18638-18639	,	_	
119-12	18640-18642	in	_	
119-13	18643-18646	the	_	
119-14	18647-18649	EC	_	
119-15	18650-18655	state	_	
119-16	18656-18660	only	_	
119-17	18660-18661	,	_	
119-18	18662-18664	SZ	_	
119-19	18665-18668	had	_	
119-20	18669-18676	reduced	_	
119-21	18677-18685	parietal	_	
119-22	18686-18696	normalized	_	
119-23	18697-18702	power	_	
119-24	18703-18704	[	_	
119-25	18704-18710	Figure	_	
119-26	18711-18713	6A	_	
119-27	18713-18714	–	_	
119-28	18714-18716	6B	_	
119-29	18716-18717	;	_	
119-30	18718-18723	State	_	
119-31	18724-18725	x	_	
119-32	18726-18731	Group	_	
119-33	18732-18743	interaction	_	
119-34	18743-18744	:	_	
119-35	18745-18746	F	_	
119-36	18746-18747	(	_	
119-37	18747-18751	1,24	_	
119-38	18751-18752	)	_	
119-39	18752-18753	=	_	
119-40	18753-18757	7.73	_	
119-41	18757-18758	,	_	
119-42	18759-18760	p	_	
119-43	18760-18761	=	_	
119-44	18761-18765	.012	_	
119-45	18765-18766	;	_	
119-46	18767-18772	Group	_	
119-47	18773-18779	effect	_	
119-48	18780-18782	at	_	
119-49	18783-18785	EC	_	
119-50	18785-18786	:	_	
119-51	18787-18788	F	_	
119-52	18788-18789	(	_	
119-53	18789-18793	1,24	_	
119-54	18793-18794	)	_	
119-55	18794-18795	=	_	
119-56	18795-18799	6.39	_	
119-57	18799-18800	,	_	
119-58	18801-18802	p	_	
119-59	18802-18803	=	_	
119-60	18803-18807	.018	_	
119-61	18807-18808	]	_	
119-62	18808-18809	,	_	
119-63	18810-18817	reduced	_	
119-64	18818-18826	absolute	_	
119-65	18827-18832	power	_	
119-66	18833-18834	[	_	
119-67	18834-18838	data	_	
119-68	18839-18842	not	_	
119-69	18843-18848	shown	_	
119-70	18848-18849	;	_	
119-71	18850-18855	State	_	
119-72	18856-18857	x	_	
119-73	18858-18863	Group	_	
119-74	18864-18875	interaction	_	
119-75	18875-18876	:	_	
119-76	18877-18878	F	_	
119-77	18878-18879	(	_	
119-78	18879-18883	1,24	_	
119-79	18883-18884	)	_	
119-80	18884-18885	=	_	
119-81	18885-18889	7.37	_	
119-82	18889-18890	,	_	
119-83	18891-18892	p	_	
119-84	18892-18893	=	_	
119-85	18893-18897	.010	_	
119-86	18897-18898	;	_	
119-87	18899-18904	Group	_	
119-88	18905-18911	effect	_	
119-89	18912-18914	at	_	
119-90	18915-18917	EC	_	
119-91	18917-18918	:	_	
119-92	18919-18920	F	_	
119-93	18920-18921	(	_	
119-94	18921-18925	1,24	_	
119-95	18925-18926	)	_	
119-96	18926-18927	=	_	
119-97	18927-18931	6.39	_	
119-98	18931-18932	,	_	
119-99	18933-18934	p	_	
119-100	18934-18935	=	_	
119-101	18935-18939	.018	_	
119-102	18939-18940	]	_	
119-103	18941-18944	and	_	
119-104	18945-18952	reduced	_	
119-105	18953-18958	alpha	_	
119-106	18959-18969	reactivity	_	
119-107	18970-18971	[	_	
119-108	18971-18977	Figure	_	
119-109	18978-18980	6C	_	
119-110	18980-18981	;	_	
119-111	18982-18987	Group	_	
119-112	18988-18994	effect	_	
119-113	18994-18995	:	_	
119-114	18996-18997	F	_	
119-115	18997-18998	(	_	
119-116	18998-19002	1,24	_	
119-117	19002-19003	)	_	
119-118	19003-19004	=	_	
119-119	19004-19008	6.16	_	
119-120	19008-19009	,	_	
119-121	19010-19011	p	_	
119-122	19011-19012	=	_	
119-123	19012-19016	.020	_	
119-124	19016-19017	]	_	
119-125	19017-19018	.	_	

#Text=These reductions in spectral power and normalized power in the EC resting-state, along with reduced alpha reactivity, remained consistent across runs and visits in SZ.
120-1	19019-19024	These	_	
120-2	19025-19035	reductions	_	
120-3	19036-19038	in	_	
120-4	19039-19047	spectral	_	
120-5	19048-19053	power	_	
120-6	19054-19057	and	_	
120-7	19058-19068	normalized	_	
120-8	19069-19074	power	_	
120-9	19075-19077	in	_	
120-10	19078-19081	the	_	
120-11	19082-19084	EC	_	
120-12	19085-19098	resting-state	_	
120-13	19098-19099	,	_	
120-14	19100-19105	along	_	
120-15	19106-19110	with	_	
120-16	19111-19118	reduced	_	
120-17	19119-19124	alpha	_	
120-18	19125-19135	reactivity	_	
120-19	19135-19136	,	_	
120-20	19137-19145	remained	_	
120-21	19146-19156	consistent	_	
120-22	19157-19163	across	_	
120-23	19164-19168	runs	_	
120-24	19169-19172	and	_	
120-25	19173-19179	visits	_	
120-26	19180-19182	in	_	
120-27	19183-19185	SZ	_	
120-28	19185-19186	.	_	

#Text=At the source level, SZ had reduced normalized power during EC in several parietal regions [Figure 6D–6E; Group effect at SupPar: F(1,24)=5.35, p=.030, InfPar: F(1,24)=6.69, p=.016, and Precuneus: F(1,24)=5.32, p=.030], along with reduced alpha reactivity [Figure 6F; Group effect: F(1,24)=12.387, p=.002].
121-1	19187-19189	At	_	
121-2	19190-19193	the	_	
121-3	19194-19200	source	_	
121-4	19201-19206	level	_	
121-5	19206-19207	,	_	
121-6	19208-19210	SZ	_	
121-7	19211-19214	had	_	
121-8	19215-19222	reduced	_	
121-9	19223-19233	normalized	_	
121-10	19234-19239	power	_	
121-11	19240-19246	during	_	
121-12	19247-19249	EC	_	
121-13	19250-19252	in	_	
121-14	19253-19260	several	_	
121-15	19261-19269	parietal	_	
121-16	19270-19277	regions	_	
121-17	19278-19279	[	_	
121-18	19279-19285	Figure	_	
121-19	19286-19288	6D	_	
121-20	19288-19289	–	_	
121-21	19289-19291	6E	_	
121-22	19291-19292	;	_	
121-23	19293-19298	Group	_	
121-24	19299-19305	effect	_	
121-25	19306-19308	at	_	
121-26	19309-19315	SupPar	_	
121-27	19315-19316	:	_	
121-28	19317-19318	F	_	
121-29	19318-19319	(	_	
121-30	19319-19323	1,24	_	
121-31	19323-19324	)	_	
121-32	19324-19325	=	_	
121-33	19325-19329	5.35	_	
121-34	19329-19330	,	_	
121-35	19331-19332	p	_	
121-36	19332-19333	=	_	
121-37	19333-19337	.030	_	
121-38	19337-19338	,	_	
121-39	19339-19345	InfPar	_	
121-40	19345-19346	:	_	
121-41	19347-19348	F	_	
121-42	19348-19349	(	_	
121-43	19349-19353	1,24	_	
121-44	19353-19354	)	_	
121-45	19354-19355	=	_	
121-46	19355-19359	6.69	_	
121-47	19359-19360	,	_	
121-48	19361-19362	p	_	
121-49	19362-19363	=	_	
121-50	19363-19367	.016	_	
121-51	19367-19368	,	_	
121-52	19369-19372	and	_	
121-53	19373-19382	Precuneus	_	
121-54	19382-19383	:	_	
121-55	19384-19385	F	_	
121-56	19385-19386	(	_	
121-57	19386-19390	1,24	_	
121-58	19390-19391	)	_	
121-59	19391-19392	=	_	
121-60	19392-19396	5.32	_	
121-61	19396-19397	,	_	
121-62	19398-19399	p	_	
121-63	19399-19400	=	_	
121-64	19400-19404	.030	_	
121-65	19404-19405	]	_	
121-66	19405-19406	,	_	
121-67	19407-19412	along	_	
121-68	19413-19417	with	_	
121-69	19418-19425	reduced	_	
121-70	19426-19431	alpha	_	
121-71	19432-19442	reactivity	_	
121-72	19443-19444	[	_	
121-73	19444-19450	Figure	_	
121-74	19451-19453	6F	_	
121-75	19453-19454	;	_	
121-76	19455-19460	Group	_	
121-77	19461-19467	effect	_	
121-78	19467-19468	:	_	
121-79	19469-19470	F	_	
121-80	19470-19471	(	_	
121-81	19471-19475	1,24	_	
121-82	19475-19476	)	_	
121-83	19476-19477	=	_	
121-84	19477-19483	12.387	_	
121-85	19483-19484	,	_	
121-86	19485-19486	p	_	
121-87	19486-19487	=	_	
121-88	19487-19491	.002	_	
121-89	19491-19492	]	_	
121-90	19492-19493	.	_	

#Text=Importantly, group effects in the individual parietal regions (SupPar, InfPar, Precuneus) remained significant following FDR correction for multiple comparisons.
122-1	19494-19505	Importantly	_	
122-2	19505-19506	,	_	
122-3	19507-19512	group	_	
122-4	19513-19520	effects	_	
122-5	19521-19523	in	_	
122-6	19524-19527	the	_	
122-7	19528-19538	individual	_	
122-8	19539-19547	parietal	_	
122-9	19548-19555	regions	_	
122-10	19556-19557	(	_	
122-11	19557-19563	SupPar	_	
122-12	19563-19564	,	_	
122-13	19565-19571	InfPar	_	
122-14	19571-19572	,	_	
122-15	19573-19582	Precuneus	_	
122-16	19582-19583	)	_	
122-17	19584-19592	remained	_	
122-18	19593-19604	significant	_	
122-19	19605-19614	following	_	
122-20	19615-19618	FDR	_	
122-21	19619-19629	correction	_	
122-22	19630-19633	for	_	
122-23	19634-19642	multiple	_	
122-24	19643-19654	comparisons	_	
122-25	19654-19655	.	_	

#Text=There were no interactions or main effects for power at the source level.
123-1	19656-19661	There	_	
123-2	19662-19666	were	_	
123-3	19667-19669	no	_	
123-4	19670-19682	interactions	_	
123-5	19683-19685	or	_	
123-6	19686-19690	main	_	
123-7	19691-19698	effects	_	
123-8	19699-19702	for	_	
123-9	19703-19708	power	_	
123-10	19709-19711	at	_	
123-11	19712-19715	the	_	
123-12	19716-19722	source	_	
123-13	19723-19728	level	_	
123-14	19728-19729	.	_	

#Text=Overall, parietal source normalized power measures paralleled sensor measures with reductions in SZ during the EC resting-state.
124-1	19730-19737	Overall	_	
124-2	19737-19738	,	_	
124-3	19739-19747	parietal	_	
124-4	19748-19754	source	_	
124-5	19755-19765	normalized	_	
124-6	19766-19771	power	_	
124-7	19772-19780	measures	_	
124-8	19781-19791	paralleled	_	
124-9	19792-19798	sensor	_	
124-10	19799-19807	measures	_	
124-11	19808-19812	with	_	
124-12	19813-19823	reductions	_	
124-13	19824-19826	in	_	
124-14	19827-19829	SZ	_	
124-15	19830-19836	during	_	
124-16	19837-19840	the	_	
124-17	19841-19843	EC	_	
124-18	19844-19857	resting-state	_	
124-19	19857-19858	.	_	

#Text=Source Functional Connectivity
#Text=Given that sensor and source analyses revealed group differences in the EC resting-state, we focused connectivity analyses on EC and selected superior parietal regions to parallel our focus on parietal alpha spectral power.
125-1	19859-19865	Source	_	
125-2	19866-19876	Functional	_	
125-3	19877-19889	Connectivity	_	
125-4	19890-19895	Given	_	
125-5	19896-19900	that	_	
125-6	19901-19907	sensor	_	
125-7	19908-19911	and	_	
125-8	19912-19918	source	_	
125-9	19919-19927	analyses	_	
125-10	19928-19936	revealed	_	
125-11	19937-19942	group	_	
125-12	19943-19954	differences	_	
125-13	19955-19957	in	_	
125-14	19958-19961	the	_	
125-15	19962-19964	EC	_	
125-16	19965-19978	resting-state	_	
125-17	19978-19979	,	_	
125-18	19980-19982	we	_	
125-19	19983-19990	focused	_	
125-20	19991-20003	connectivity	_	
125-21	20004-20012	analyses	_	
125-22	20013-20015	on	_	
125-23	20016-20018	EC	_	
125-24	20019-20022	and	_	
125-25	20023-20031	selected	_	
125-26	20032-20040	superior	_	
125-27	20041-20049	parietal	_	
125-28	20050-20057	regions	_	
125-29	20058-20060	to	_	
125-30	20061-20069	parallel	_	
125-31	20070-20073	our	_	
125-32	20074-20079	focus	_	
125-33	20080-20082	on	_	
125-34	20083-20091	parietal	_	
125-35	20092-20097	alpha	_	
125-36	20098-20106	spectral	_	
125-37	20107-20112	power	_	
125-38	20112-20113	.	_	

#Text=For short- and long-range connectivity we selected Superior Parietal to Lateral Occipital and Entorhinal regions.
126-1	20114-20117	For	_	
126-2	20118-20123	short	_	
126-3	20123-20124	-	_	
126-4	20125-20128	and	_	
126-5	20129-20139	long-range	_	
126-6	20140-20152	connectivity	_	
126-7	20153-20155	we	_	
126-8	20156-20164	selected	_	
126-9	20165-20173	Superior	_	
126-10	20174-20182	Parietal	_	
126-11	20183-20185	to	_	
126-12	20186-20193	Lateral	_	
126-13	20194-20203	Occipital	_	
126-14	20204-20207	and	_	
126-15	20208-20218	Entorhinal	_	
126-16	20219-20226	regions	_	
126-17	20226-20227	.	_	

#Text=All intervals tested in both groups had poor test-retest reliability [HC ICCAvg=0.12, SZ ICCAvg=0.03], Supplementary Table S2.
127-1	20228-20231	All	_	
127-2	20232-20241	intervals	_	
127-3	20242-20248	tested	_	
127-4	20249-20251	in	_	
127-5	20252-20256	both	_	
127-6	20257-20263	groups	_	
127-7	20264-20267	had	_	
127-8	20268-20272	poor	_	
127-9	20273-20284	test-retest	_	
127-10	20285-20296	reliability	_	
127-11	20297-20298	[	_	
127-12	20298-20300	HC	_	
127-13	20301-20307	ICCAvg	_	
127-14	20307-20308	=	_	
127-15	20308-20312	0.12	_	
127-16	20312-20313	,	_	
127-17	20314-20316	SZ	_	
127-18	20317-20323	ICCAvg	_	
127-19	20323-20324	=	_	
127-20	20324-20328	0.03	_	
127-21	20328-20329	]	_	
127-22	20329-20330	,	_	
127-23	20331-20344	Supplementary	_	
127-24	20345-20350	Table	_	
127-25	20351-20353	S2	_	
127-26	20353-20354	.	_	

#Text=RM-ANOVAs were conducted on connectivity pairs with Run (Visit/Task) as the within-subject factor.
128-1	20355-20364	RM-ANOVAs	_	
128-2	20365-20369	were	_	
128-3	20370-20379	conducted	_	
128-4	20380-20382	on	_	
128-5	20383-20395	connectivity	_	
128-6	20396-20401	pairs	_	
128-7	20402-20406	with	_	
128-8	20407-20410	Run	_	
128-9	20411-20412	(	_	
128-10	20412-20417	Visit	_	
128-11	20417-20418	/	_	
128-12	20418-20422	Task	_	
128-13	20422-20423	)	_	
128-14	20424-20426	as	_	
128-15	20427-20430	the	_	
128-16	20431-20445	within-subject	_	
128-17	20446-20452	factor	_	
128-18	20452-20453	.	_	

#Text=There was higher connectivity in SZ between left hemisphere Superior Parietal to Lateral Occipital regions during the Visit2_Rest10 task only [Figure 7A; Run x Group interaction: F(2.15,51.56)=3.15, p=.04; Group effect at Run 3 (p=.007), all others (p>0.13)].
129-1	20454-20459	There	_	
129-2	20460-20463	was	_	
129-3	20464-20470	higher	_	
129-4	20471-20483	connectivity	_	
129-5	20484-20486	in	_	
129-6	20487-20489	SZ	_	
129-7	20490-20497	between	_	
129-8	20498-20502	left	_	
129-9	20503-20513	hemisphere	_	
129-10	20514-20522	Superior	_	
129-11	20523-20531	Parietal	_	
129-12	20532-20534	to	_	
129-13	20535-20542	Lateral	_	
129-14	20543-20552	Occipital	_	
129-15	20553-20560	regions	_	
129-16	20561-20567	during	_	
129-17	20568-20571	the	_	
129-18	20572-20578	Visit2	_	
129-19	20578-20579	_	_	
129-20	20579-20585	Rest10	_	
129-21	20586-20590	task	_	
129-22	20591-20595	only	_	
129-23	20596-20597	[	_	
129-24	20597-20603	Figure	_	
129-25	20604-20606	7A	_	
129-26	20606-20607	;	_	
129-27	20608-20611	Run	_	
129-28	20612-20613	x	_	
129-29	20614-20619	Group	_	
129-30	20620-20631	interaction	_	
129-31	20631-20632	:	_	
129-32	20633-20634	F	_	
129-33	20634-20635	(	_	
129-34	20635-20645	2.15,51.56	_	
129-35	20645-20646	)	_	
129-36	20646-20647	=	_	
129-37	20647-20651	3.15	_	
129-38	20651-20652	,	_	
129-39	20653-20654	p	_	
129-40	20654-20655	=	_	
129-41	20655-20658	.04	_	
129-42	20658-20659	;	_	
129-43	20660-20665	Group	_	
129-44	20666-20672	effect	_	
129-45	20673-20675	at	_	
129-46	20676-20679	Run	_	
129-47	20680-20681	3	_	
129-48	20682-20683	(	_	
129-49	20683-20684	p	_	
129-50	20684-20685	=	_	
129-51	20685-20689	.007	_	
129-52	20689-20690	)	_	
129-53	20690-20691	,	_	
129-54	20692-20695	all	_	
129-55	20696-20702	others	_	
129-56	20703-20704	(	_	
129-57	20704-20705	p	_	
129-58	20705-20706	>	_	
129-59	20706-20710	0.13	_	
129-60	20710-20711	)	_	
129-61	20711-20712	]	_	
129-62	20712-20713	.	_	

#Text=SZ also had higher connectivity between Superior Parietal to Entorhinal regions during the Visit1_Rest10 task only [Figure 7B; Run x Group interaction: F(2.13,51.16)=3.34, p=.041; Group effect at Run 3 (p=.029), all others (p>0.09)].
130-1	20714-20716	SZ	_	
130-2	20717-20721	also	_	
130-3	20722-20725	had	_	
130-4	20726-20732	higher	_	
130-5	20733-20745	connectivity	_	
130-6	20746-20753	between	_	
130-7	20754-20762	Superior	_	
130-8	20763-20771	Parietal	_	
130-9	20772-20774	to	_	
130-10	20775-20785	Entorhinal	_	
130-11	20786-20793	regions	_	
130-12	20794-20800	during	_	
130-13	20801-20804	the	_	
130-14	20805-20811	Visit1	_	
130-15	20811-20812	_	_	
130-16	20812-20818	Rest10	_	
130-17	20819-20823	task	_	
130-18	20824-20828	only	_	
130-19	20829-20830	[	_	
130-20	20830-20836	Figure	_	
130-21	20837-20839	7B	_	
130-22	20839-20840	;	_	
130-23	20841-20844	Run	_	
130-24	20845-20846	x	_	
130-25	20847-20852	Group	_	
130-26	20853-20864	interaction	_	
130-27	20864-20865	:	_	
130-28	20866-20867	F	_	
130-29	20867-20868	(	_	
130-30	20868-20878	2.13,51.16	_	
130-31	20878-20879	)	_	
130-32	20879-20880	=	_	
130-33	20880-20884	3.34	_	
130-34	20884-20885	,	_	
130-35	20886-20887	p	_	
130-36	20887-20888	=	_	
130-37	20888-20892	.041	_	
130-38	20892-20893	;	_	
130-39	20894-20899	Group	_	
130-40	20900-20906	effect	_	
130-41	20907-20909	at	_	
130-42	20910-20913	Run	_	
130-43	20914-20915	3	_	
130-44	20916-20917	(	_	
130-45	20917-20918	p	_	
130-46	20918-20919	=	_	
130-47	20919-20923	.029	_	
130-48	20923-20924	)	_	
130-49	20924-20925	,	_	
130-50	20926-20929	all	_	
130-51	20930-20936	others	_	
130-52	20937-20938	(	_	
130-53	20938-20939	p	_	
130-54	20939-20940	>	_	
130-55	20940-20944	0.09	_	
130-56	20944-20945	)	_	
130-57	20945-20946	]	_	
130-58	20946-20947	.	_	

#Text=Overall, these results show the wPLI-debiased functional connectivity measure lacked consistent FNC findings per run, along with poor ICC values.
131-1	20948-20955	Overall	_	
131-2	20955-20956	,	_	
131-3	20957-20962	these	_	
131-4	20963-20970	results	_	
131-5	20971-20975	show	_	
131-6	20976-20979	the	_	
131-7	20980-20993	wPLI-debiased	_	
131-8	20994-21004	functional	_	
131-9	21005-21017	connectivity	_	
131-10	21018-21025	measure	_	
131-11	21026-21032	lacked	_	
131-12	21033-21043	consistent	_	
131-13	21044-21047	FNC	_	
131-14	21048-21056	findings	_	
131-15	21057-21060	per	_	
131-16	21061-21064	run	_	
131-17	21064-21065	,	_	
131-18	21066-21071	along	_	
131-19	21072-21076	with	_	
131-20	21077-21081	poor	_	
131-21	21082-21085	ICC	_	
131-22	21086-21092	values	_	
131-23	21092-21093	.	_	

#Text=Correlation of MEG Spectral Measures with PANSS Scores
#Text=To determine if resting-state normalized power correlated with symptom measures in SZ, we examined normalized power during the Rest10 task with PANSS scores (Positive, Negative, General Scores) from the same visit.
132-1	21094-21105	Correlation	_	
132-2	21106-21108	of	_	
132-3	21109-21112	MEG	_	
132-4	21113-21121	Spectral	_	
132-5	21122-21130	Measures	_	
132-6	21131-21135	with	_	
132-7	21136-21141	PANSS	_	
132-8	21142-21148	Scores	_	
132-9	21149-21151	To	_	
132-10	21152-21161	determine	_	
132-11	21162-21164	if	_	
132-12	21165-21178	resting-state	_	
132-13	21179-21189	normalized	_	
132-14	21190-21195	power	_	
132-15	21196-21206	correlated	_	
132-16	21207-21211	with	_	
132-17	21212-21219	symptom	_	
132-18	21220-21228	measures	_	
132-19	21229-21231	in	_	
132-20	21232-21234	SZ	_	
132-21	21234-21235	,	_	
132-22	21236-21238	we	_	
132-23	21239-21247	examined	_	
132-24	21248-21258	normalized	_	
132-25	21259-21264	power	_	
132-26	21265-21271	during	_	
132-27	21272-21275	the	_	
132-28	21276-21282	Rest10	_	
132-29	21283-21287	task	_	
132-30	21288-21292	with	_	
132-31	21293-21298	PANSS	_	
132-32	21299-21305	scores	_	
132-33	21306-21307	(	_	
132-34	21307-21315	Positive	_	
132-35	21315-21316	,	_	
132-36	21317-21325	Negative	_	
132-37	21325-21326	,	_	
132-38	21327-21334	General	_	
132-39	21335-21341	Scores	_	
132-40	21341-21342	)	_	
132-41	21343-21347	from	_	
132-42	21348-21351	the	_	
132-43	21352-21356	same	_	
132-44	21357-21362	visit	_	
132-45	21362-21363	.	_	

#Text=We found a moderate negative correlation between EC normalized power in sensor parietal region and PANSS positive scores, Figure 8.
133-1	21364-21366	We	_	
133-2	21367-21372	found	_	
133-3	21373-21374	a	_	
133-4	21375-21383	moderate	_	
133-5	21384-21392	negative	_	
133-6	21393-21404	correlation	_	
133-7	21405-21412	between	_	
133-8	21413-21415	EC	_	
133-9	21416-21426	normalized	_	
133-10	21427-21432	power	_	
133-11	21433-21435	in	_	
133-12	21436-21442	sensor	_	
133-13	21443-21451	parietal	_	
133-14	21452-21458	region	_	
133-15	21459-21462	and	_	
133-16	21463-21468	PANSS	_	
133-17	21469-21477	positive	_	
133-18	21478-21484	scores	_	
133-19	21484-21485	,	_	
133-20	21486-21492	Figure	_	
133-21	21493-21494	8	_	
133-22	21494-21495	.	_	

#Text=Higher positive symptom scores were related to lower alpha normalized power in the EC resting-state during Visit1 [r= −0.622, 95% BCa CI [−.885, −.106], R2=0.387, p=0.023] and during Visit2 [r= −0.606, 95% BCa CI [−.870, −.046], R2=0.368, p=0.028] accounting for 38.7% and 36.8% of the shared variance, Figure 8A and 8B.
134-1	21496-21502	Higher	_	
134-2	21503-21511	positive	_	
134-3	21512-21519	symptom	_	
134-4	21520-21526	scores	_	
134-5	21527-21531	were	_	
134-6	21532-21539	related	_	
134-7	21540-21542	to	_	
134-8	21543-21548	lower	_	
134-9	21549-21554	alpha	_	
134-10	21555-21565	normalized	_	
134-11	21566-21571	power	_	
134-12	21572-21574	in	_	
134-13	21575-21578	the	_	
134-14	21579-21581	EC	_	
134-15	21582-21595	resting-state	_	
134-16	21596-21602	during	_	
134-17	21603-21609	Visit1	_	
134-18	21610-21611	[	_	
134-19	21611-21612	r	_	
134-20	21612-21613	=	_	
134-21	21614-21615	−	_	
134-22	21615-21620	0.622	_	
134-23	21620-21621	,	_	
134-24	21622-21625	95%	_	
134-25	21626-21629	BCa	_	
134-26	21630-21632	CI	_	
134-27	21633-21634	[	_	
134-28	21634-21635	−	_	
134-29	21635-21639	.885	_	
134-30	21639-21640	,	_	
134-31	21641-21642	−	_	
134-32	21642-21646	.106	_	
134-33	21646-21647	]	_	
134-34	21647-21648	,	_	
134-35	21649-21651	R2	_	
134-36	21651-21652	=	_	
134-37	21652-21657	0.387	_	
134-38	21657-21658	,	_	
134-39	21659-21660	p	_	
134-40	21660-21661	=	_	
134-41	21661-21666	0.023	_	
134-42	21666-21667	]	_	
134-43	21668-21671	and	_	
134-44	21672-21678	during	_	
134-45	21679-21685	Visit2	_	
134-46	21686-21687	[	_	
134-47	21687-21688	r	_	
134-48	21688-21689	=	_	
134-49	21690-21691	−	_	
134-50	21691-21696	0.606	_	
134-51	21696-21697	,	_	
134-52	21698-21701	95%	_	
134-53	21702-21705	BCa	_	
134-54	21706-21708	CI	_	
134-55	21709-21710	[	_	
134-56	21710-21711	−	_	
134-57	21711-21715	.870	_	
134-58	21715-21716	,	_	
134-59	21717-21718	−	_	
134-60	21718-21722	.046	_	
134-61	21722-21723	]	_	
134-62	21723-21724	,	_	
134-63	21725-21727	R2	_	
134-64	21727-21728	=	_	
134-65	21728-21733	0.368	_	
134-66	21733-21734	,	_	
134-67	21735-21736	p	_	
134-68	21736-21737	=	_	
134-69	21737-21742	0.028	_	
134-70	21742-21743	]	_	
134-71	21744-21754	accounting	_	
134-72	21755-21758	for	_	
134-73	21759-21764	38.7%	_	
134-74	21765-21768	and	_	
134-75	21769-21774	36.8%	_	
134-76	21775-21777	of	_	
134-77	21778-21781	the	_	
134-78	21782-21788	shared	_	
134-79	21789-21797	variance	_	
134-80	21797-21798	,	_	
134-81	21799-21805	Figure	_	
134-82	21806-21808	8A	_	
134-83	21809-21812	and	_	
134-84	21813-21815	8B	_	
134-85	21815-21816	.	_	

#Text=The Rest4 task had similar findings to the Rest10task, higher positive symptom scores were related to lower alpha normalized power in the EC resting-state, during Visit1 [r= −0.639, 95% BCa CI [−.888, −.246], R2=0.408, p=0.019] and during Visit2 [r= −0.582, 95% BCa CI [−.890, −.029], R2=0.339, p=0.037], data not shown.
135-1	21817-21820	The	_	
135-2	21821-21826	Rest4	_	
135-3	21827-21831	task	_	
135-4	21832-21835	had	_	
135-5	21836-21843	similar	_	
135-6	21844-21852	findings	_	
135-7	21853-21855	to	_	
135-8	21856-21859	the	_	
135-9	21860-21870	Rest10task	_	
135-10	21870-21871	,	_	
135-11	21872-21878	higher	_	
135-12	21879-21887	positive	_	
135-13	21888-21895	symptom	_	
135-14	21896-21902	scores	_	
135-15	21903-21907	were	_	
135-16	21908-21915	related	_	
135-17	21916-21918	to	_	
135-18	21919-21924	lower	_	
135-19	21925-21930	alpha	_	
135-20	21931-21941	normalized	_	
135-21	21942-21947	power	_	
135-22	21948-21950	in	_	
135-23	21951-21954	the	_	
135-24	21955-21957	EC	_	
135-25	21958-21971	resting-state	_	
135-26	21971-21972	,	_	
135-27	21973-21979	during	_	
135-28	21980-21986	Visit1	_	
135-29	21987-21988	[	_	
135-30	21988-21989	r	_	
135-31	21989-21990	=	_	
135-32	21991-21992	−	_	
135-33	21992-21997	0.639	_	
135-34	21997-21998	,	_	
135-35	21999-22002	95%	_	
135-36	22003-22006	BCa	_	
135-37	22007-22009	CI	_	
135-38	22010-22011	[	_	
135-39	22011-22012	−	_	
135-40	22012-22016	.888	_	
135-41	22016-22017	,	_	
135-42	22018-22019	−	_	
135-43	22019-22023	.246	_	
135-44	22023-22024	]	_	
135-45	22024-22025	,	_	
135-46	22026-22028	R2	_	
135-47	22028-22029	=	_	
135-48	22029-22034	0.408	_	
135-49	22034-22035	,	_	
135-50	22036-22037	p	_	
135-51	22037-22038	=	_	
135-52	22038-22043	0.019	_	
135-53	22043-22044	]	_	
135-54	22045-22048	and	_	
135-55	22049-22055	during	_	
135-56	22056-22062	Visit2	_	
135-57	22063-22064	[	_	
135-58	22064-22065	r	_	
135-59	22065-22066	=	_	
135-60	22067-22068	−	_	
135-61	22068-22073	0.582	_	
135-62	22073-22074	,	_	
135-63	22075-22078	95%	_	
135-64	22079-22082	BCa	_	
135-65	22083-22085	CI	_	
135-66	22086-22087	[	_	
135-67	22087-22088	−	_	
135-68	22088-22092	.890	_	
135-69	22092-22093	,	_	
135-70	22094-22095	−	_	
135-71	22095-22099	.029	_	
135-72	22099-22100	]	_	
135-73	22100-22101	,	_	
135-74	22102-22104	R2	_	
135-75	22104-22105	=	_	
135-76	22105-22110	0.339	_	
135-77	22110-22111	,	_	
135-78	22112-22113	p	_	
135-79	22113-22114	=	_	
135-80	22114-22119	0.037	_	
135-81	22119-22120	]	_	
135-82	22120-22121	,	_	
135-83	22122-22126	data	_	
135-84	22127-22130	not	_	
135-85	22131-22136	shown	_	
135-86	22136-22137	.	_	

#Text=Discussion
#Text=We examined the test-retest reliability of sensor and source-based resting-state spectral power oscillations in neuromagnetic data across one week.
136-1	22138-22148	Discussion	_	
136-2	22149-22151	We	_	
136-3	22152-22160	examined	_	
136-4	22161-22164	the	_	
136-5	22165-22176	test-retest	_	
136-6	22177-22188	reliability	_	
136-7	22189-22191	of	_	
136-8	22192-22198	sensor	_	
136-9	22199-22202	and	_	
136-10	22203-22215	source-based	_	
136-11	22216-22229	resting-state	_	
136-12	22230-22238	spectral	_	
136-13	22239-22244	power	_	
136-14	22245-22257	oscillations	_	
136-15	22258-22260	in	_	
136-16	22261-22274	neuromagnetic	_	
136-17	22275-22279	data	_	
136-18	22280-22286	across	_	
136-19	22287-22290	one	_	
136-20	22291-22295	week	_	
136-21	22295-22296	.	_	

#Text=We found excellent test-retest reliability of most MEG spectral measures, replicating previous research while extending findings to schizophrenia.
137-1	22297-22299	We	_	
137-2	22300-22305	found	_	
137-3	22306-22315	excellent	_	
137-4	22316-22327	test-retest	_	
137-5	22328-22339	reliability	_	
137-6	22340-22342	of	_	
137-7	22343-22347	most	_	
137-8	22348-22351	MEG	_	
137-9	22352-22360	spectral	_	
137-10	22361-22369	measures	_	
137-11	22369-22370	,	_	
137-12	22371-22382	replicating	_	
137-13	22383-22391	previous	_	
137-14	22392-22400	research	_	
137-15	22401-22406	while	_	
137-16	22407-22416	extending	_	
137-17	22417-22425	findings	_	
137-18	22426-22428	to	_	
137-19	22429-22442	schizophrenia	_	
137-20	22442-22443	.	_	

#Text=Our reliability results indicate: 1) Global spectral measures of normalized power showed excellent test-retest reliability in theta-gamma bands and good reliability in delta band in both groups, 2) Regional normalized power across one week showed excellent reliability in both groups but lower reliability in SZ, 3) Parietal alpha spectral measures had excellent reliability across one hour and one week in both groups, but poor reliability in source power across one hour in SZ, and 4) Source functional connectivity had unreliable ICC values suggesting the wPLI-debiased measure may not be optimal for test-retest reliability and may not yield replicable findings in SZ.
138-1	22444-22447	Our	_	
138-2	22448-22459	reliability	_	
138-3	22460-22467	results	_	
138-4	22468-22476	indicate	_	
138-5	22476-22477	:	_	
138-6	22478-22479	1	_	
138-7	22479-22480	)	_	
138-8	22481-22487	Global	_	
138-9	22488-22496	spectral	_	
138-10	22497-22505	measures	_	
138-11	22506-22508	of	_	
138-12	22509-22519	normalized	_	
138-13	22520-22525	power	_	
138-14	22526-22532	showed	_	
138-15	22533-22542	excellent	_	
138-16	22543-22554	test-retest	_	
138-17	22555-22566	reliability	_	
138-18	22567-22569	in	_	
138-19	22570-22581	theta-gamma	_	
138-20	22582-22587	bands	_	
138-21	22588-22591	and	_	
138-22	22592-22596	good	_	
138-23	22597-22608	reliability	_	
138-24	22609-22611	in	_	
138-25	22612-22617	delta	_	
138-26	22618-22622	band	_	
138-27	22623-22625	in	_	
138-28	22626-22630	both	_	
138-29	22631-22637	groups	_	
138-30	22637-22638	,	_	
138-31	22639-22640	2	_	
138-32	22640-22641	)	_	
138-33	22642-22650	Regional	_	
138-34	22651-22661	normalized	_	
138-35	22662-22667	power	_	
138-36	22668-22674	across	_	
138-37	22675-22678	one	_	
138-38	22679-22683	week	_	
138-39	22684-22690	showed	_	
138-40	22691-22700	excellent	_	
138-41	22701-22712	reliability	_	
138-42	22713-22715	in	_	
138-43	22716-22720	both	_	
138-44	22721-22727	groups	_	
138-45	22728-22731	but	_	
138-46	22732-22737	lower	_	
138-47	22738-22749	reliability	_	
138-48	22750-22752	in	_	
138-49	22753-22755	SZ	_	
138-50	22755-22756	,	_	
138-51	22757-22758	3	_	
138-52	22758-22759	)	_	
138-53	22760-22768	Parietal	_	
138-54	22769-22774	alpha	_	
138-55	22775-22783	spectral	_	
138-56	22784-22792	measures	_	
138-57	22793-22796	had	_	
138-58	22797-22806	excellent	_	
138-59	22807-22818	reliability	_	
138-60	22819-22825	across	_	
138-61	22826-22829	one	_	
138-62	22830-22834	hour	_	
138-63	22835-22838	and	_	
138-64	22839-22842	one	_	
138-65	22843-22847	week	_	
138-66	22848-22850	in	_	
138-67	22851-22855	both	_	
138-68	22856-22862	groups	_	
138-69	22862-22863	,	_	
138-70	22864-22867	but	_	
138-71	22868-22872	poor	_	
138-72	22873-22884	reliability	_	
138-73	22885-22887	in	_	
138-74	22888-22894	source	_	
138-75	22895-22900	power	_	
138-76	22901-22907	across	_	
138-77	22908-22911	one	_	
138-78	22912-22916	hour	_	
138-79	22917-22919	in	_	
138-80	22920-22922	SZ	_	
138-81	22922-22923	,	_	
138-82	22924-22927	and	_	
138-83	22928-22929	4	_	
138-84	22929-22930	)	_	
138-85	22931-22937	Source	_	
138-86	22938-22948	functional	_	
138-87	22949-22961	connectivity	_	
138-88	22962-22965	had	_	
138-89	22966-22976	unreliable	_	
138-90	22977-22980	ICC	_	
138-91	22981-22987	values	_	
138-92	22988-22998	suggesting	_	
138-93	22999-23002	the	_	
138-94	23003-23016	wPLI-debiased	_	
138-95	23017-23024	measure	_	
138-96	23025-23028	may	_	
138-97	23029-23032	not	_	
138-98	23033-23035	be	_	
138-99	23036-23043	optimal	_	
138-100	23044-23047	for	_	
138-101	23048-23059	test-retest	_	
138-102	23060-23071	reliability	_	
138-103	23072-23075	and	_	
138-104	23076-23079	may	_	
138-105	23080-23083	not	_	
138-106	23084-23089	yield	_	
138-107	23090-23100	replicable	_	
138-108	23101-23109	findings	_	
138-109	23110-23112	in	_	
138-110	23113-23115	SZ	_	
138-111	23115-23116	.	_	

#Text=Our study found reduced normalized power and alpha reactivity in SZ during the EC resting-state which negatively correlated with PANSS positive scores indicating higher PANSS positive scores were related to lower parietal alpha normalized power.
139-1	23117-23120	Our	_	
139-2	23121-23126	study	_	
139-3	23127-23132	found	_	
139-4	23133-23140	reduced	_	
139-5	23141-23151	normalized	_	
139-6	23152-23157	power	_	
139-7	23158-23161	and	_	
139-8	23162-23167	alpha	_	
139-9	23168-23178	reactivity	_	
139-10	23179-23181	in	_	
139-11	23182-23184	SZ	_	
139-12	23185-23191	during	_	
139-13	23192-23195	the	_	
139-14	23196-23198	EC	_	
139-15	23199-23212	resting-state	_	
139-16	23213-23218	which	_	
139-17	23219-23229	negatively	_	
139-18	23230-23240	correlated	_	
139-19	23241-23245	with	_	
139-20	23246-23251	PANSS	_	
139-21	23252-23260	positive	_	
139-22	23261-23267	scores	_	
139-23	23268-23278	indicating	_	
139-24	23279-23285	higher	_	
139-25	23286-23291	PANSS	_	
139-26	23292-23300	positive	_	
139-27	23301-23307	scores	_	
139-28	23308-23312	were	_	
139-29	23313-23320	related	_	
139-30	23321-23323	to	_	
139-31	23324-23329	lower	_	
139-32	23330-23338	parietal	_	
139-33	23339-23344	alpha	_	
139-34	23345-23355	normalized	_	
139-35	23356-23361	power	_	
139-36	23361-23362	.	_	

#Text=Reductions in resting-state alpha oscillations in SZ have been reported previously in MEG studies during EC and EO and with EEG, while the underlying functional significance of these alpha differences is unclear.
140-1	23363-23373	Reductions	_	
140-2	23374-23376	in	_	
140-3	23377-23390	resting-state	_	
140-4	23391-23396	alpha	_	
140-5	23397-23409	oscillations	_	
140-6	23410-23412	in	_	
140-7	23413-23415	SZ	_	
140-8	23416-23420	have	_	
140-9	23421-23425	been	_	
140-10	23426-23434	reported	_	
140-11	23435-23445	previously	_	
140-12	23446-23448	in	_	
140-13	23449-23452	MEG	_	
140-14	23453-23460	studies	_	
140-15	23461-23467	during	_	
140-16	23468-23470	EC	_	
140-17	23471-23474	and	_	
140-18	23475-23477	EO	_	
140-19	23478-23481	and	_	
140-20	23482-23486	with	_	
140-21	23487-23490	EEG	_	
140-22	23490-23491	,	_	
140-23	23492-23497	while	_	
140-24	23498-23501	the	_	
140-25	23502-23512	underlying	_	
140-26	23513-23523	functional	_	
140-27	23524-23536	significance	_	
140-28	23537-23539	of	_	
140-29	23540-23545	these	_	
140-30	23546-23551	alpha	_	
140-31	23552-23563	differences	_	
140-32	23564-23566	is	_	
140-33	23567-23574	unclear	_	
140-34	23574-23575	.	_	

#Text=Patients with schizophrenia may have an intrinsic deficit in the ability to generate alpha band oscillations, as reflected by reduced alpha power at illness onset, similar alpha power deficits in unmedicated and medicated patients and similar alpha band connectivity disruptions between first episode and chronic durations of illness.
141-1	23576-23584	Patients	_	
141-2	23585-23589	with	_	
141-3	23590-23603	schizophrenia	_	
141-4	23604-23607	may	_	
141-5	23608-23612	have	_	
141-6	23613-23615	an	_	
141-7	23616-23625	intrinsic	_	
141-8	23626-23633	deficit	_	
141-9	23634-23636	in	_	
141-10	23637-23640	the	_	
141-11	23641-23648	ability	_	
141-12	23649-23651	to	_	
141-13	23652-23660	generate	_	
141-14	23661-23666	alpha	_	
141-15	23667-23671	band	_	
141-16	23672-23684	oscillations	_	
141-17	23684-23685	,	_	
141-18	23686-23688	as	_	
141-19	23689-23698	reflected	_	
141-20	23699-23701	by	_	
141-21	23702-23709	reduced	_	
141-22	23710-23715	alpha	_	
141-23	23716-23721	power	_	
141-24	23722-23724	at	_	
141-25	23725-23732	illness	_	
141-26	23733-23738	onset	_	
141-27	23738-23739	,	_	
141-28	23740-23747	similar	_	
141-29	23748-23753	alpha	_	
141-30	23754-23759	power	_	
141-31	23760-23768	deficits	_	
141-32	23769-23771	in	_	
141-33	23772-23783	unmedicated	_	
141-34	23784-23787	and	_	
141-35	23788-23797	medicated	_	
141-36	23798-23806	patients	_	
141-37	23807-23810	and	_	
141-38	23811-23818	similar	_	
141-39	23819-23824	alpha	_	
141-40	23825-23829	band	_	
141-41	23830-23842	connectivity	_	
141-42	23843-23854	disruptions	_	
141-43	23855-23862	between	_	
141-44	23863-23868	first	_	
141-45	23869-23876	episode	_	
141-46	23877-23880	and	_	
141-47	23881-23888	chronic	_	
141-48	23889-23898	durations	_	
141-49	23899-23901	of	_	
141-50	23902-23909	illness	_	
141-51	23909-23910	.	_	

#Text=In the current study, we found reduced alpha spectral power in SZ at both visits across 7 days, with a high reliability/stability of alpha measures between visits (parietal ICCAvg=0.84).
142-1	23911-23913	In	_	
142-2	23914-23917	the	_	
142-3	23918-23925	current	_	
142-4	23926-23931	study	_	
142-5	23931-23932	,	_	
142-6	23933-23935	we	_	
142-7	23936-23941	found	_	
142-8	23942-23949	reduced	_	
142-9	23950-23955	alpha	_	
142-10	23956-23964	spectral	_	
142-11	23965-23970	power	_	
142-12	23971-23973	in	_	
142-13	23974-23976	SZ	_	
142-14	23977-23979	at	_	
142-15	23980-23984	both	_	
142-16	23985-23991	visits	_	
142-17	23992-23998	across	_	
142-18	23999-24000	7	_	
142-19	24001-24005	days	_	
142-20	24005-24006	,	_	
142-21	24007-24011	with	_	
142-22	24012-24013	a	_	
142-23	24014-24018	high	_	
142-24	24019-24030	reliability	_	
142-25	24030-24031	/	_	
142-26	24031-24040	stability	_	
142-27	24041-24043	of	_	
142-28	24044-24049	alpha	_	
142-29	24050-24058	measures	_	
142-30	24059-24066	between	_	
142-31	24067-24073	visits	_	
142-32	24074-24075	(	_	
142-33	24075-24083	parietal	_	
142-34	24084-24090	ICCAvg	_	
142-35	24090-24091	=	_	
142-36	24091-24095	0.84	_	
142-37	24095-24096	)	_	
142-38	24096-24097	.	_	

#Text=There is suggestion the alpha deficit would persist, as EEG alpha spectral power values remained stable over 36 months in adult outpatients diagnosed with schizophrenia (parietal ICCs=0.46–0.75) and moderately stable over a 9 month period in schizophrenia, bipolar, and nonpsychiatric patients.
143-1	24098-24103	There	_	
143-2	24104-24106	is	_	
143-3	24107-24117	suggestion	_	
143-4	24118-24121	the	_	
143-5	24122-24127	alpha	_	
143-6	24128-24135	deficit	_	
143-7	24136-24141	would	_	
143-8	24142-24149	persist	_	
143-9	24149-24150	,	_	
143-10	24151-24153	as	_	
143-11	24154-24157	EEG	_	
143-12	24158-24163	alpha	_	
143-13	24164-24172	spectral	_	
143-14	24173-24178	power	_	
143-15	24179-24185	values	_	
143-16	24186-24194	remained	_	
143-17	24195-24201	stable	_	
143-18	24202-24206	over	_	
143-19	24207-24209	36	_	
143-20	24210-24216	months	_	
143-21	24217-24219	in	_	
143-22	24220-24225	adult	_	
143-23	24226-24237	outpatients	_	
143-24	24238-24247	diagnosed	_	
143-25	24248-24252	with	_	
143-26	24253-24266	schizophrenia	_	
143-27	24267-24268	(	_	
143-28	24268-24276	parietal	_	
143-29	24277-24281	ICCs	_	
143-30	24281-24282	=	_	
143-31	24282-24286	0.46	_	
143-32	24286-24287	–	_	
143-33	24287-24291	0.75	_	
143-34	24291-24292	)	_	
143-35	24293-24296	and	_	
143-36	24297-24307	moderately	_	
143-37	24308-24314	stable	_	
143-38	24315-24319	over	_	
143-39	24320-24321	a	_	
143-40	24322-24323	9	_	
143-41	24324-24329	month	_	
143-42	24330-24336	period	_	
143-43	24337-24339	in	_	
143-44	24340-24353	schizophrenia	_	
143-45	24353-24354	,	_	
143-46	24355-24362	bipolar	_	
143-47	24362-24363	,	_	
143-48	24364-24367	and	_	
143-49	24368-24382	nonpsychiatric	_	
143-50	24383-24391	patients	_	
143-51	24391-24392	.	_	

#Text=Although, an EEG study indicated that while SZ may have similar reliability levels as HC, 40% more data may be required to obtain similar levels of artifact-free epochs, if using epoch-rejection to control for artifact contamination.
144-1	24393-24401	Although	_	
144-2	24401-24402	,	_	
144-3	24403-24405	an	_	
144-4	24406-24409	EEG	_	
144-5	24410-24415	study	_	
144-6	24416-24425	indicated	_	
144-7	24426-24430	that	_	
144-8	24431-24436	while	_	
144-9	24437-24439	SZ	_	
144-10	24440-24443	may	_	
144-11	24444-24448	have	_	
144-12	24449-24456	similar	_	
144-13	24457-24468	reliability	_	
144-14	24469-24475	levels	_	
144-15	24476-24478	as	_	
144-16	24479-24481	HC	_	
144-17	24481-24482	,	_	
144-18	24483-24486	40%	_	
144-19	24487-24491	more	_	
144-20	24492-24496	data	_	
144-21	24497-24500	may	_	
144-22	24501-24503	be	_	
144-23	24504-24512	required	_	
144-24	24513-24515	to	_	
144-25	24516-24522	obtain	_	
144-26	24523-24530	similar	_	
144-27	24531-24537	levels	_	
144-28	24538-24540	of	_	
144-29	24541-24554	artifact-free	_	
144-30	24555-24561	epochs	_	
144-31	24561-24562	,	_	
144-32	24563-24565	if	_	
144-33	24566-24571	using	_	
144-34	24572-24587	epoch-rejection	_	
144-35	24588-24590	to	_	
144-36	24591-24598	control	_	
144-37	24599-24602	for	_	
144-38	24603-24611	artifact	_	
144-39	24612-24625	contamination	_	
144-40	24625-24626	.	_	

#Text=Given that the thalamus plays an important role in generating alpha oscillatory activity in the parietal-occipital areas, reduced alpha power may arise from thalamic dysfunction or tonically enhanced arousal.
145-1	24627-24632	Given	_	
145-2	24633-24637	that	_	
145-3	24638-24641	the	_	
145-4	24642-24650	thalamus	_	
145-5	24651-24656	plays	_	
145-6	24657-24659	an	_	
145-7	24660-24669	important	_	
145-8	24670-24674	role	_	
145-9	24675-24677	in	_	
145-10	24678-24688	generating	_	
145-11	24689-24694	alpha	_	
145-12	24695-24706	oscillatory	_	
145-13	24707-24715	activity	_	
145-14	24716-24718	in	_	
145-15	24719-24722	the	_	
145-16	24723-24741	parietal-occipital	_	
145-17	24742-24747	areas	_	
145-18	24747-24748	,	_	
145-19	24749-24756	reduced	_	
145-20	24757-24762	alpha	_	
145-21	24763-24768	power	_	
145-22	24769-24772	may	_	
145-23	24773-24778	arise	_	
145-24	24779-24783	from	_	
145-25	24784-24792	thalamic	_	
145-26	24793-24804	dysfunction	_	
145-27	24805-24807	or	_	
145-28	24808-24817	tonically	_	
145-29	24818-24826	enhanced	_	
145-30	24827-24834	arousal	_	
145-31	24834-24835	.	_	

#Text=Alternatively, cortical generators from the parieto-occipital sulcus, visual cortex and/or other visual areas such as the fusiform/lingual gyrus, along with local and global neural organization may be altered in SZ.
146-1	24836-24849	Alternatively	_	
146-2	24849-24850	,	_	
146-3	24851-24859	cortical	_	
146-4	24860-24870	generators	_	
146-5	24871-24875	from	_	
146-6	24876-24879	the	_	
146-7	24880-24897	parieto-occipital	_	
146-8	24898-24904	sulcus	_	
146-9	24904-24905	,	_	
146-10	24906-24912	visual	_	
146-11	24913-24919	cortex	_	
146-12	24920-24923	and	_	
146-13	24923-24924	/	_	
146-14	24924-24926	or	_	
146-15	24927-24932	other	_	
146-16	24933-24939	visual	_	
146-17	24940-24945	areas	_	
146-18	24946-24950	such	_	
146-19	24951-24953	as	_	
146-20	24954-24957	the	_	
146-21	24958-24966	fusiform	_	
146-22	24966-24967	/	_	
146-23	24967-24974	lingual	_	
146-24	24975-24980	gyrus	_	
146-25	24980-24981	,	_	
146-26	24982-24987	along	_	
146-27	24988-24992	with	_	
146-28	24993-24998	local	_	
146-29	24999-25002	and	_	
146-30	25003-25009	global	_	
146-31	25010-25016	neural	_	
146-32	25017-25029	organization	_	
146-33	25030-25033	may	_	
146-34	25034-25036	be	_	
146-35	25037-25044	altered	_	
146-36	25045-25047	in	_	
146-37	25048-25050	SZ	_	
146-38	25050-25051	.	_	

#Text=The neural oscillations recorded with MEG may arise from a mixture of generating processes ranging from local circuitry to large-scale networks; therefore, it is possible that different generators are involved in abnormal alpha oscillations in patients with SZ.
147-1	25052-25055	The	_	
147-2	25056-25062	neural	_	
147-3	25063-25075	oscillations	_	
147-4	25076-25084	recorded	_	
147-5	25085-25089	with	_	
147-6	25090-25093	MEG	_	
147-7	25094-25097	may	_	
147-8	25098-25103	arise	_	
147-9	25104-25108	from	_	
147-10	25109-25110	a	_	
147-11	25111-25118	mixture	_	
147-12	25119-25121	of	_	
147-13	25122-25132	generating	_	
147-14	25133-25142	processes	_	
147-15	25143-25150	ranging	_	
147-16	25151-25155	from	_	
147-17	25156-25161	local	_	
147-18	25162-25171	circuitry	_	
147-19	25172-25174	to	_	
147-20	25175-25186	large-scale	_	
147-21	25187-25195	networks	_	
147-22	25195-25196	;	_	
147-23	25197-25206	therefore	_	
147-24	25206-25207	,	_	
147-25	25208-25210	it	_	
147-26	25211-25213	is	_	
147-27	25214-25222	possible	_	
147-28	25223-25227	that	_	
147-29	25228-25237	different	_	
147-30	25238-25248	generators	_	
147-31	25249-25252	are	_	
147-32	25253-25261	involved	_	
147-33	25262-25264	in	_	
147-34	25265-25273	abnormal	_	
147-35	25274-25279	alpha	_	
147-36	25280-25292	oscillations	_	
147-37	25293-25295	in	_	
147-38	25296-25304	patients	_	
147-39	25305-25309	with	_	
147-40	25310-25312	SZ	_	
147-41	25312-25313	.	_	

#Text=Targeting parietal alpha power with Transcranial Magnetic Stimulation (TMS) represents a novel treatment, especially since EEG research has found improvement in patient positive and general psychotic symptoms and alpha power normalization following TMS treatment.
148-1	25314-25323	Targeting	_	
148-2	25324-25332	parietal	_	
148-3	25333-25338	alpha	_	
148-4	25339-25344	power	_	
148-5	25345-25349	with	_	
148-6	25350-25362	Transcranial	_	
148-7	25363-25371	Magnetic	_	
148-8	25372-25383	Stimulation	_	
148-9	25384-25385	(	_	
148-10	25385-25388	TMS	_	
148-11	25388-25389	)	_	
148-12	25390-25400	represents	_	
148-13	25401-25402	a	_	
148-14	25403-25408	novel	_	
148-15	25409-25418	treatment	_	
148-16	25418-25419	,	_	
148-17	25420-25430	especially	_	
148-18	25431-25436	since	_	
148-19	25437-25440	EEG	_	
148-20	25441-25449	research	_	
148-21	25450-25453	has	_	
148-22	25454-25459	found	_	
148-23	25460-25471	improvement	_	
148-24	25472-25474	in	_	
148-25	25475-25482	patient	_	
148-26	25483-25491	positive	_	
148-27	25492-25495	and	_	
148-28	25496-25503	general	_	
148-29	25504-25513	psychotic	_	
148-30	25514-25522	symptoms	_	
148-31	25523-25526	and	_	
148-32	25527-25532	alpha	_	
148-33	25533-25538	power	_	
148-34	25539-25552	normalization	_	
148-35	25553-25562	following	_	
148-36	25563-25566	TMS	_	
148-37	25567-25576	treatment	_	
148-38	25576-25577	.	_	

#Text=To our knowledge, this is the first MEG test-retest study in participants with schizophrenia.
149-1	25578-25580	To	_	
149-2	25581-25584	our	_	
149-3	25585-25594	knowledge	_	
149-4	25594-25595	,	_	
149-5	25596-25600	this	_	
149-6	25601-25603	is	_	
149-7	25604-25607	the	_	
149-8	25608-25613	first	_	
149-9	25614-25617	MEG	_	
149-10	25618-25629	test-retest	_	
149-11	25630-25635	study	_	
149-12	25636-25638	in	_	
149-13	25639-25651	participants	_	
149-14	25652-25656	with	_	
149-15	25657-25670	schizophrenia	_	
149-16	25670-25671	.	_	

#Text=While participants with schizophrenia had excellent reliability in many spectral measures, there were a few instances of lower reliability (i.e. source power across one hour and generally lower one week values), as well as larger 95% CI around ICC estimates indicating greater variability between visits.
150-1	25672-25677	While	_	
150-2	25678-25690	participants	_	
150-3	25691-25695	with	_	
150-4	25696-25709	schizophrenia	_	
150-5	25710-25713	had	_	
150-6	25714-25723	excellent	_	
150-7	25724-25735	reliability	_	
150-8	25736-25738	in	_	
150-9	25739-25743	many	_	
150-10	25744-25752	spectral	_	
150-11	25753-25761	measures	_	
150-12	25761-25762	,	_	
150-13	25763-25768	there	_	
150-14	25769-25773	were	_	
150-15	25774-25775	a	_	
150-16	25776-25779	few	_	
150-17	25780-25789	instances	_	
150-18	25790-25792	of	_	
150-19	25793-25798	lower	_	
150-20	25799-25810	reliability	_	
150-21	25811-25812	(	_	
150-22	25812-25815	i.e	_	
150-23	25815-25816	.	_	
150-24	25817-25823	source	_	
150-25	25824-25829	power	_	
150-26	25830-25836	across	_	
150-27	25837-25840	one	_	
150-28	25841-25845	hour	_	
150-29	25846-25849	and	_	
150-30	25850-25859	generally	_	
150-31	25860-25865	lower	_	
150-32	25866-25869	one	_	
150-33	25870-25874	week	_	
150-34	25875-25881	values	_	
150-35	25881-25882	)	_	
150-36	25882-25883	,	_	
150-37	25884-25886	as	_	
150-38	25887-25891	well	_	
150-39	25892-25894	as	_	
150-40	25895-25901	larger	_	
150-41	25902-25905	95%	_	
150-42	25906-25908	CI	_	
150-43	25909-25915	around	_	
150-44	25916-25919	ICC	_	
150-45	25920-25929	estimates	_	
150-46	25930-25940	indicating	_	
150-47	25941-25948	greater	_	
150-48	25949-25960	variability	_	
150-49	25961-25968	between	_	
150-50	25969-25975	visits	_	
150-51	25975-25976	.	_	

#Text=However, it is unclear what factors may be driving lower reliability in patients.
151-1	25977-25984	However	_	
151-2	25984-25985	,	_	
151-3	25986-25988	it	_	
151-4	25989-25991	is	_	
151-5	25992-25999	unclear	_	
151-6	26000-26004	what	_	
151-7	26005-26012	factors	_	
151-8	26013-26016	may	_	
151-9	26017-26019	be	_	
151-10	26020-26027	driving	_	
151-11	26028-26033	lower	_	
151-12	26034-26045	reliability	_	
151-13	26046-26048	in	_	
151-14	26049-26057	patients	_	
151-15	26057-26058	.	_	

#Text=In the current study we monitored several variables such as time of day, PANSS scores, and medication, and found no difference between visits.
152-1	26059-26061	In	_	
152-2	26062-26065	the	_	
152-3	26066-26073	current	_	
152-4	26074-26079	study	_	
152-5	26080-26082	we	_	
152-6	26083-26092	monitored	_	
152-7	26093-26100	several	_	
152-8	26101-26110	variables	_	
152-9	26111-26115	such	_	
152-10	26116-26118	as	_	
152-11	26119-26123	time	_	
152-12	26124-26126	of	_	
152-13	26127-26130	day	_	
152-14	26130-26131	,	_	
152-15	26132-26137	PANSS	_	
152-16	26138-26144	scores	_	
152-17	26144-26145	,	_	
152-18	26146-26149	and	_	
152-19	26150-26160	medication	_	
152-20	26160-26161	,	_	
152-21	26162-26165	and	_	
152-22	26166-26171	found	_	
152-23	26172-26174	no	_	
152-24	26175-26185	difference	_	
152-25	26186-26193	between	_	
152-26	26194-26200	visits	_	
152-27	26200-26201	.	_	

#Text=Additionally, to ensure compliance with the test-retest design, we recruited a stable cohort of patients who successfully completed other neuroimaging studies and were familiar with imaging procedures minimizing anxiety or task unfamiliarity confounds.
153-1	26202-26214	Additionally	_	
153-2	26214-26215	,	_	
153-3	26216-26218	to	_	
153-4	26219-26225	ensure	_	
153-5	26226-26236	compliance	_	
153-6	26237-26241	with	_	
153-7	26242-26245	the	_	
153-8	26246-26257	test-retest	_	
153-9	26258-26264	design	_	
153-10	26264-26265	,	_	
153-11	26266-26268	we	_	
153-12	26269-26278	recruited	_	
153-13	26279-26280	a	_	
153-14	26281-26287	stable	_	
153-15	26288-26294	cohort	_	
153-16	26295-26297	of	_	
153-17	26298-26306	patients	_	
153-18	26307-26310	who	_	
153-19	26311-26323	successfully	_	
153-20	26324-26333	completed	_	
153-21	26334-26339	other	_	
153-22	26340-26352	neuroimaging	_	
153-23	26353-26360	studies	_	
153-24	26361-26364	and	_	
153-25	26365-26369	were	_	
153-26	26370-26378	familiar	_	
153-27	26379-26383	with	_	
153-28	26384-26391	imaging	_	
153-29	26392-26402	procedures	_	
153-30	26403-26413	minimizing	_	
153-31	26414-26421	anxiety	_	
153-32	26422-26424	or	_	
153-33	26425-26429	task	_	
153-34	26430-26443	unfamiliarity	_	
153-35	26444-26453	confounds	_	
153-36	26453-26454	.	_	

#Text=Prior MEG spectral test-retest studies have been performed exclusively in healthy controls. reported good reliability for power in sensor and source space in the theta, alpha, and beta frequency bands (ICCs >0.6), with lower reliability in delta and gamma bands in EO.
154-1	26455-26460	Prior	_	
154-2	26461-26464	MEG	_	
154-3	26465-26473	spectral	_	
154-4	26474-26485	test-retest	_	
154-5	26486-26493	studies	_	
154-6	26494-26498	have	_	
154-7	26499-26503	been	_	
154-8	26504-26513	performed	_	
154-9	26514-26525	exclusively	_	
154-10	26526-26528	in	_	
154-11	26529-26536	healthy	_	
154-12	26537-26545	controls	_	
154-13	26545-26546	.	_	
154-14	26547-26555	reported	_	
154-15	26556-26560	good	_	
154-16	26561-26572	reliability	_	
154-17	26573-26576	for	_	
154-18	26577-26582	power	_	
154-19	26583-26585	in	_	
154-20	26586-26592	sensor	_	
154-21	26593-26596	and	_	
154-22	26597-26603	source	_	
154-23	26604-26609	space	_	
154-24	26610-26612	in	_	
154-25	26613-26616	the	_	
154-26	26617-26622	theta	_	
154-27	26622-26623	,	_	
154-28	26624-26629	alpha	_	
154-29	26629-26630	,	_	
154-30	26631-26634	and	_	
154-31	26635-26639	beta	_	
154-32	26640-26649	frequency	_	
154-33	26650-26655	bands	_	
154-34	26656-26657	(	_	
154-35	26657-26661	ICCs	_	
154-36	26662-26663	>	_	
154-37	26663-26666	0.6	_	
154-38	26666-26667	)	_	
154-39	26667-26668	,	_	
154-40	26669-26673	with	_	
154-41	26674-26679	lower	_	
154-42	26680-26691	reliability	_	
154-43	26692-26694	in	_	
154-44	26695-26700	delta	_	
154-45	26701-26704	and	_	
154-46	26705-26710	gamma	_	
154-47	26711-26716	bands	_	
154-48	26717-26719	in	_	
154-49	26720-26722	EO	_	
154-50	26722-26723	.	_	

#Text=The current study found similar excellent reliability across one week in most regions and bands in HC (ICCs >0.72) with lower reliability in delta band EC (ICCs >0.46).
155-1	26724-26727	The	_	
155-2	26728-26735	current	_	
155-3	26736-26741	study	_	
155-4	26742-26747	found	_	
155-5	26748-26755	similar	_	
155-6	26756-26765	excellent	_	
155-7	26766-26777	reliability	_	
155-8	26778-26784	across	_	
155-9	26785-26788	one	_	
155-10	26789-26793	week	_	
155-11	26794-26796	in	_	
155-12	26797-26801	most	_	
155-13	26802-26809	regions	_	
155-14	26810-26813	and	_	
155-15	26814-26819	bands	_	
155-16	26820-26822	in	_	
155-17	26823-26825	HC	_	
155-18	26826-26827	(	_	
155-19	26827-26831	ICCs	_	
155-20	26832-26833	>	_	
155-21	26833-26837	0.72	_	
155-22	26837-26838	)	_	
155-23	26839-26843	with	_	
155-24	26844-26849	lower	_	
155-25	26850-26861	reliability	_	
155-26	26862-26864	in	_	
155-27	26865-26870	delta	_	
155-28	26871-26875	band	_	
155-29	26876-26878	EC	_	
155-30	26879-26880	(	_	
155-31	26880-26884	ICCs	_	
155-32	26885-26886	>	_	
155-33	26886-26890	0.46	_	
155-34	26890-26891	)	_	
155-35	26891-26892	.	_	

#Text=These results suggest that delta measurements may be impacted by environmental and biological noise.
156-1	26893-26898	These	_	
156-2	26899-26906	results	_	
156-3	26907-26914	suggest	_	
156-4	26915-26919	that	_	
156-5	26920-26925	delta	_	
156-6	26926-26938	measurements	_	
156-7	26939-26942	may	_	
156-8	26943-26945	be	_	
156-9	26946-26954	impacted	_	
156-10	26955-26957	by	_	
156-11	26958-26971	environmental	_	
156-12	26972-26975	and	_	
156-13	26976-26986	biological	_	
156-14	26987-26992	noise	_	
156-15	26992-26993	.	_	

#Text=While the results between studies are similar, ICC estimates were modeled differently and ICC values will fluctuate based on the model and variance assumptions.
157-1	26994-26999	While	_	
157-2	27000-27003	the	_	
157-3	27004-27011	results	_	
157-4	27012-27019	between	_	
157-5	27020-27027	studies	_	
157-6	27028-27031	are	_	
157-7	27032-27039	similar	_	
157-8	27039-27040	,	_	
157-9	27041-27044	ICC	_	
157-10	27045-27054	estimates	_	
157-11	27055-27059	were	_	
157-12	27060-27067	modeled	_	
157-13	27068-27079	differently	_	
157-14	27080-27083	and	_	
157-15	27084-27087	ICC	_	
157-16	27088-27094	values	_	
157-17	27095-27099	will	_	
157-18	27100-27109	fluctuate	_	
157-19	27110-27115	based	_	
157-20	27116-27118	on	_	
157-21	27119-27122	the	_	
157-22	27123-27128	model	_	
157-23	27129-27132	and	_	
157-24	27133-27141	variance	_	
157-25	27142-27153	assumptions	_	
157-26	27153-27154	.	_	

#Text=Other MEG-derived task specific signals at the sensor and source level have also shown high reliability, particularly, auditory steady-state spectral power [ICCs ~0.61–0.82] and phase coherence [ICCs ~0.86–0.96], visually induced gamma band oscillations [average ICC=0.861], mismatch negativity amplitude [ICC ~0.81–0.90] and peak latency [ICC ~0.74–0.88], paired-click auditory gating [ICCs >0.80], N-back working memory M170 response amplitude [ICCs >0.44] and late positive potential [ICCs > 0.93].
158-1	27155-27160	Other	_	
158-2	27161-27172	MEG-derived	_	
158-3	27173-27177	task	_	
158-4	27178-27186	specific	_	
158-5	27187-27194	signals	_	
158-6	27195-27197	at	_	
158-7	27198-27201	the	_	
158-8	27202-27208	sensor	_	
158-9	27209-27212	and	_	
158-10	27213-27219	source	_	
158-11	27220-27225	level	_	
158-12	27226-27230	have	_	
158-13	27231-27235	also	_	
158-14	27236-27241	shown	_	
158-15	27242-27246	high	_	
158-16	27247-27258	reliability	_	
158-17	27258-27259	,	_	
158-18	27260-27272	particularly	_	
158-19	27272-27273	,	_	
158-20	27274-27282	auditory	_	
158-21	27283-27295	steady-state	_	
158-22	27296-27304	spectral	_	
158-23	27305-27310	power	_	
158-24	27311-27312	[	_	
158-25	27312-27316	ICCs	_	
158-26	27317-27318	~	_	
158-27	27318-27322	0.61	_	
158-28	27322-27323	–	_	
158-29	27323-27327	0.82	_	
158-30	27327-27328	]	_	
158-31	27329-27332	and	_	
158-32	27333-27338	phase	_	
158-33	27339-27348	coherence	_	
158-34	27349-27350	[	_	
158-35	27350-27354	ICCs	_	
158-36	27355-27356	~	_	
158-37	27356-27360	0.86	_	
158-38	27360-27361	–	_	
158-39	27361-27365	0.96	_	
158-40	27365-27366	]	_	
158-41	27366-27367	,	_	
158-42	27368-27376	visually	_	
158-43	27377-27384	induced	_	
158-44	27385-27390	gamma	_	
158-45	27391-27395	band	_	
158-46	27396-27408	oscillations	_	
158-47	27409-27410	[	_	
158-48	27410-27417	average	_	
158-49	27418-27421	ICC	_	
158-50	27421-27422	=	_	
158-51	27422-27427	0.861	_	
158-52	27427-27428	]	_	
158-53	27428-27429	,	_	
158-54	27430-27438	mismatch	_	
158-55	27439-27449	negativity	_	
158-56	27450-27459	amplitude	_	
158-57	27460-27461	[	_	
158-58	27461-27464	ICC	_	
158-59	27465-27466	~	_	
158-60	27466-27470	0.81	_	
158-61	27470-27471	–	_	
158-62	27471-27475	0.90	_	
158-63	27475-27476	]	_	
158-64	27477-27480	and	_	
158-65	27481-27485	peak	_	
158-66	27486-27493	latency	_	
158-67	27494-27495	[	_	
158-68	27495-27498	ICC	_	
158-69	27499-27500	~	_	
158-70	27500-27504	0.74	_	
158-71	27504-27505	–	_	
158-72	27505-27509	0.88	_	
158-73	27509-27510	]	_	
158-74	27510-27511	,	_	
158-75	27512-27524	paired-click	_	
158-76	27525-27533	auditory	_	
158-77	27534-27540	gating	_	
158-78	27541-27542	[	_	
158-79	27542-27546	ICCs	_	
158-80	27547-27548	>	_	
158-81	27548-27552	0.80	_	
158-82	27552-27553	]	_	
158-83	27553-27554	,	_	
158-84	27555-27561	N-back	_	
158-85	27562-27569	working	_	
158-86	27570-27576	memory	_	
158-87	27577-27581	M170	_	
158-88	27582-27590	response	_	
158-89	27591-27600	amplitude	_	
158-90	27601-27602	[	_	
158-91	27602-27606	ICCs	_	
158-92	27607-27608	>	_	
158-93	27608-27612	0.44	_	
158-94	27612-27613	]	_	
158-95	27614-27617	and	_	
158-96	27618-27622	late	_	
158-97	27623-27631	positive	_	
158-98	27632-27641	potential	_	
158-99	27642-27643	[	_	
158-100	27643-27647	ICCs	_	
158-101	27648-27649	>	_	
158-102	27650-27654	0.93	_	
158-103	27654-27655	]	_	
158-104	27655-27656	.	_	

#Text=Here we found that source functional connectivity reliability based on weighted-phase lag index (ICC=0–0.32) was much lower than power spectrum reliability (ICC=0.68–0.95).
159-1	27657-27661	Here	_	
159-2	27662-27664	we	_	
159-3	27665-27670	found	_	
159-4	27671-27675	that	_	
159-5	27676-27682	source	_	
159-6	27683-27693	functional	_	
159-7	27694-27706	connectivity	_	
159-8	27707-27718	reliability	_	
159-9	27719-27724	based	_	
159-10	27725-27727	on	_	
159-11	27728-27742	weighted-phase	_	
159-12	27743-27746	lag	_	
159-13	27747-27752	index	_	
159-14	27753-27754	(	_	
159-15	27754-27757	ICC	_	
159-16	27757-27758	=	_	
159-17	27758-27759	0	_	
159-18	27759-27760	–	_	
159-19	27760-27764	0.32	_	
159-20	27764-27765	)	_	
159-21	27766-27769	was	_	
159-22	27770-27774	much	_	
159-23	27775-27780	lower	_	
159-24	27781-27785	than	_	
159-25	27786-27791	power	_	
159-26	27792-27800	spectrum	_	
159-27	27801-27812	reliability	_	
159-28	27813-27814	(	_	
159-29	27814-27817	ICC	_	
159-30	27817-27818	=	_	
159-31	27818-27822	0.68	_	
159-32	27822-27823	–	_	
159-33	27823-27827	0.95	_	
159-34	27827-27828	)	_	
159-35	27828-27829	.	_	

#Text=Weighted-phase lag index was used to minimize the impact of volume conduction and zero-lag synchronization, known problems in MEG connectivity analysis; however, it is now clear phase-related connectivity may be poorly suited for test-retest reliability.
160-1	27830-27844	Weighted-phase	_	
160-2	27845-27848	lag	_	
160-3	27849-27854	index	_	
160-4	27855-27858	was	_	
160-5	27859-27863	used	_	
160-6	27864-27866	to	_	
160-7	27867-27875	minimize	_	
160-8	27876-27879	the	_	
160-9	27880-27886	impact	_	
160-10	27887-27889	of	_	
160-11	27890-27896	volume	_	
160-12	27897-27907	conduction	_	
160-13	27908-27911	and	_	
160-14	27912-27920	zero-lag	_	
160-15	27921-27936	synchronization	_	
160-16	27936-27937	,	_	
160-17	27938-27943	known	_	
160-18	27944-27952	problems	_	
160-19	27953-27955	in	_	
160-20	27956-27959	MEG	_	
160-21	27960-27972	connectivity	_	
160-22	27973-27981	analysis	_	
160-23	27981-27982	;	_	
160-24	27983-27990	however	_	
160-25	27990-27991	,	_	
160-26	27992-27994	it	_	
160-27	27995-27997	is	_	
160-28	27998-28001	now	_	
160-29	28002-28007	clear	_	
160-30	28008-28021	phase-related	_	
160-31	28022-28034	connectivity	_	
160-32	28035-28038	may	_	
160-33	28039-28041	be	_	
160-34	28042-28048	poorly	_	
160-35	28049-28055	suited	_	
160-36	28056-28059	for	_	
160-37	28060-28071	test-retest	_	
160-38	28072-28083	reliability	_	
160-39	28083-28084	.	_	

#Text=Prior studies in HC have shown MEG resting-state functional connectivity reliability depends greatly on the frequency band and connectivity measure used, with greatest reliability of phase-locking values in alpha, beta, and gamma bands (averages 0.74–0.82), and lowest reliability for phase-lag index in all frequency bands (ICCs<0.1).
161-1	28085-28090	Prior	_	
161-2	28091-28098	studies	_	
161-3	28099-28101	in	_	
161-4	28102-28104	HC	_	
161-5	28105-28109	have	_	
161-6	28110-28115	shown	_	
161-7	28116-28119	MEG	_	
161-8	28120-28133	resting-state	_	
161-9	28134-28144	functional	_	
161-10	28145-28157	connectivity	_	
161-11	28158-28169	reliability	_	
161-12	28170-28177	depends	_	
161-13	28178-28185	greatly	_	
161-14	28186-28188	on	_	
161-15	28189-28192	the	_	
161-16	28193-28202	frequency	_	
161-17	28203-28207	band	_	
161-18	28208-28211	and	_	
161-19	28212-28224	connectivity	_	
161-20	28225-28232	measure	_	
161-21	28233-28237	used	_	
161-22	28237-28238	,	_	
161-23	28239-28243	with	_	
161-24	28244-28252	greatest	_	
161-25	28253-28264	reliability	_	
161-26	28265-28267	of	_	
161-27	28268-28281	phase-locking	_	
161-28	28282-28288	values	_	
161-29	28289-28291	in	_	
161-30	28292-28297	alpha	_	
161-31	28297-28298	,	_	
161-32	28299-28303	beta	_	
161-33	28303-28304	,	_	
161-34	28305-28308	and	_	
161-35	28309-28314	gamma	_	
161-36	28315-28320	bands	_	
161-37	28321-28322	(	_	
161-38	28322-28330	averages	_	
161-39	28331-28335	0.74	_	
161-40	28335-28336	–	_	
161-41	28336-28340	0.82	_	
161-42	28340-28341	)	_	
161-43	28341-28342	,	_	
161-44	28343-28346	and	_	
161-45	28347-28353	lowest	_	
161-46	28354-28365	reliability	_	
161-47	28366-28369	for	_	
161-48	28370-28379	phase-lag	_	
161-49	28380-28385	index	_	
161-50	28386-28388	in	_	
161-51	28389-28392	all	_	
161-52	28393-28402	frequency	_	
161-53	28403-28408	bands	_	
161-54	28409-28410	(	_	
161-55	28410-28414	ICCs	_	
161-56	28414-28415	<	_	
161-57	28415-28418	0.1	_	
161-58	28418-28419	)	_	
161-59	28419-28420	.	_	

#Text=As suggested by others, connectivity measures should employ correlation between orthogonalized, band-limited, power envelopes, and/or longer epochs and recordings to increase SNR.
162-1	28421-28423	As	_	
162-2	28424-28433	suggested	_	
162-3	28434-28436	by	_	
162-4	28437-28443	others	_	
162-5	28443-28444	,	_	
162-6	28445-28457	connectivity	_	
162-7	28458-28466	measures	_	
162-8	28467-28473	should	_	
162-9	28474-28480	employ	_	
162-10	28481-28492	correlation	_	
162-11	28493-28500	between	_	
162-12	28501-28515	orthogonalized	_	
162-13	28515-28516	,	_	
162-14	28517-28529	band-limited	_	
162-15	28529-28530	,	_	
162-16	28531-28536	power	_	
162-17	28537-28546	envelopes	_	
162-18	28546-28547	,	_	
162-19	28548-28551	and	_	
162-20	28551-28552	/	_	
162-21	28552-28554	or	_	
162-22	28555-28561	longer	_	
162-23	28562-28568	epochs	_	
162-24	28569-28572	and	_	
162-25	28573-28583	recordings	_	
162-26	28584-28586	to	_	
162-27	28587-28595	increase	_	
162-28	28596-28599	SNR	_	
162-29	28599-28600	.	_	

#Text=While phase-based measures have fair repeatability for group-level inference in large datasets, phase-based measures may be noisier estimates in short or noisy recordings, or in smaller studies.
163-1	28601-28606	While	_	
163-2	28607-28618	phase-based	_	
163-3	28619-28627	measures	_	
163-4	28628-28632	have	_	
163-5	28633-28637	fair	_	
163-6	28638-28651	repeatability	_	
163-7	28652-28655	for	_	
163-8	28656-28667	group-level	_	
163-9	28668-28677	inference	_	
163-10	28678-28680	in	_	
163-11	28681-28686	large	_	
163-12	28687-28695	datasets	_	
163-13	28695-28696	,	_	
163-14	28697-28708	phase-based	_	
163-15	28709-28717	measures	_	
163-16	28718-28721	may	_	
163-17	28722-28724	be	_	
163-18	28725-28732	noisier	_	
163-19	28733-28742	estimates	_	
163-20	28743-28745	in	_	
163-21	28746-28751	short	_	
163-22	28752-28754	or	_	
163-23	28755-28760	noisy	_	
163-24	28761-28771	recordings	_	
163-25	28771-28772	,	_	
163-26	28773-28775	or	_	
163-27	28776-28778	in	_	
163-28	28779-28786	smaller	_	
163-29	28787-28794	studies	_	
163-30	28794-28795	.	_	

#Text=Future studies with a larger sample size may find higher reliability of the wpli-debiased measure than reported here, given our small sample size.
164-1	28796-28802	Future	_	
164-2	28803-28810	studies	_	
164-3	28811-28815	with	_	
164-4	28816-28817	a	_	
164-5	28818-28824	larger	_	
164-6	28825-28831	sample	_	
164-7	28832-28836	size	_	
164-8	28837-28840	may	_	
164-9	28841-28845	find	_	
164-10	28846-28852	higher	_	
164-11	28853-28864	reliability	_	
164-12	28865-28867	of	_	
164-13	28868-28871	the	_	
164-14	28872-28885	wpli-debiased	_	
164-15	28886-28893	measure	_	
164-16	28894-28898	than	_	
164-17	28899-28907	reported	_	
164-18	28908-28912	here	_	
164-19	28912-28913	,	_	
164-20	28914-28919	given	_	
164-21	28920-28923	our	_	
164-22	28924-28929	small	_	
164-23	28930-28936	sample	_	
164-24	28937-28941	size	_	
164-25	28941-28942	.	_	

#Text=Furthermore, it remains unknown if the low reliability is due to the FNC measure itself, or the dynamic nature of the brain.
165-1	28943-28954	Furthermore	_	
165-2	28954-28955	,	_	
165-3	28956-28958	it	_	
165-4	28959-28966	remains	_	
165-5	28967-28974	unknown	_	
165-6	28975-28977	if	_	
165-7	28978-28981	the	_	
165-8	28982-28985	low	_	
165-9	28986-28997	reliability	_	
165-10	28998-29000	is	_	
165-11	29001-29004	due	_	
165-12	29005-29007	to	_	
165-13	29008-29011	the	_	
165-14	29012-29015	FNC	_	
165-15	29016-29023	measure	_	
165-16	29024-29030	itself	_	
165-17	29030-29031	,	_	
165-18	29032-29034	or	_	
165-19	29035-29038	the	_	
165-20	29039-29046	dynamic	_	
165-21	29047-29053	nature	_	
165-22	29054-29056	of	_	
165-23	29057-29060	the	_	
165-24	29061-29066	brain	_	
165-25	29066-29067	.	_	

#Text=Although the current study had a small sample size, we could examine the impact of recording length on reliability.
166-1	29068-29076	Although	_	
166-2	29077-29080	the	_	
166-3	29081-29088	current	_	
166-4	29089-29094	study	_	
166-5	29095-29098	had	_	
166-6	29099-29100	a	_	
166-7	29101-29106	small	_	
166-8	29107-29113	sample	_	
166-9	29114-29118	size	_	
166-10	29118-29119	,	_	
166-11	29120-29122	we	_	
166-12	29123-29128	could	_	
166-13	29129-29136	examine	_	
166-14	29137-29140	the	_	
166-15	29141-29147	impact	_	
166-16	29148-29150	of	_	
166-17	29151-29160	recording	_	
166-18	29161-29167	length	_	
166-19	29168-29170	on	_	
166-20	29171-29182	reliability	_	
166-21	29182-29183	.	_	

#Text=In the current study the longer task (Rest10 vs.
167-1	29184-29186	In	_	
167-2	29187-29190	the	_	
167-3	29191-29198	current	_	
167-4	29199-29204	study	_	
167-5	29205-29208	the	_	
167-6	29209-29215	longer	_	
167-7	29216-29220	task	_	
167-8	29221-29222	(	_	
167-9	29222-29228	Rest10	_	
167-10	29229-29231	vs	_	
167-11	29231-29232	.	_	

#Text=Rest4) did not offer significant improvement in wpli connectivity ICC values [HC ICCAvg=0.28, SZ ICCAvg=0.04 for long task vs.
168-1	29233-29238	Rest4	_	
168-2	29238-29239	)	_	
168-3	29240-29243	did	_	
168-4	29244-29247	not	_	
168-5	29248-29253	offer	_	
168-6	29254-29265	significant	_	
168-7	29266-29277	improvement	_	
168-8	29278-29280	in	_	
168-9	29281-29285	wpli	_	
168-10	29286-29298	connectivity	_	
168-11	29299-29302	ICC	_	
168-12	29303-29309	values	_	
168-13	29310-29311	[	_	
168-14	29311-29313	HC	_	
168-15	29314-29320	ICCAvg	_	
168-16	29320-29321	=	_	
168-17	29321-29325	0.28	_	
168-18	29325-29326	,	_	
168-19	29327-29329	SZ	_	
168-20	29330-29336	ICCAvg	_	
168-21	29336-29337	=	_	
168-22	29337-29341	0.04	_	
168-23	29342-29345	for	_	
168-24	29346-29350	long	_	
168-25	29351-29355	task	_	
168-26	29356-29358	vs	_	
168-27	29358-29359	.	_	

#Text=HC ICCAvg=0.02, SZ ICCAvg=0.09 for short task].
169-1	29360-29362	HC	_	
169-2	29363-29369	ICCAvg	_	
169-3	29369-29370	=	_	
169-4	29370-29374	0.02	_	
169-5	29374-29375	,	_	
169-6	29376-29378	SZ	_	
169-7	29379-29385	ICCAvg	_	
169-8	29385-29386	=	_	
169-9	29386-29390	0.09	_	
169-10	29391-29394	for	_	
169-11	29395-29400	short	_	
169-12	29401-29405	task	_	
169-13	29405-29406	]	_	
169-14	29406-29407	.	_	

#Text=Although analyzing data in source space minimizes the known issues to field spread and volume conduction that may be present in sensor data, the current study found generally lower reliability values at the source level.
170-1	29408-29416	Although	_	
170-2	29417-29426	analyzing	_	
170-3	29427-29431	data	_	
170-4	29432-29434	in	_	
170-5	29435-29441	source	_	
170-6	29442-29447	space	_	
170-7	29448-29457	minimizes	_	
170-8	29458-29461	the	_	
170-9	29462-29467	known	_	
170-10	29468-29474	issues	_	
170-11	29475-29477	to	_	
170-12	29478-29483	field	_	
170-13	29484-29490	spread	_	
170-14	29491-29494	and	_	
170-15	29495-29501	volume	_	
170-16	29502-29512	conduction	_	
170-17	29513-29517	that	_	
170-18	29518-29521	may	_	
170-19	29522-29524	be	_	
170-20	29525-29532	present	_	
170-21	29533-29535	in	_	
170-22	29536-29542	sensor	_	
170-23	29543-29547	data	_	
170-24	29547-29548	,	_	
170-25	29549-29552	the	_	
170-26	29553-29560	current	_	
170-27	29561-29566	study	_	
170-28	29567-29572	found	_	
170-29	29573-29582	generally	_	
170-30	29583-29588	lower	_	
170-31	29589-29600	reliability	_	
170-32	29601-29607	values	_	
170-33	29608-29610	at	_	
170-34	29611-29614	the	_	
170-35	29615-29621	source	_	
170-36	29622-29627	level	_	
170-37	29627-29628	.	_	

#Text=Perhaps the lower source reliability may be a reflection of the methods used to attain MEG source constructions (i.e. differences in anatomical versus functional source constructions, or inverse modeling method with MNE dSPM versus beamformer).
171-1	29629-29636	Perhaps	_	
171-2	29637-29640	the	_	
171-3	29641-29646	lower	_	
171-4	29647-29653	source	_	
171-5	29654-29665	reliability	_	
171-6	29666-29669	may	_	
171-7	29670-29672	be	_	
171-8	29673-29674	a	_	
171-9	29675-29685	reflection	_	
171-10	29686-29688	of	_	
171-11	29689-29692	the	_	
171-12	29693-29700	methods	_	
171-13	29701-29705	used	_	
171-14	29706-29708	to	_	
171-15	29709-29715	attain	_	
171-16	29716-29719	MEG	_	
171-17	29720-29726	source	_	
171-18	29727-29740	constructions	_	
171-19	29741-29742	(	_	
171-20	29742-29745	i.e	_	
171-21	29745-29746	.	_	
171-22	29747-29758	differences	_	
171-23	29759-29761	in	_	
171-24	29762-29772	anatomical	_	
171-25	29773-29779	versus	_	
171-26	29780-29790	functional	_	
171-27	29791-29797	source	_	
171-28	29798-29811	constructions	_	
171-29	29811-29812	,	_	
171-30	29813-29815	or	_	
171-31	29816-29823	inverse	_	
171-32	29824-29832	modeling	_	
171-33	29833-29839	method	_	
171-34	29840-29844	with	_	
171-35	29845-29848	MNE	_	
171-36	29849-29853	dSPM	_	
171-37	29854-29860	versus	_	
171-38	29861-29871	beamformer	_	
171-39	29871-29872	)	_	
171-40	29872-29873	.	_	

#Text=While other MEG rest studies have used anatomical boundaries to define source regions, grouping time courses based on anatomy may blur functional differences.
172-1	29874-29879	While	_	
172-2	29880-29885	other	_	
172-3	29886-29889	MEG	_	
172-4	29890-29894	rest	_	
172-5	29895-29902	studies	_	
172-6	29903-29907	have	_	
172-7	29908-29912	used	_	
172-8	29913-29923	anatomical	_	
172-9	29924-29934	boundaries	_	
172-10	29935-29937	to	_	
172-11	29938-29944	define	_	
172-12	29945-29951	source	_	
172-13	29952-29959	regions	_	
172-14	29959-29960	,	_	
172-15	29961-29969	grouping	_	
172-16	29970-29974	time	_	
172-17	29975-29982	courses	_	
172-18	29983-29988	based	_	
172-19	29989-29991	on	_	
172-20	29992-29999	anatomy	_	
172-21	30000-30003	may	_	
172-22	30004-30008	blur	_	
172-23	30009-30019	functional	_	
172-24	30020-30031	differences	_	
172-25	30031-30032	.	_	

#Text=There have been several recent papers using ICA to define functional regions for connectivity analysis in healthy controls and patients with schizophrenia, however those reports did not address test-retest reliability of ICA driven functional connectivity.
173-1	30033-30038	There	_	
173-2	30039-30043	have	_	
173-3	30044-30048	been	_	
173-4	30049-30056	several	_	
173-5	30057-30063	recent	_	
173-6	30064-30070	papers	_	
173-7	30071-30076	using	_	
173-8	30077-30080	ICA	_	
173-9	30081-30083	to	_	
173-10	30084-30090	define	_	
173-11	30091-30101	functional	_	
173-12	30102-30109	regions	_	
173-13	30110-30113	for	_	
173-14	30114-30126	connectivity	_	
173-15	30127-30135	analysis	_	
173-16	30136-30138	in	_	
173-17	30139-30146	healthy	_	
173-18	30147-30155	controls	_	
173-19	30156-30159	and	_	
173-20	30160-30168	patients	_	
173-21	30169-30173	with	_	
173-22	30174-30187	schizophrenia	_	
173-23	30187-30188	,	_	
173-24	30189-30196	however	_	
173-25	30197-30202	those	_	
173-26	30203-30210	reports	_	
173-27	30211-30214	did	_	
173-28	30215-30218	not	_	
173-29	30219-30226	address	_	
173-30	30227-30238	test-retest	_	
173-31	30239-30250	reliability	_	
173-32	30251-30253	of	_	
173-33	30254-30257	ICA	_	
173-34	30258-30264	driven	_	
173-35	30265-30275	functional	_	
173-36	30276-30288	connectivity	_	
173-37	30288-30289	.	_	

#Text=Static functional connectivity estimates may also have lower reliability as critical information is lost by time-averaging the signal.
174-1	30290-30296	Static	_	
174-2	30297-30307	functional	_	
174-3	30308-30320	connectivity	_	
174-4	30321-30330	estimates	_	
174-5	30331-30334	may	_	
174-6	30335-30339	also	_	
174-7	30340-30344	have	_	
174-8	30345-30350	lower	_	
174-9	30351-30362	reliability	_	
174-10	30363-30365	as	_	
174-11	30366-30374	critical	_	
174-12	30375-30386	information	_	
174-13	30387-30389	is	_	
174-14	30390-30394	lost	_	
174-15	30395-30397	by	_	
174-16	30398-30412	time-averaging	_	
174-17	30413-30416	the	_	
174-18	30417-30423	signal	_	
174-19	30423-30424	.	_	

#Text=Dynamic functional connectivity estimates which take into account the rapidly modulating, dynamic nature of brain states may have better reliability.
175-1	30425-30432	Dynamic	_	
175-2	30433-30443	functional	_	
175-3	30444-30456	connectivity	_	
175-4	30457-30466	estimates	_	
175-5	30467-30472	which	_	
175-6	30473-30477	take	_	
175-7	30478-30482	into	_	
175-8	30483-30490	account	_	
175-9	30491-30494	the	_	
175-10	30495-30502	rapidly	_	
175-11	30503-30513	modulating	_	
175-12	30513-30514	,	_	
175-13	30515-30522	dynamic	_	
175-14	30523-30529	nature	_	
175-15	30530-30532	of	_	
175-16	30533-30538	brain	_	
175-17	30539-30545	states	_	
175-18	30546-30549	may	_	
175-19	30550-30554	have	_	
175-20	30555-30561	better	_	
175-21	30562-30573	reliability	_	
175-22	30573-30574	.	_	

#Text=The current study has several limitations which warrant caution.
176-1	30575-30578	The	_	
176-2	30579-30586	current	_	
176-3	30587-30592	study	_	
176-4	30593-30596	has	_	
176-5	30597-30604	several	_	
176-6	30605-30616	limitations	_	
176-7	30617-30622	which	_	
176-8	30623-30630	warrant	_	
176-9	30631-30638	caution	_	
176-10	30638-30639	.	_	

#Text=First, this was a stable, medicated cohort of patients and as such it is unknown how well the results will generalize to other populations.
177-1	30640-30645	First	_	
177-2	30645-30646	,	_	
177-3	30647-30651	this	_	
177-4	30652-30655	was	_	
177-5	30656-30657	a	_	
177-6	30658-30664	stable	_	
177-7	30664-30665	,	_	
177-8	30666-30675	medicated	_	
177-9	30676-30682	cohort	_	
177-10	30683-30685	of	_	
177-11	30686-30694	patients	_	
177-12	30695-30698	and	_	
177-13	30699-30701	as	_	
177-14	30702-30706	such	_	
177-15	30707-30709	it	_	
177-16	30710-30712	is	_	
177-17	30713-30720	unknown	_	
177-18	30721-30724	how	_	
177-19	30725-30729	well	_	
177-20	30730-30733	the	_	
177-21	30734-30741	results	_	
177-22	30742-30746	will	_	
177-23	30747-30757	generalize	_	
177-24	30758-30760	to	_	
177-25	30761-30766	other	_	
177-26	30767-30778	populations	_	
177-27	30778-30779	.	_	

#Text=Additionally, all SZ were on various antipsychotic medications; therefore, it cannot be determined whether the spectral abnormalities found were due to the disorder or driven by medication.
178-1	30780-30792	Additionally	_	
178-2	30792-30793	,	_	
178-3	30794-30797	all	_	
178-4	30798-30800	SZ	_	
178-5	30801-30805	were	_	
178-6	30806-30808	on	_	
178-7	30809-30816	various	_	
178-8	30817-30830	antipsychotic	_	
178-9	30831-30842	medications	_	
178-10	30842-30843	;	_	
178-11	30844-30853	therefore	_	
178-12	30853-30854	,	_	
178-13	30855-30857	it	_	
178-14	30858-30864	cannot	_	
178-15	30865-30867	be	_	
178-16	30868-30878	determined	_	
178-17	30879-30886	whether	_	
178-18	30887-30890	the	_	
178-19	30891-30899	spectral	_	
178-20	30900-30913	abnormalities	_	
178-21	30914-30919	found	_	
178-22	30920-30924	were	_	
178-23	30925-30928	due	_	
178-24	30929-30931	to	_	
178-25	30932-30935	the	_	
178-26	30936-30944	disorder	_	
178-27	30945-30947	or	_	
178-28	30948-30954	driven	_	
178-29	30955-30957	by	_	
178-30	30958-30968	medication	_	
178-31	30968-30969	.	_	

#Text=Given the small group size (n=13) there was limited statistical power for investigating gender differences, medication, diagnosis effects, and all-to-all functional connectivity.
179-1	30970-30975	Given	_	
179-2	30976-30979	the	_	
179-3	30980-30985	small	_	
179-4	30986-30991	group	_	
179-5	30992-30996	size	_	
179-6	30997-30998	(	_	
179-7	30998-30999	n	_	
179-8	30999-31000	=	_	
179-9	31000-31002	13	_	
179-10	31002-31003	)	_	
179-11	31004-31009	there	_	
179-12	31010-31013	was	_	
179-13	31014-31021	limited	_	
179-14	31022-31033	statistical	_	
179-15	31034-31039	power	_	
179-16	31040-31043	for	_	
179-17	31044-31057	investigating	_	
179-18	31058-31064	gender	_	
179-19	31065-31076	differences	_	
179-20	31076-31077	,	_	
179-21	31078-31088	medication	_	
179-22	31088-31089	,	_	
179-23	31090-31099	diagnosis	_	
179-24	31100-31107	effects	_	
179-25	31107-31108	,	_	
179-26	31109-31112	and	_	
179-27	31113-31123	all-to-all	_	
179-28	31124-31134	functional	_	
179-29	31135-31147	connectivity	_	
179-30	31147-31148	.	_	

#Text=It is important to keep in mind that test-retest ICCs are variance measures that report relative changes within or between subject variance over time.
180-1	31149-31151	It	_	
180-2	31152-31154	is	_	
180-3	31155-31164	important	_	
180-4	31165-31167	to	_	
180-5	31168-31172	keep	_	
180-6	31173-31175	in	_	
180-7	31176-31180	mind	_	
180-8	31181-31185	that	_	
180-9	31186-31197	test-retest	_	
180-10	31198-31202	ICCs	_	
180-11	31203-31206	are	_	
180-12	31207-31215	variance	_	
180-13	31216-31224	measures	_	
180-14	31225-31229	that	_	
180-15	31230-31236	report	_	
180-16	31237-31245	relative	_	
180-17	31246-31253	changes	_	
180-18	31254-31260	within	_	
180-19	31261-31263	or	_	
180-20	31264-31271	between	_	
180-21	31272-31279	subject	_	
180-22	31280-31288	variance	_	
180-23	31289-31293	over	_	
180-24	31294-31298	time	_	
180-25	31298-31299	.	_	

#Text=Even low ICCs do not necessarily imply the measure itself is inaccurate, but perhaps a true within-subject change occurred, or the sample was too homogenous.
181-1	31300-31304	Even	_	
181-2	31305-31308	low	_	
181-3	31309-31313	ICCs	_	
181-4	31314-31316	do	_	
181-5	31317-31320	not	_	
181-6	31321-31332	necessarily	_	
181-7	31333-31338	imply	_	
181-8	31339-31342	the	_	
181-9	31343-31350	measure	_	
181-10	31351-31357	itself	_	
181-11	31358-31360	is	_	
181-12	31361-31371	inaccurate	_	
181-13	31371-31372	,	_	
181-14	31373-31376	but	_	
181-15	31377-31384	perhaps	_	
181-16	31385-31386	a	_	
181-17	31387-31391	true	_	
181-18	31392-31406	within-subject	_	
181-19	31407-31413	change	_	
181-20	31414-31422	occurred	_	
181-21	31422-31423	,	_	
181-22	31424-31426	or	_	
181-23	31427-31430	the	_	
181-24	31431-31437	sample	_	
181-25	31438-31441	was	_	
181-26	31442-31445	too	_	
181-27	31446-31456	homogenous	_	
181-28	31456-31457	.	_	

#Text=Although we found that ICC group average value was a bit higher for EC relative to EO in SZ, it is important for future studies to directly test if a particular rest condition (EO or EC) creates meaningfully different results.
182-1	31458-31466	Although	_	
182-2	31467-31469	we	_	
182-3	31470-31475	found	_	
182-4	31476-31480	that	_	
182-5	31481-31484	ICC	_	
182-6	31485-31490	group	_	
182-7	31491-31498	average	_	
182-8	31499-31504	value	_	
182-9	31505-31508	was	_	
182-10	31509-31510	a	_	
182-11	31511-31514	bit	_	
182-12	31515-31521	higher	_	
182-13	31522-31525	for	_	
182-14	31526-31528	EC	_	
182-15	31529-31537	relative	_	
182-16	31538-31540	to	_	
182-17	31541-31543	EO	_	
182-18	31544-31546	in	_	
182-19	31547-31549	SZ	_	
182-20	31549-31550	,	_	
182-21	31551-31553	it	_	
182-22	31554-31556	is	_	
182-23	31557-31566	important	_	
182-24	31567-31570	for	_	
182-25	31571-31577	future	_	
182-26	31578-31585	studies	_	
182-27	31586-31588	to	_	
182-28	31589-31597	directly	_	
182-29	31598-31602	test	_	
182-30	31603-31605	if	_	
182-31	31606-31607	a	_	
182-32	31608-31618	particular	_	
182-33	31619-31623	rest	_	
182-34	31624-31633	condition	_	
182-35	31634-31635	(	_	
182-36	31635-31637	EO	_	
182-37	31638-31640	or	_	
182-38	31641-31643	EC	_	
182-39	31643-31644	)	_	
182-40	31645-31652	creates	_	
182-41	31653-31665	meaningfully	_	
182-42	31666-31675	different	_	
182-43	31676-31683	results	_	
182-44	31683-31684	.	_	

#Text=While we controlled for variables such as nicotine and illicit drug use between sessions, general patterns or alterations in sleep, caffeine intake and/or alcohol use were not monitored.
183-1	31685-31690	While	_	
183-2	31691-31693	we	_	
183-3	31694-31704	controlled	_	
183-4	31705-31708	for	_	
183-5	31709-31718	variables	_	
183-6	31719-31723	such	_	
183-7	31724-31726	as	_	
183-8	31727-31735	nicotine	_	
183-9	31736-31739	and	_	
183-10	31740-31747	illicit	_	
183-11	31748-31752	drug	_	
183-12	31753-31756	use	_	
183-13	31757-31764	between	_	
183-14	31765-31773	sessions	_	
183-15	31773-31774	,	_	
183-16	31775-31782	general	_	
183-17	31783-31791	patterns	_	
183-18	31792-31794	or	_	
183-19	31795-31806	alterations	_	
183-20	31807-31809	in	_	
183-21	31810-31815	sleep	_	
183-22	31815-31816	,	_	
183-23	31817-31825	caffeine	_	
183-24	31826-31832	intake	_	
183-25	31833-31836	and	_	
183-26	31836-31837	/	_	
183-27	31837-31839	or	_	
183-28	31840-31847	alcohol	_	
183-29	31848-31851	use	_	
183-30	31852-31856	were	_	
183-31	31857-31860	not	_	
183-32	31861-31870	monitored	_	
183-33	31870-31871	.	_	

#Text=Given that lack of sleep, excess caffeine, or alcohol withdrawal may impact frequency specific ratios or spectral power, ideally these would be monitored between sessions in future studies.
184-1	31872-31877	Given	_	
184-2	31878-31882	that	_	
184-3	31883-31887	lack	_	
184-4	31888-31890	of	_	
184-5	31891-31896	sleep	_	
184-6	31896-31897	,	_	
184-7	31898-31904	excess	_	
184-8	31905-31913	caffeine	_	
184-9	31913-31914	,	_	
184-10	31915-31917	or	_	
184-11	31918-31925	alcohol	_	
184-12	31926-31936	withdrawal	_	
184-13	31937-31940	may	_	
184-14	31941-31947	impact	_	
184-15	31948-31957	frequency	_	
184-16	31958-31966	specific	_	
184-17	31967-31973	ratios	_	
184-18	31974-31976	or	_	
184-19	31977-31985	spectral	_	
184-20	31986-31991	power	_	
184-21	31991-31992	,	_	
184-22	31993-32000	ideally	_	
184-23	32001-32006	these	_	
184-24	32007-32012	would	_	
184-25	32013-32015	be	_	
184-26	32016-32025	monitored	_	
184-27	32026-32033	between	_	
184-28	32034-32042	sessions	_	
184-29	32043-32045	in	_	
184-30	32046-32052	future	_	
184-31	32053-32060	studies	_	
184-32	32060-32061	.	_	

#Text=Also, it remains to be seen if the lower reliability of delta, especially in orbital regions, may be partially attributed to eye movements that were not eye-blinks.
185-1	32062-32066	Also	_	
185-2	32066-32067	,	_	
185-3	32068-32070	it	_	
185-4	32071-32078	remains	_	
185-5	32079-32081	to	_	
185-6	32082-32084	be	_	
185-7	32085-32089	seen	_	
185-8	32090-32092	if	_	
185-9	32093-32096	the	_	
185-10	32097-32102	lower	_	
185-11	32103-32114	reliability	_	
185-12	32115-32117	of	_	
185-13	32118-32123	delta	_	
185-14	32123-32124	,	_	
185-15	32125-32135	especially	_	
185-16	32136-32138	in	_	
185-17	32139-32146	orbital	_	
185-18	32147-32154	regions	_	
185-19	32154-32155	,	_	
185-20	32156-32159	may	_	
185-21	32160-32162	be	_	
185-22	32163-32172	partially	_	
185-23	32173-32183	attributed	_	
185-24	32184-32186	to	_	
185-25	32187-32190	eye	_	
185-26	32191-32200	movements	_	
185-27	32201-32205	that	_	
185-28	32206-32210	were	_	
185-29	32211-32214	not	_	
185-30	32215-32225	eye-blinks	_	
185-31	32225-32226	.	_	

#Text=Finally, as a test-retest study this is a single imaging site with a single Elekta Neuromag MEG system; therefore, without a larger sample size, validation on multiple MEG systems and/or multiple sites, definitive conclusions on reliability cannot be made.
186-1	32227-32234	Finally	_	
186-2	32234-32235	,	_	
186-3	32236-32238	as	_	
186-4	32239-32240	a	_	
186-5	32241-32252	test-retest	_	
186-6	32253-32258	study	_	
186-7	32259-32263	this	_	
186-8	32264-32266	is	_	
186-9	32267-32268	a	_	
186-10	32269-32275	single	_	
186-11	32276-32283	imaging	_	
186-12	32284-32288	site	_	
186-13	32289-32293	with	_	
186-14	32294-32295	a	_	
186-15	32296-32302	single	_	
186-16	32303-32309	Elekta	_	
186-17	32310-32318	Neuromag	_	
186-18	32319-32322	MEG	_	
186-19	32323-32329	system	_	
186-20	32329-32330	;	_	
186-21	32331-32340	therefore	_	
186-22	32340-32341	,	_	
186-23	32342-32349	without	_	
186-24	32350-32351	a	_	
186-25	32352-32358	larger	_	
186-26	32359-32365	sample	_	
186-27	32366-32370	size	_	
186-28	32370-32371	,	_	
186-29	32372-32382	validation	_	
186-30	32383-32385	on	_	
186-31	32386-32394	multiple	_	
186-32	32395-32398	MEG	_	
186-33	32399-32406	systems	_	
186-34	32407-32410	and	_	
186-35	32410-32411	/	_	
186-36	32411-32413	or	_	
186-37	32414-32422	multiple	_	
186-38	32423-32428	sites	_	
186-39	32428-32429	,	_	
186-40	32430-32440	definitive	_	
186-41	32441-32452	conclusions	_	
186-42	32453-32455	on	_	
186-43	32456-32467	reliability	_	
186-44	32468-32474	cannot	_	
186-45	32475-32477	be	_	
186-46	32478-32482	made	_	
186-47	32482-32483	.	_	

#Text=The search for reliable biomarkers in schizophrenia that provide an objective and quantifiable index of network activity is an important avenue of research.
187-1	32484-32487	The	_	
187-2	32488-32494	search	_	
187-3	32495-32498	for	_	
187-4	32499-32507	reliable	_	
187-5	32508-32518	biomarkers	_	
187-6	32519-32521	in	_	
187-7	32522-32535	schizophrenia	_	
187-8	32536-32540	that	_	
187-9	32541-32548	provide	_	
187-10	32549-32551	an	_	
187-11	32552-32561	objective	_	
187-12	32562-32565	and	_	
187-13	32566-32578	quantifiable	_	
187-14	32579-32584	index	_	
187-15	32585-32587	of	_	
187-16	32588-32595	network	_	
187-17	32596-32604	activity	_	
187-18	32605-32607	is	_	
187-19	32608-32610	an	_	
187-20	32611-32620	important	_	
187-21	32621-32627	avenue	_	
187-22	32628-32630	of	_	
187-23	32631-32639	research	_	
187-24	32639-32640	.	_	

#Text=Our contribution advances the understanding of reliability of MEG resting-state data in schizophrenia.
188-1	32641-32644	Our	_	
188-2	32645-32657	contribution	_	
188-3	32658-32666	advances	_	
188-4	32667-32670	the	_	
188-5	32671-32684	understanding	_	
188-6	32685-32687	of	_	
188-7	32688-32699	reliability	_	
188-8	32700-32702	of	_	
188-9	32703-32706	MEG	_	
188-10	32707-32720	resting-state	_	
188-11	32721-32725	data	_	
188-12	32726-32728	in	_	
188-13	32729-32742	schizophrenia	_	
188-14	32742-32743	.	_	

#Text=While our results represent a preliminary exploration of reliability in this clinical population, these results can be built upon to assess population reliability.
189-1	32744-32749	While	_	
189-2	32750-32753	our	_	
189-3	32754-32761	results	_	
189-4	32762-32771	represent	_	
189-5	32772-32773	a	_	
189-6	32774-32785	preliminary	_	
189-7	32786-32797	exploration	_	
189-8	32798-32800	of	_	
189-9	32801-32812	reliability	_	
189-10	32813-32815	in	_	
189-11	32816-32820	this	_	
189-12	32821-32829	clinical	_	
189-13	32830-32840	population	_	
189-14	32840-32841	,	_	
189-15	32842-32847	these	_	
189-16	32848-32855	results	_	
189-17	32856-32859	can	_	
189-18	32860-32862	be	_	
189-19	32863-32868	built	_	
189-20	32869-32873	upon	_	
189-21	32874-32876	to	_	
189-22	32877-32883	assess	_	
189-23	32884-32894	population	_	
189-24	32895-32906	reliability	_	
189-25	32906-32907	.	_	

#Text=This research demonstrates that resting-state information in clinical populations can be informative and that MEG is a beneficial tool to capture neural oscillations with good spatial precision and reliability.
190-1	32908-32912	This	_	
190-2	32913-32921	research	_	
190-3	32922-32934	demonstrates	_	
190-4	32935-32939	that	_	
190-5	32940-32953	resting-state	_	
190-6	32954-32965	information	_	
190-7	32966-32968	in	_	
190-8	32969-32977	clinical	_	
190-9	32978-32989	populations	_	
190-10	32990-32993	can	_	
190-11	32994-32996	be	_	
190-12	32997-33008	informative	_	
190-13	33009-33012	and	_	
190-14	33013-33017	that	_	
190-15	33018-33021	MEG	_	
190-16	33022-33024	is	_	
190-17	33025-33026	a	_	
190-18	33027-33037	beneficial	_	
190-19	33038-33042	tool	_	
190-20	33043-33045	to	_	
190-21	33046-33053	capture	_	
190-22	33054-33060	neural	_	
190-23	33061-33073	oscillations	_	
190-24	33074-33078	with	_	
190-25	33079-33083	good	_	
190-26	33084-33091	spatial	_	
190-27	33092-33101	precision	_	
190-28	33102-33105	and	_	
190-29	33106-33117	reliability	_	
190-30	33117-33118	.	_	

#Text=Given that theta-gamma frequency bands in both resting-states were stable over sessions for both groups we suggest recording both EO and EC data to better capture the neural dynamics.
191-1	33119-33124	Given	_	
191-2	33125-33129	that	_	
191-3	33130-33141	theta-gamma	_	
191-4	33142-33151	frequency	_	
191-5	33152-33157	bands	_	
191-6	33158-33160	in	_	
191-7	33161-33165	both	_	
191-8	33166-33180	resting-states	_	
191-9	33181-33185	were	_	
191-10	33186-33192	stable	_	
191-11	33193-33197	over	_	
191-12	33198-33206	sessions	_	
191-13	33207-33210	for	_	
191-14	33211-33215	both	_	
191-15	33216-33222	groups	_	
191-16	33223-33225	we	_	
191-17	33226-33233	suggest	_	
191-18	33234-33243	recording	_	
191-19	33244-33248	both	_	
191-20	33249-33251	EO	_	
191-21	33252-33255	and	_	
191-22	33256-33258	EC	_	
191-23	33259-33263	data	_	
191-24	33264-33266	to	_	
191-25	33267-33273	better	_	
191-26	33274-33281	capture	_	
191-27	33282-33285	the	_	
191-28	33286-33292	neural	_	
191-29	33293-33301	dynamics	_	
191-30	33301-33302	.	_	

#Text=An important next step is to tease out the factors that drive the decreased reliability in patients and find ways to mitigate the issue.
192-1	33303-33305	An	_	
192-2	33306-33315	important	_	
192-3	33316-33320	next	_	
192-4	33321-33325	step	_	
192-5	33326-33328	is	_	
192-6	33329-33331	to	_	
192-7	33332-33337	tease	_	
192-8	33338-33341	out	_	
192-9	33342-33345	the	_	
192-10	33346-33353	factors	_	
192-11	33354-33358	that	_	
192-12	33359-33364	drive	_	
192-13	33365-33368	the	_	
192-14	33369-33378	decreased	_	
192-15	33379-33390	reliability	_	
192-16	33391-33393	in	_	
192-17	33394-33402	patients	_	
192-18	33403-33406	and	_	
192-19	33407-33411	find	_	
192-20	33412-33416	ways	_	
192-21	33417-33419	to	_	
192-22	33420-33428	mitigate	_	
192-23	33429-33432	the	_	
192-24	33433-33438	issue	_	
192-25	33438-33439	.	_	

#Text=Supplementary Material
#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
193-1	33440-33453	Supplementary	_	
193-2	33454-33462	Material	_	
193-3	33463-33467	This	_	
193-4	33468-33470	is	_	
193-5	33471-33472	a	_	
193-6	33473-33476	PDF	_	
193-7	33477-33481	file	_	
193-8	33482-33484	of	_	
193-9	33485-33487	an	_	
193-10	33488-33496	unedited	_	
193-11	33497-33507	manuscript	_	
193-12	33508-33512	that	_	
193-13	33513-33516	has	_	
193-14	33517-33521	been	_	
193-15	33522-33530	accepted	_	
193-16	33531-33534	for	_	
193-17	33535-33546	publication	_	
193-18	33546-33547	.	_	

#Text=As a service to our customers we are providing this early version of the manuscript.
194-1	33548-33550	As	_	
194-2	33551-33552	a	_	
194-3	33553-33560	service	_	
194-4	33561-33563	to	_	
194-5	33564-33567	our	_	
194-6	33568-33577	customers	_	
194-7	33578-33580	we	_	
194-8	33581-33584	are	_	
194-9	33585-33594	providing	_	
194-10	33595-33599	this	_	
194-11	33600-33605	early	_	
194-12	33606-33613	version	_	
194-13	33614-33616	of	_	
194-14	33617-33620	the	_	
194-15	33621-33631	manuscript	_	
194-16	33631-33632	.	_	

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form.
195-1	33633-33636	The	_	
195-2	33637-33647	manuscript	_	
195-3	33648-33652	will	_	
195-4	33653-33660	undergo	_	
195-5	33661-33672	copyediting	_	
195-6	33672-33673	,	_	
195-7	33674-33685	typesetting	_	
195-8	33685-33686	,	_	
195-9	33687-33690	and	_	
195-10	33691-33697	review	_	
195-11	33698-33700	of	_	
195-12	33701-33704	the	_	
195-13	33705-33714	resulting	_	
195-14	33715-33720	proof	_	
195-15	33721-33727	before	_	
195-16	33728-33730	it	_	
195-17	33731-33733	is	_	
195-18	33734-33743	published	_	
195-19	33744-33746	in	_	
195-20	33747-33750	its	_	
195-21	33751-33756	final	_	
195-22	33757-33761	form	_	
195-23	33761-33762	.	_	

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
196-1	33763-33769	Please	_	
196-2	33770-33774	note	_	
196-3	33775-33779	that	_	
196-4	33780-33786	during	_	
196-5	33787-33790	the	_	
196-6	33791-33801	production	_	
196-7	33802-33809	process	_	
196-8	33810-33816	errors	_	
196-9	33817-33820	may	_	
196-10	33821-33823	be	_	
196-11	33824-33834	discovered	_	
196-12	33835-33840	which	_	
196-13	33841-33846	could	_	
196-14	33847-33853	affect	_	
196-15	33854-33857	the	_	
196-16	33858-33865	content	_	
196-17	33865-33866	,	_	
196-18	33867-33870	and	_	
196-19	33871-33874	all	_	
196-20	33875-33880	legal	_	
196-21	33881-33892	disclaimers	_	
196-22	33893-33897	that	_	
196-23	33898-33903	apply	_	
196-24	33904-33906	to	_	
196-25	33907-33910	the	_	
196-26	33911-33918	journal	_	
196-27	33919-33926	pertain	_	
196-28	33926-33927	.	_	

#Text=Conflict of Interest
#Text=All authors declare they have no potential conflicts of interest in relation to the work described.
197-1	33928-33936	Conflict	_	
197-2	33937-33939	of	_	
197-3	33940-33948	Interest	_	
197-4	33949-33952	All	_	
197-5	33953-33960	authors	_	
197-6	33961-33968	declare	_	
197-7	33969-33973	they	_	
197-8	33974-33978	have	_	
197-9	33979-33981	no	_	
197-10	33982-33991	potential	_	
197-11	33992-34001	conflicts	_	
197-12	34002-34004	of	_	
197-13	34005-34013	interest	_	
197-14	34014-34016	in	_	
197-15	34017-34025	relation	_	
197-16	34026-34028	to	_	
197-17	34029-34032	the	_	
197-18	34033-34037	work	_	
197-19	34038-34047	described	_	
197-20	34047-34048	.	_	

#Text=References
#Text=Within- and between-session replicability of cognitive brain processes: An MEG study with an N-back task
#Text=Measuring alterations in oscillatory brain networks in schizophrenia with resting-state MEG: State-of-the-art and methodological challenges
#Text=Tracking Whole-Brain Connectivity Dynamics in the Resting State
#Text=Reproducibility of Single-Subject Functional Connectivity Measurements
#Text=Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
#Text=Frequency and power of human alpha oscillations drift systematically with time-on-task
#Text=The effect of scan length on the reliability of resting-state fMRI connectivity estimates
#Text=The status of spectral EEG abnormality as a diagnostic test for schizophrenia
#Text=Altered temporal stability in dynamic neural networks underlies connectivity changes in neurodevelopment
#Text=Measuring temporal, spectral and spatial changes in electrophysiological brain network connectivity
#Text=Investigating the electrophysiological basis of resting state networks using magnetoencephalography
#Text=Spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole
#Text=Magnetoencephalographic assessment of spontaneous brain activity in schizophrenia
#Text=Thalamus and posterior temporal lobe show greater inter-network connectivity at rest and across sensory paradigms in schizophrenia
#Text=Multimodal Classification of Schizophrenia Patients with MEG and fMRI Data Using Static and Dynamic Connectivity Measures
#Text=Frontal slow-wave activity as a predictor of negative symptoms, cognition and functional capacity in schizophrenia
#Text=
#Text=Resting EEG in first-episode schizophrenia patients, bipolar psychosis patients, and their first-degree relatives
#Text=How reliable are MEG resting-state connectivity metrics?
198-1	34049-34059	References	_	
198-2	34060-34066	Within	_	
198-3	34066-34067	-	_	
198-4	34068-34071	and	_	
198-5	34072-34087	between-session	_	
198-6	34088-34101	replicability	_	
198-7	34102-34104	of	_	
198-8	34105-34114	cognitive	_	
198-9	34115-34120	brain	_	
198-10	34121-34130	processes	_	
198-11	34130-34131	:	_	
198-12	34132-34134	An	_	
198-13	34135-34138	MEG	_	
198-14	34139-34144	study	_	
198-15	34145-34149	with	_	
198-16	34150-34152	an	_	
198-17	34153-34159	N-back	_	
198-18	34160-34164	task	_	
198-19	34165-34174	Measuring	_	
198-20	34175-34186	alterations	_	
198-21	34187-34189	in	_	
198-22	34190-34201	oscillatory	_	
198-23	34202-34207	brain	_	
198-24	34208-34216	networks	_	
198-25	34217-34219	in	_	
198-26	34220-34233	schizophrenia	_	
198-27	34234-34238	with	_	
198-28	34239-34252	resting-state	_	
198-29	34253-34256	MEG	_	
198-30	34256-34257	:	_	
198-31	34258-34274	State-of-the-art	_	
198-32	34275-34278	and	_	
198-33	34279-34293	methodological	_	
198-34	34294-34304	challenges	_	
198-35	34305-34313	Tracking	_	
198-36	34314-34325	Whole-Brain	_	
198-37	34326-34338	Connectivity	_	
198-38	34339-34347	Dynamics	_	
198-39	34348-34350	in	_	
198-40	34351-34354	the	_	
198-41	34355-34362	Resting	_	
198-42	34363-34368	State	_	
198-43	34369-34384	Reproducibility	_	
198-44	34385-34387	of	_	
198-45	34388-34402	Single-Subject	_	
198-46	34403-34413	Functional	_	
198-47	34414-34426	Connectivity	_	
198-48	34427-34439	Measurements	_	
198-49	34440-34451	Controlling	_	
198-50	34452-34455	the	_	
198-51	34456-34461	False	_	
198-52	34462-34471	Discovery	_	
198-53	34472-34476	Rate	_	
198-54	34476-34477	:	_	
198-55	34478-34479	A	_	
198-56	34480-34489	Practical	_	
198-57	34490-34493	and	_	
198-58	34494-34502	Powerful	_	
198-59	34503-34511	Approach	_	
198-60	34512-34514	to	_	
198-61	34515-34523	Multiple	_	
198-62	34524-34531	Testing	_	
198-63	34532-34541	Frequency	_	
198-64	34542-34545	and	_	
198-65	34546-34551	power	_	
198-66	34552-34554	of	_	
198-67	34555-34560	human	_	
198-68	34561-34566	alpha	_	
198-69	34567-34579	oscillations	_	
198-70	34580-34585	drift	_	
198-71	34586-34600	systematically	_	
198-72	34601-34605	with	_	
198-73	34606-34618	time-on-task	_	
198-74	34619-34622	The	_	
198-75	34623-34629	effect	_	
198-76	34630-34632	of	_	
198-77	34633-34637	scan	_	
198-78	34638-34644	length	_	
198-79	34645-34647	on	_	
198-80	34648-34651	the	_	
198-81	34652-34663	reliability	_	
198-82	34664-34666	of	_	
198-83	34667-34680	resting-state	_	
198-84	34681-34685	fMRI	_	
198-85	34686-34698	connectivity	_	
198-86	34699-34708	estimates	_	
198-87	34709-34712	The	_	
198-88	34713-34719	status	_	
198-89	34720-34722	of	_	
198-90	34723-34731	spectral	_	
198-91	34732-34735	EEG	_	
198-92	34736-34747	abnormality	_	
198-93	34748-34750	as	_	
198-94	34751-34752	a	_	
198-95	34753-34763	diagnostic	_	
198-96	34764-34768	test	_	
198-97	34769-34772	for	_	
198-98	34773-34786	schizophrenia	_	
198-99	34787-34794	Altered	_	
198-100	34795-34803	temporal	_	
198-101	34804-34813	stability	_	
198-102	34814-34816	in	_	
198-103	34817-34824	dynamic	_	
198-104	34825-34831	neural	_	
198-105	34832-34840	networks	_	
198-106	34841-34850	underlies	_	
198-107	34851-34863	connectivity	_	
198-108	34864-34871	changes	_	
198-109	34872-34874	in	_	
198-110	34875-34891	neurodevelopment	_	
198-111	34892-34901	Measuring	_	
198-112	34902-34910	temporal	_	
198-113	34910-34911	,	_	
198-114	34912-34920	spectral	_	
198-115	34921-34924	and	_	
198-116	34925-34932	spatial	_	
198-117	34933-34940	changes	_	
198-118	34941-34943	in	_	
198-119	34944-34964	electrophysiological	_	
198-120	34965-34970	brain	_	
198-121	34971-34978	network	_	
198-122	34979-34991	connectivity	_	
198-123	34992-35005	Investigating	_	
198-124	35006-35009	the	_	
198-125	35010-35030	electrophysiological	_	
198-126	35031-35036	basis	_	
198-127	35037-35039	of	_	
198-128	35040-35047	resting	_	
198-129	35048-35053	state	_	
198-130	35054-35062	networks	_	
198-131	35063-35068	using	_	
198-132	35069-35091	magnetoencephalography	_	
198-133	35092-35103	Spontaneous	_	
198-134	35104-35109	brain	_	
198-135	35110-35118	magnetic	_	
198-136	35119-35127	activity	_	
198-137	35128-35130	in	_	
198-138	35131-35144	schizophrenia	_	
198-139	35145-35153	patients	_	
198-140	35154-35161	treated	_	
198-141	35162-35166	with	_	
198-142	35167-35179	aripiprazole	_	
198-143	35180-35203	Magnetoencephalographic	_	
198-144	35204-35214	assessment	_	
198-145	35215-35217	of	_	
198-146	35218-35229	spontaneous	_	
198-147	35230-35235	brain	_	
198-148	35236-35244	activity	_	
198-149	35245-35247	in	_	
198-150	35248-35261	schizophrenia	_	
198-151	35262-35270	Thalamus	_	
198-152	35271-35274	and	_	
198-153	35275-35284	posterior	_	
198-154	35285-35293	temporal	_	
198-155	35294-35298	lobe	_	
198-156	35299-35303	show	_	
198-157	35304-35311	greater	_	
198-158	35312-35325	inter-network	_	
198-159	35326-35338	connectivity	_	
198-160	35339-35341	at	_	
198-161	35342-35346	rest	_	
198-162	35347-35350	and	_	
198-163	35351-35357	across	_	
198-164	35358-35365	sensory	_	
198-165	35366-35375	paradigms	_	
198-166	35376-35378	in	_	
198-167	35379-35392	schizophrenia	_	
198-168	35393-35403	Multimodal	_	
198-169	35404-35418	Classification	_	
198-170	35419-35421	of	_	
198-171	35422-35435	Schizophrenia	_	
198-172	35436-35444	Patients	_	
198-173	35445-35449	with	_	
198-174	35450-35453	MEG	_	
198-175	35454-35457	and	_	
198-176	35458-35462	fMRI	_	
198-177	35463-35467	Data	_	
198-178	35468-35473	Using	_	
198-179	35474-35480	Static	_	
198-180	35481-35484	and	_	
198-181	35485-35492	Dynamic	_	
198-182	35493-35505	Connectivity	_	
198-183	35506-35514	Measures	_	
198-184	35515-35522	Frontal	_	
198-185	35523-35532	slow-wave	_	
198-186	35533-35541	activity	_	
198-187	35542-35544	as	_	
198-188	35545-35546	a	_	
198-189	35547-35556	predictor	_	
198-190	35557-35559	of	_	
198-191	35560-35568	negative	_	
198-192	35569-35577	symptoms	_	
198-193	35577-35578	,	_	
198-194	35579-35588	cognition	_	
198-195	35589-35592	and	_	
198-196	35593-35603	functional	_	
198-197	35604-35612	capacity	_	
198-198	35613-35615	in	_	
198-199	35616-35629	schizophrenia	_	
198-200	35631-35638	Resting	_	
198-201	35639-35642	EEG	_	
198-202	35643-35645	in	_	
198-203	35646-35659	first-episode	_	
198-204	35660-35673	schizophrenia	_	
198-205	35674-35682	patients	_	
198-206	35682-35683	,	_	
198-207	35684-35691	bipolar	_	
198-208	35692-35701	psychosis	_	
198-209	35702-35710	patients	_	
198-210	35710-35711	,	_	
198-211	35712-35715	and	_	
198-212	35716-35721	their	_	
198-213	35722-35734	first-degree	_	
198-214	35735-35744	relatives	_	
198-215	35745-35748	How	_	
198-216	35749-35757	reliable	_	
198-217	35758-35761	are	_	
198-218	35762-35765	MEG	_	
198-219	35766-35779	resting-state	_	
198-220	35780-35792	connectivity	_	
198-221	35793-35800	metrics	_	
198-222	35800-35801	?	_	

#Text=Resting-State Oscillatory Activity in Autism Spectrum Disorders
#Text=Dynamic Statistical Parametric Mapping: Combining fMRI and MEG for High-Resolution Imaging of Cortical Activity
#Text=Temporal dynamics of spontaneous MEG activity in brain networks
#Text=An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest
#Text=Altered resting-state EEG source functional connectivity in schizophrenia: the effect of illness duration
#Text=
#Text=Source distribution of neuromagnetic slow waves and MEG-delta activity in schizophrenic patients
#Text=Source distribution of neuromagnetic slow-wave activity in schizophrenic patients--effects of activation
#Text=The dysconnection hypothesis (2016)
#Text=The disconnection hypothesis
#Text=Quantifying the Test-Retest Reliability of Magnetoencephalography Resting-State Functional Connectivity
#Text=International consensus study of antipsychotic dosing
#Text=Topographic deficits in alpha-range resting EEG activity and steady state visual evoked responses in schizophrenia
#Text=MEG and EEG data analysis with MNE-Python
#Text=MNE software for processing MEG and EEG data
#Text=MEG-measured visually induced gamma-band oscillations in chronic schizophrenia: Evidence for impaired generation of rhythmic activity in ventral stream regions
#Text=Human cortical oscillations: a neuromagnetic view through the skull
#Text=Frequency-dependent functional connectivity within resting-state networks: An atlas-based MEG beamformer solution
#Text=Direction of information flow in large-scale resting-state networks is frequency-dependent
#Text=Cognitive Impairments in Schizophrenia as Assessed Through Activation and Connectivity Measures of Magnetoencephalography (MEG) Data
#Text=Clinical symptoms and alpha band resting-state functional connectivity imaging in patients with schizophrenia: implications for novel approaches to treatment
#Text=Magnetoencephalographic and functional MRI connectomics in schizophrenia via intra- and inter-network connectivity
#Text=Dynamic functional connectivity: Promise, issues, and interpretations
#Text=Independent component analysis of short-time Fourier transforms for spontaneous EEG/MEG analysis
#Text=Long-term stability of resting frontal EEG alpha asymmetry and power in a sample of stable community outpatients with schizophrenia
#Text=Alpha EEG guided TMS in schizophrenia
#Text=Power spectral aspects of the default mode network in schizophrenia: an MEG study
#Text=Altered Development and Multifaceted Band-Specific Abnormalities of Resting State Networks in Autism
#Text=101 Labeled Brain Images and a Consistent Human Cortical Labeling Protocol
#Text=A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research
#Text=Improved test-retest reliability of 50-ms paired-click auditory gating using magneto encephalography source modeling
#Text=Internal consistency reliability of resting EEG power spectra in schizophrenic and normal subjects
#Text=Test-retest reliability of resting-state magnetoencephalography power in sensor and source space
#Text=Forming inferences about some intraclass correlation coefficients
#Text=Deriving frequency-dependent spatial patterns in MEG-derived resting state sensorimotor network: A novel multiband ICA technique
#Text=Group differences in MEG-ICA derived resting state networks: Application to major depressive disorder
#Text=Dynamic recruitment of resting state sub-networks
#Text=Extraction of spectral based measures from MEG background oscillations in Alzheimer’s disease
#Text=Test-retest reliability of the magnetic mismatch negativity response to sound duration and omission deviants
#Text=On the role of prestimulus alpha rhythms over occipito-parietal areas in visual input regulation: correlation or causation?
199-1	35802-35815	Resting-State	_	
199-2	35816-35827	Oscillatory	_	
199-3	35828-35836	Activity	_	
199-4	35837-35839	in	_	
199-5	35840-35846	Autism	_	
199-6	35847-35855	Spectrum	_	
199-7	35856-35865	Disorders	_	
199-8	35866-35873	Dynamic	_	
199-9	35874-35885	Statistical	_	
199-10	35886-35896	Parametric	_	
199-11	35897-35904	Mapping	_	
199-12	35904-35905	:	_	
199-13	35906-35915	Combining	_	
199-14	35916-35920	fMRI	_	
199-15	35921-35924	and	_	
199-16	35925-35928	MEG	_	
199-17	35929-35932	for	_	
199-18	35933-35948	High-Resolution	_	
199-19	35949-35956	Imaging	_	
199-20	35957-35959	of	_	
199-21	35960-35968	Cortical	_	
199-22	35969-35977	Activity	_	
199-23	35978-35986	Temporal	_	
199-24	35987-35995	dynamics	_	
199-25	35996-35998	of	_	
199-26	35999-36010	spontaneous	_	
199-27	36011-36014	MEG	_	
199-28	36015-36023	activity	_	
199-29	36024-36026	in	_	
199-30	36027-36032	brain	_	
199-31	36033-36041	networks	_	
199-32	36042-36044	An	_	
199-33	36045-36054	automated	_	
199-34	36055-36063	labeling	_	
199-35	36064-36070	system	_	
199-36	36071-36074	for	_	
199-37	36075-36086	subdividing	_	
199-38	36087-36090	the	_	
199-39	36091-36096	human	_	
199-40	36097-36105	cerebral	_	
199-41	36106-36112	cortex	_	
199-42	36113-36115	on	_	
199-43	36116-36119	MRI	_	
199-44	36120-36125	scans	_	
199-45	36126-36130	into	_	
199-46	36131-36136	gyral	_	
199-47	36137-36142	based	_	
199-48	36143-36150	regions	_	
199-49	36151-36153	of	_	
199-50	36154-36162	interest	_	
199-51	36163-36170	Altered	_	
199-52	36171-36184	resting-state	_	
199-53	36185-36188	EEG	_	
199-54	36189-36195	source	_	
199-55	36196-36206	functional	_	
199-56	36207-36219	connectivity	_	
199-57	36220-36222	in	_	
199-58	36223-36236	schizophrenia	_	
199-59	36236-36237	:	_	
199-60	36238-36241	the	_	
199-61	36242-36248	effect	_	
199-62	36249-36251	of	_	
199-63	36252-36259	illness	_	
199-64	36260-36268	duration	_	
199-65	36270-36276	Source	_	
199-66	36277-36289	distribution	_	
199-67	36290-36292	of	_	
199-68	36293-36306	neuromagnetic	_	
199-69	36307-36311	slow	_	
199-70	36312-36317	waves	_	
199-71	36318-36321	and	_	
199-72	36322-36331	MEG-delta	_	
199-73	36332-36340	activity	_	
199-74	36341-36343	in	_	
199-75	36344-36357	schizophrenic	_	
199-76	36358-36366	patients	_	
199-77	36367-36373	Source	_	
199-78	36374-36386	distribution	_	
199-79	36387-36389	of	_	
199-80	36390-36403	neuromagnetic	_	
199-81	36404-36413	slow-wave	_	
199-82	36414-36422	activity	_	
199-83	36423-36425	in	_	
199-84	36426-36439	schizophrenic	_	
199-85	36440-36448	patients	_	
199-86	36448-36449	-	_	
199-87	36449-36450	-	_	
199-88	36450-36457	effects	_	
199-89	36458-36460	of	_	
199-90	36461-36471	activation	_	
199-91	36472-36475	The	_	
199-92	36476-36489	dysconnection	_	
199-93	36490-36500	hypothesis	_	
199-94	36501-36502	(	_	
199-95	36502-36506	2016	_	
199-96	36506-36507	)	_	
199-97	36508-36511	The	_	
199-98	36512-36525	disconnection	_	
199-99	36526-36536	hypothesis	_	
199-100	36537-36548	Quantifying	_	
199-101	36549-36552	the	_	
199-102	36553-36564	Test-Retest	_	
199-103	36565-36576	Reliability	_	
199-104	36577-36579	of	_	
199-105	36580-36602	Magnetoencephalography	_	
199-106	36603-36616	Resting-State	_	
199-107	36617-36627	Functional	_	
199-108	36628-36640	Connectivity	_	
199-109	36641-36654	International	_	
199-110	36655-36664	consensus	_	
199-111	36665-36670	study	_	
199-112	36671-36673	of	_	
199-113	36674-36687	antipsychotic	_	
199-114	36688-36694	dosing	_	
199-115	36695-36706	Topographic	_	
199-116	36707-36715	deficits	_	
199-117	36716-36718	in	_	
199-118	36719-36730	alpha-range	_	
199-119	36731-36738	resting	_	
199-120	36739-36742	EEG	_	
199-121	36743-36751	activity	_	
199-122	36752-36755	and	_	
199-123	36756-36762	steady	_	
199-124	36763-36768	state	_	
199-125	36769-36775	visual	_	
199-126	36776-36782	evoked	_	
199-127	36783-36792	responses	_	
199-128	36793-36795	in	_	
199-129	36796-36809	schizophrenia	_	
199-130	36810-36813	MEG	_	
199-131	36814-36817	and	_	
199-132	36818-36821	EEG	_	
199-133	36822-36826	data	_	
199-134	36827-36835	analysis	_	
199-135	36836-36840	with	_	
199-136	36841-36851	MNE-Python	_	
199-137	36852-36855	MNE	_	
199-138	36856-36864	software	_	
199-139	36865-36868	for	_	
199-140	36869-36879	processing	_	
199-141	36880-36883	MEG	_	
199-142	36884-36887	and	_	
199-143	36888-36891	EEG	_	
199-144	36892-36896	data	_	
199-145	36897-36909	MEG-measured	_	
199-146	36910-36918	visually	_	
199-147	36919-36926	induced	_	
199-148	36927-36937	gamma-band	_	
199-149	36938-36950	oscillations	_	
199-150	36951-36953	in	_	
199-151	36954-36961	chronic	_	
199-152	36962-36975	schizophrenia	_	
199-153	36975-36976	:	_	
199-154	36977-36985	Evidence	_	
199-155	36986-36989	for	_	
199-156	36990-36998	impaired	_	
199-157	36999-37009	generation	_	
199-158	37010-37012	of	_	
199-159	37013-37021	rhythmic	_	
199-160	37022-37030	activity	_	
199-161	37031-37033	in	_	
199-162	37034-37041	ventral	_	
199-163	37042-37048	stream	_	
199-164	37049-37056	regions	_	
199-165	37057-37062	Human	_	
199-166	37063-37071	cortical	_	
199-167	37072-37084	oscillations	_	
199-168	37084-37085	:	_	
199-169	37086-37087	a	_	
199-170	37088-37101	neuromagnetic	_	
199-171	37102-37106	view	_	
199-172	37107-37114	through	_	
199-173	37115-37118	the	_	
199-174	37119-37124	skull	_	
199-175	37125-37144	Frequency-dependent	_	
199-176	37145-37155	functional	_	
199-177	37156-37168	connectivity	_	
199-178	37169-37175	within	_	
199-179	37176-37189	resting-state	_	
199-180	37190-37198	networks	_	
199-181	37198-37199	:	_	
199-182	37200-37202	An	_	
199-183	37203-37214	atlas-based	_	
199-184	37215-37218	MEG	_	
199-185	37219-37229	beamformer	_	
199-186	37230-37238	solution	_	
199-187	37239-37248	Direction	_	
199-188	37249-37251	of	_	
199-189	37252-37263	information	_	
199-190	37264-37268	flow	_	
199-191	37269-37271	in	_	
199-192	37272-37283	large-scale	_	
199-193	37284-37297	resting-state	_	
199-194	37298-37306	networks	_	
199-195	37307-37309	is	_	
199-196	37310-37329	frequency-dependent	_	
199-197	37330-37339	Cognitive	_	
199-198	37340-37351	Impairments	_	
199-199	37352-37354	in	_	
199-200	37355-37368	Schizophrenia	_	
199-201	37369-37371	as	_	
199-202	37372-37380	Assessed	_	
199-203	37381-37388	Through	_	
199-204	37389-37399	Activation	_	
199-205	37400-37403	and	_	
199-206	37404-37416	Connectivity	_	
199-207	37417-37425	Measures	_	
199-208	37426-37428	of	_	
199-209	37429-37451	Magnetoencephalography	_	
199-210	37452-37453	(	_	
199-211	37453-37456	MEG	_	
199-212	37456-37457	)	_	
199-213	37458-37462	Data	_	
199-214	37463-37471	Clinical	_	
199-215	37472-37480	symptoms	_	
199-216	37481-37484	and	_	
199-217	37485-37490	alpha	_	
199-218	37491-37495	band	_	
199-219	37496-37509	resting-state	_	
199-220	37510-37520	functional	_	
199-221	37521-37533	connectivity	_	
199-222	37534-37541	imaging	_	
199-223	37542-37544	in	_	
199-224	37545-37553	patients	_	
199-225	37554-37558	with	_	
199-226	37559-37572	schizophrenia	_	
199-227	37572-37573	:	_	
199-228	37574-37586	implications	_	
199-229	37587-37590	for	_	
199-230	37591-37596	novel	_	
199-231	37597-37607	approaches	_	
199-232	37608-37610	to	_	
199-233	37611-37620	treatment	_	
199-234	37621-37644	Magnetoencephalographic	_	
199-235	37645-37648	and	_	
199-236	37649-37659	functional	_	
199-237	37660-37663	MRI	_	
199-238	37664-37676	connectomics	_	
199-239	37677-37679	in	_	
199-240	37680-37693	schizophrenia	_	
199-241	37694-37697	via	_	
199-242	37698-37703	intra	_	
199-243	37703-37704	-	_	
199-244	37705-37708	and	_	
199-245	37709-37722	inter-network	_	
199-246	37723-37735	connectivity	_	
199-247	37736-37743	Dynamic	_	
199-248	37744-37754	functional	_	
199-249	37755-37767	connectivity	_	
199-250	37767-37768	:	_	
199-251	37769-37776	Promise	_	
199-252	37776-37777	,	_	
199-253	37778-37784	issues	_	
199-254	37784-37785	,	_	
199-255	37786-37789	and	_	
199-256	37790-37805	interpretations	_	
199-257	37806-37817	Independent	_	
199-258	37818-37827	component	_	
199-259	37828-37836	analysis	_	
199-260	37837-37839	of	_	
199-261	37840-37850	short-time	_	
199-262	37851-37858	Fourier	_	
199-263	37859-37869	transforms	_	
199-264	37870-37873	for	_	
199-265	37874-37885	spontaneous	_	
199-266	37886-37889	EEG	_	
199-267	37889-37890	/	_	
199-268	37890-37893	MEG	_	
199-269	37894-37902	analysis	_	
199-270	37903-37912	Long-term	_	
199-271	37913-37922	stability	_	
199-272	37923-37925	of	_	
199-273	37926-37933	resting	_	
199-274	37934-37941	frontal	_	
199-275	37942-37945	EEG	_	
199-276	37946-37951	alpha	_	
199-277	37952-37961	asymmetry	_	
199-278	37962-37965	and	_	
199-279	37966-37971	power	_	
199-280	37972-37974	in	_	
199-281	37975-37976	a	_	
199-282	37977-37983	sample	_	
199-283	37984-37986	of	_	
199-284	37987-37993	stable	_	
199-285	37994-38003	community	_	
199-286	38004-38015	outpatients	_	
199-287	38016-38020	with	_	
199-288	38021-38034	schizophrenia	_	
199-289	38035-38040	Alpha	_	
199-290	38041-38044	EEG	_	
199-291	38045-38051	guided	_	
199-292	38052-38055	TMS	_	
199-293	38056-38058	in	_	
199-294	38059-38072	schizophrenia	_	
199-295	38073-38078	Power	_	
199-296	38079-38087	spectral	_	
199-297	38088-38095	aspects	_	
199-298	38096-38098	of	_	
199-299	38099-38102	the	_	
199-300	38103-38110	default	_	
199-301	38111-38115	mode	_	
199-302	38116-38123	network	_	
199-303	38124-38126	in	_	
199-304	38127-38140	schizophrenia	_	
199-305	38140-38141	:	_	
199-306	38142-38144	an	_	
199-307	38145-38148	MEG	_	
199-308	38149-38154	study	_	
199-309	38155-38162	Altered	_	
199-310	38163-38174	Development	_	
199-311	38175-38178	and	_	
199-312	38179-38191	Multifaceted	_	
199-313	38192-38205	Band-Specific	_	
199-314	38206-38219	Abnormalities	_	
199-315	38220-38222	of	_	
199-316	38223-38230	Resting	_	
199-317	38231-38236	State	_	
199-318	38237-38245	Networks	_	
199-319	38246-38248	in	_	
199-320	38249-38255	Autism	_	
199-321	38256-38259	101	_	
199-322	38260-38267	Labeled	_	
199-323	38268-38273	Brain	_	
199-324	38274-38280	Images	_	
199-325	38281-38284	and	_	
199-326	38285-38286	a	_	
199-327	38287-38297	Consistent	_	
199-328	38298-38303	Human	_	
199-329	38304-38312	Cortical	_	
199-330	38313-38321	Labeling	_	
199-331	38322-38330	Protocol	_	
199-332	38331-38332	A	_	
199-333	38333-38342	Guideline	_	
199-334	38343-38345	of	_	
199-335	38346-38355	Selecting	_	
199-336	38356-38359	and	_	
199-337	38360-38369	Reporting	_	
199-338	38370-38380	Intraclass	_	
199-339	38381-38392	Correlation	_	
199-340	38393-38405	Coefficients	_	
199-341	38406-38409	for	_	
199-342	38410-38421	Reliability	_	
199-343	38422-38430	Research	_	
199-344	38431-38439	Improved	_	
199-345	38440-38451	test-retest	_	
199-346	38452-38463	reliability	_	
199-347	38464-38466	of	_	
199-348	38467-38469	50	_	
199-349	38469-38470	-	_	
199-350	38470-38472	ms	_	
199-351	38473-38485	paired-click	_	
199-352	38486-38494	auditory	_	
199-353	38495-38501	gating	_	
199-354	38502-38507	using	_	
199-355	38508-38515	magneto	_	
199-356	38516-38531	encephalography	_	
199-357	38532-38538	source	_	
199-358	38539-38547	modeling	_	
199-359	38548-38556	Internal	_	
199-360	38557-38568	consistency	_	
199-361	38569-38580	reliability	_	
199-362	38581-38583	of	_	
199-363	38584-38591	resting	_	
199-364	38592-38595	EEG	_	
199-365	38596-38601	power	_	
199-366	38602-38609	spectra	_	
199-367	38610-38612	in	_	
199-368	38613-38626	schizophrenic	_	
199-369	38627-38630	and	_	
199-370	38631-38637	normal	_	
199-371	38638-38646	subjects	_	
199-372	38647-38658	Test-retest	_	
199-373	38659-38670	reliability	_	
199-374	38671-38673	of	_	
199-375	38674-38687	resting-state	_	
199-376	38688-38710	magnetoencephalography	_	
199-377	38711-38716	power	_	
199-378	38717-38719	in	_	
199-379	38720-38726	sensor	_	
199-380	38727-38730	and	_	
199-381	38731-38737	source	_	
199-382	38738-38743	space	_	
199-383	38744-38751	Forming	_	
199-384	38752-38762	inferences	_	
199-385	38763-38768	about	_	
199-386	38769-38773	some	_	
199-387	38774-38784	intraclass	_	
199-388	38785-38796	correlation	_	
199-389	38797-38809	coefficients	_	
199-390	38810-38818	Deriving	_	
199-391	38819-38838	frequency-dependent	_	
199-392	38839-38846	spatial	_	
199-393	38847-38855	patterns	_	
199-394	38856-38858	in	_	
199-395	38859-38870	MEG-derived	_	
199-396	38871-38878	resting	_	
199-397	38879-38884	state	_	
199-398	38885-38897	sensorimotor	_	
199-399	38898-38905	network	_	
199-400	38905-38906	:	_	
199-401	38907-38908	A	_	
199-402	38909-38914	novel	_	
199-403	38915-38924	multiband	_	
199-404	38925-38928	ICA	_	
199-405	38929-38938	technique	_	
199-406	38939-38944	Group	_	
199-407	38945-38956	differences	_	
199-408	38957-38959	in	_	
199-409	38960-38967	MEG-ICA	_	
199-410	38968-38975	derived	_	
199-411	38976-38983	resting	_	
199-412	38984-38989	state	_	
199-413	38990-38998	networks	_	
199-414	38998-38999	:	_	
199-415	39000-39011	Application	_	
199-416	39012-39014	to	_	
199-417	39015-39020	major	_	
199-418	39021-39031	depressive	_	
199-419	39032-39040	disorder	_	
199-420	39041-39048	Dynamic	_	
199-421	39049-39060	recruitment	_	
199-422	39061-39063	of	_	
199-423	39064-39071	resting	_	
199-424	39072-39077	state	_	
199-425	39078-39090	sub-networks	_	
199-426	39091-39101	Extraction	_	
199-427	39102-39104	of	_	
199-428	39105-39113	spectral	_	
199-429	39114-39119	based	_	
199-430	39120-39128	measures	_	
199-431	39129-39133	from	_	
199-432	39134-39137	MEG	_	
199-433	39138-39148	background	_	
199-434	39149-39161	oscillations	_	
199-435	39162-39164	in	_	
199-436	39165-39174	Alzheimer	_	
199-437	39174-39175	’	_	
199-438	39175-39176	s	_	
199-439	39177-39184	disease	_	
199-440	39185-39196	Test-retest	_	
199-441	39197-39208	reliability	_	
199-442	39209-39211	of	_	
199-443	39212-39215	the	_	
199-444	39216-39224	magnetic	_	
199-445	39225-39233	mismatch	_	
199-446	39234-39244	negativity	_	
199-447	39245-39253	response	_	
199-448	39254-39256	to	_	
199-449	39257-39262	sound	_	
199-450	39263-39271	duration	_	
199-451	39272-39275	and	_	
199-452	39276-39284	omission	_	
199-453	39285-39293	deviants	_	
199-454	39294-39296	On	_	
199-455	39297-39300	the	_	
199-456	39301-39305	role	_	
199-457	39306-39308	of	_	
199-458	39309-39320	prestimulus	_	
199-459	39321-39326	alpha	_	
199-460	39327-39334	rhythms	_	
199-461	39335-39339	over	_	
199-462	39340-39357	occipito-parietal	_	
199-463	39358-39363	areas	_	
199-464	39364-39366	in	_	
199-465	39367-39373	visual	_	
199-466	39374-39379	input	_	
199-467	39380-39390	regulation	_	
199-468	39390-39391	:	_	
199-469	39392-39403	correlation	_	
199-470	39404-39406	or	_	
199-471	39407-39416	causation	_	
199-472	39416-39417	?	_	

#Text=Magnetoencephalographic gamma power reduction in patients with schizophrenia during resting condition
#Text=Dynamic Functional Network Connectivity In Schizophrenia With MEG And fMRI, Do Different Time Scales Tell A Different Story?
200-1	39418-39441	Magnetoencephalographic	_	
200-2	39442-39447	gamma	_	
200-3	39448-39453	power	_	
200-4	39454-39463	reduction	_	
200-5	39464-39466	in	_	
200-6	39467-39475	patients	_	
200-7	39476-39480	with	_	
200-8	39481-39494	schizophrenia	_	
200-9	39495-39501	during	_	
200-10	39502-39509	resting	_	
200-11	39510-39519	condition	_	
200-12	39520-39527	Dynamic	_	
200-13	39528-39538	Functional	_	
200-14	39539-39546	Network	_	
200-15	39547-39559	Connectivity	_	
200-16	39560-39562	In	_	
200-17	39563-39576	Schizophrenia	_	
200-18	39577-39581	With	_	
200-19	39582-39585	MEG	_	
200-20	39586-39589	And	_	
200-21	39590-39594	fMRI	_	
200-22	39594-39595	,	_	
200-23	39596-39598	Do	_	
200-24	39599-39608	Different	_	
200-25	39609-39613	Time	_	
200-26	39614-39620	Scales	_	
200-27	39621-39625	Tell	_	
200-28	39626-39627	A	_	
200-29	39628-39637	Different	_	
200-30	39638-39643	Story	_	
200-31	39643-39644	?	_	

#Text=Intraclass correlations: uses in assessing rater reliability
#Text=Patterns of spontaneous magnetoencephalographic activity in patients with schizophrenia
#Text=Spontaneous, slow and fast magnetoencephalographic activity in patients with schizophrenia
#Text=Resting EEG in first-episode and chronic schizophrenia
#Text=Clinical and biological concomitants of resting state EEG power abnormalities in schizophrenia
#Text=Evidence for dysregulated high-frequency oscillations during sensory processing in medication-naive, first episode schizophrenia
#Text=MEG-measured auditory steady-state oscillations show high test-retest reliability: A sensor and source-space analysis
#Text=MEG sensor and source measures of visually induced gamma-band oscillations are highly reliable
#Text=Removal of Magnetoencephalographic Artifacts With Temporal Signal-Space Separation: Demonstration With Single-Trial Auditory-Evoked Responses
#Text=Presentation of electromagnetic multichannel data: The signal space separation method
#Text=Structural degree predicts functional network connectivity: A multimodal resting-state fMRI and MEG study
#Text=The Role of Oscillations and Synchrony in Cortical Networks and Their Putative Relevance for the Pathophysiology of Schizophrenia
#Text=Magnetoencephalography as a Tool in Psychiatric Research: Current Status and Perspective.
201-1	39645-39655	Intraclass	_	
201-2	39656-39668	correlations	_	
201-3	39668-39669	:	_	
201-4	39670-39674	uses	_	
201-5	39675-39677	in	_	
201-6	39678-39687	assessing	_	
201-7	39688-39693	rater	_	
201-8	39694-39705	reliability	_	
201-9	39706-39714	Patterns	_	
201-10	39715-39717	of	_	
201-11	39718-39729	spontaneous	_	
201-12	39730-39753	magnetoencephalographic	_	
201-13	39754-39762	activity	_	
201-14	39763-39765	in	_	
201-15	39766-39774	patients	_	
201-16	39775-39779	with	_	
201-17	39780-39793	schizophrenia	_	
201-18	39794-39805	Spontaneous	_	
201-19	39805-39806	,	_	
201-20	39807-39811	slow	_	
201-21	39812-39815	and	_	
201-22	39816-39820	fast	_	
201-23	39821-39844	magnetoencephalographic	_	
201-24	39845-39853	activity	_	
201-25	39854-39856	in	_	
201-26	39857-39865	patients	_	
201-27	39866-39870	with	_	
201-28	39871-39884	schizophrenia	_	
201-29	39885-39892	Resting	_	
201-30	39893-39896	EEG	_	
201-31	39897-39899	in	_	
201-32	39900-39913	first-episode	_	
201-33	39914-39917	and	_	
201-34	39918-39925	chronic	_	
201-35	39926-39939	schizophrenia	_	
201-36	39940-39948	Clinical	_	
201-37	39949-39952	and	_	
201-38	39953-39963	biological	_	
201-39	39964-39976	concomitants	_	
201-40	39977-39979	of	_	
201-41	39980-39987	resting	_	
201-42	39988-39993	state	_	
201-43	39994-39997	EEG	_	
201-44	39998-40003	power	_	
201-45	40004-40017	abnormalities	_	
201-46	40018-40020	in	_	
201-47	40021-40034	schizophrenia	_	
201-48	40035-40043	Evidence	_	
201-49	40044-40047	for	_	
201-50	40048-40060	dysregulated	_	
201-51	40061-40075	high-frequency	_	
201-52	40076-40088	oscillations	_	
201-53	40089-40095	during	_	
201-54	40096-40103	sensory	_	
201-55	40104-40114	processing	_	
201-56	40115-40117	in	_	
201-57	40118-40134	medication-naive	_	
201-58	40134-40135	,	_	
201-59	40136-40141	first	_	
201-60	40142-40149	episode	_	
201-61	40150-40163	schizophrenia	_	
201-62	40164-40176	MEG-measured	_	
201-63	40177-40185	auditory	_	
201-64	40186-40198	steady-state	_	
201-65	40199-40211	oscillations	_	
201-66	40212-40216	show	_	
201-67	40217-40221	high	_	
201-68	40222-40233	test-retest	_	
201-69	40234-40245	reliability	_	
201-70	40245-40246	:	_	
201-71	40247-40248	A	_	
201-72	40249-40255	sensor	_	
201-73	40256-40259	and	_	
201-74	40260-40272	source-space	_	
201-75	40273-40281	analysis	_	
201-76	40282-40285	MEG	_	
201-77	40286-40292	sensor	_	
201-78	40293-40296	and	_	
201-79	40297-40303	source	_	
201-80	40304-40312	measures	_	
201-81	40313-40315	of	_	
201-82	40316-40324	visually	_	
201-83	40325-40332	induced	_	
201-84	40333-40343	gamma-band	_	
201-85	40344-40356	oscillations	_	
201-86	40357-40360	are	_	
201-87	40361-40367	highly	_	
201-88	40368-40376	reliable	_	
201-89	40377-40384	Removal	_	
201-90	40385-40387	of	_	
201-91	40388-40411	Magnetoencephalographic	_	
201-92	40412-40421	Artifacts	_	
201-93	40422-40426	With	_	
201-94	40427-40435	Temporal	_	
201-95	40436-40448	Signal-Space	_	
201-96	40449-40459	Separation	_	
201-97	40459-40460	:	_	
201-98	40461-40474	Demonstration	_	
201-99	40475-40479	With	_	
201-100	40480-40492	Single-Trial	_	
201-101	40493-40508	Auditory-Evoked	_	
201-102	40509-40518	Responses	_	
201-103	40519-40531	Presentation	_	
201-104	40532-40534	of	_	
201-105	40535-40550	electromagnetic	_	
201-106	40551-40563	multichannel	_	
201-107	40564-40568	data	_	
201-108	40568-40569	:	_	
201-109	40570-40573	The	_	
201-110	40574-40580	signal	_	
201-111	40581-40586	space	_	
201-112	40587-40597	separation	_	
201-113	40598-40604	method	_	
201-114	40605-40615	Structural	_	
201-115	40616-40622	degree	_	
201-116	40623-40631	predicts	_	
201-117	40632-40642	functional	_	
201-118	40643-40650	network	_	
201-119	40651-40663	connectivity	_	
201-120	40663-40664	:	_	
201-121	40665-40666	A	_	
201-122	40667-40677	multimodal	_	
201-123	40678-40691	resting-state	_	
201-124	40692-40696	fMRI	_	
201-125	40697-40700	and	_	
201-126	40701-40704	MEG	_	
201-127	40705-40710	study	_	
201-128	40711-40714	The	_	
201-129	40715-40719	Role	_	
201-130	40720-40722	of	_	
201-131	40723-40735	Oscillations	_	
201-132	40736-40739	and	_	
201-133	40740-40749	Synchrony	_	
201-134	40750-40752	in	_	
201-135	40753-40761	Cortical	_	
201-136	40762-40770	Networks	_	
201-137	40771-40774	and	_	
201-138	40775-40780	Their	_	
201-139	40781-40789	Putative	_	
201-140	40790-40799	Relevance	_	
201-141	40800-40803	for	_	
201-142	40804-40807	the	_	
201-143	40808-40823	Pathophysiology	_	
201-144	40824-40826	of	_	
201-145	40827-40840	Schizophrenia	_	
201-146	40841-40863	Magnetoencephalography	_	
201-147	40864-40866	as	_	
201-148	40867-40868	a	_	
201-149	40869-40873	Tool	_	
201-150	40874-40876	in	_	
201-151	40877-40888	Psychiatric	_	
201-152	40889-40897	Research	_	
201-153	40897-40898	:	_	
201-154	40899-40906	Current	_	
201-155	40907-40913	Status	_	
201-156	40914-40917	and	_	
201-157	40918-40929	Perspective	_	
201-158	40929-40930	.	_	

#Text=Biological Psychiatry
#Text=Signal-space projection method for separating MEG or EEG into components
#Text=Evaluation and tracking of Alzheimer’s disease severity using resting-state magnetoencephalography
#Text=An improved index of phase-synchronization for electrophysiological data in the presence of volume-conduction, noise and sample-size bias
#Text=Inter- and intra-subject variability of neuromagnetic resting state networks
#Text=MEG resting-state oscillations and their relationship to clinical symptoms in schizophrenia
#Text=Rest Task Design.
202-1	40931-40941	Biological	_	
202-2	40942-40952	Psychiatry	_	
202-3	40953-40965	Signal-space	_	
202-4	40966-40976	projection	_	
202-5	40977-40983	method	_	
202-6	40984-40987	for	_	
202-7	40988-40998	separating	_	
202-8	40999-41002	MEG	_	
202-9	41003-41005	or	_	
202-10	41006-41009	EEG	_	
202-11	41010-41014	into	_	
202-12	41015-41025	components	_	
202-13	41026-41036	Evaluation	_	
202-14	41037-41040	and	_	
202-15	41041-41049	tracking	_	
202-16	41050-41052	of	_	
202-17	41053-41062	Alzheimer	_	
202-18	41062-41063	’	_	
202-19	41063-41064	s	_	
202-20	41065-41072	disease	_	
202-21	41073-41081	severity	_	
202-22	41082-41087	using	_	
202-23	41088-41101	resting-state	_	
202-24	41102-41124	magnetoencephalography	_	
202-25	41125-41127	An	_	
202-26	41128-41136	improved	_	
202-27	41137-41142	index	_	
202-28	41143-41145	of	_	
202-29	41146-41167	phase-synchronization	_	
202-30	41168-41171	for	_	
202-31	41172-41192	electrophysiological	_	
202-32	41193-41197	data	_	
202-33	41198-41200	in	_	
202-34	41201-41204	the	_	
202-35	41205-41213	presence	_	
202-36	41214-41216	of	_	
202-37	41217-41234	volume-conduction	_	
202-38	41234-41235	,	_	
202-39	41236-41241	noise	_	
202-40	41242-41245	and	_	
202-41	41246-41257	sample-size	_	
202-42	41258-41262	bias	_	
202-43	41263-41268	Inter	_	
202-44	41268-41269	-	_	
202-45	41270-41273	and	_	
202-46	41274-41287	intra-subject	_	
202-47	41288-41299	variability	_	
202-48	41300-41302	of	_	
202-49	41303-41316	neuromagnetic	_	
202-50	41317-41324	resting	_	
202-51	41325-41330	state	_	
202-52	41331-41339	networks	_	
202-53	41340-41343	MEG	_	
202-54	41344-41357	resting-state	_	
202-55	41358-41370	oscillations	_	
202-56	41371-41374	and	_	
202-57	41375-41380	their	_	
202-58	41381-41393	relationship	_	
202-59	41394-41396	to	_	
202-60	41397-41405	clinical	_	
202-61	41406-41414	symptoms	_	
202-62	41415-41417	in	_	
202-63	41418-41431	schizophrenia	_	
202-64	41432-41436	Rest	_	
202-65	41437-41441	Task	_	
202-66	41442-41448	Design	_	
202-67	41448-41449	.	_	

#Text=Rest10 (a 10-minute task) alternates between 2.5 minutes of eyes closed followed by 2.5 minutes of eyes open fixated on a cross.
203-1	41450-41456	Rest10	_	
203-2	41457-41458	(	_	
203-3	41458-41459	a	_	
203-4	41460-41462	10	_	
203-5	41462-41463	-	_	
203-6	41463-41469	minute	_	
203-7	41470-41474	task	_	
203-8	41474-41475	)	_	
203-9	41476-41486	alternates	_	
203-10	41487-41494	between	_	
203-11	41495-41498	2.5	_	
203-12	41499-41506	minutes	_	
203-13	41507-41509	of	_	
203-14	41510-41514	eyes	_	
203-15	41515-41521	closed	_	
203-16	41522-41530	followed	_	
203-17	41531-41533	by	_	
203-18	41534-41537	2.5	_	
203-19	41538-41545	minutes	_	
203-20	41546-41548	of	_	
203-21	41549-41553	eyes	_	
203-22	41554-41558	open	_	
203-23	41559-41566	fixated	_	
203-24	41567-41569	on	_	
203-25	41570-41571	a	_	
203-26	41572-41577	cross	_	
203-27	41577-41578	.	_	

#Text=Rest4 (a 4-minute task) alternates between 2 minutes of eyes closed followed by 2 minutes of eyes open fixated on a cross.
204-1	41579-41584	Rest4	_	
204-2	41585-41586	(	_	
204-3	41586-41587	a	_	
204-4	41588-41589	4	_	
204-5	41589-41590	-	_	
204-6	41590-41596	minute	_	
204-7	41597-41601	task	_	
204-8	41601-41602	)	_	
204-9	41603-41613	alternates	_	
204-10	41614-41621	between	_	
204-11	41622-41623	2	_	
204-12	41624-41631	minutes	_	
204-13	41632-41634	of	_	
204-14	41635-41639	eyes	_	
204-15	41640-41646	closed	_	
204-16	41647-41655	followed	_	
204-17	41656-41658	by	_	
204-18	41659-41660	2	_	
204-19	41661-41668	minutes	_	
204-20	41669-41671	of	_	
204-21	41672-41676	eyes	_	
204-22	41677-41681	open	_	
204-23	41682-41689	fixated	_	
204-24	41690-41692	on	_	
204-25	41693-41694	a	_	
204-26	41695-41700	cross	_	
204-27	41700-41701	.	_	

#Text=Sensor Spectral Analysis.
205-1	41702-41708	Sensor	_	
205-2	41709-41717	Spectral	_	
205-3	41718-41726	Analysis	_	
205-4	41726-41727	.	_	

#Text=To simplify multichannel spectral data, we divided the MEG sensor array into regions with an equivalent number of planar gradiometers.
206-1	41728-41730	To	_	
206-2	41731-41739	simplify	_	
206-3	41740-41752	multichannel	_	
206-4	41753-41761	spectral	_	
206-5	41762-41766	data	_	
206-6	41766-41767	,	_	
206-7	41768-41770	we	_	
206-8	41771-41778	divided	_	
206-9	41779-41782	the	_	
206-10	41783-41786	MEG	_	
206-11	41787-41793	sensor	_	
206-12	41794-41799	array	_	
206-13	41800-41804	into	_	
206-14	41805-41812	regions	_	
206-15	41813-41817	with	_	
206-16	41818-41820	an	_	
206-17	41821-41831	equivalent	_	
206-18	41832-41838	number	_	
206-19	41839-41841	of	_	
206-20	41842-41848	planar	_	
206-21	41849-41861	gradiometers	_	
206-22	41861-41862	.	_	

#Text=The left and right regions included frontal, central, parietal, occipital, anterior, and posterior temporal cortex.
207-1	41863-41866	The	_	
207-2	41867-41871	left	_	
207-3	41872-41875	and	_	
207-4	41876-41881	right	_	
207-5	41882-41889	regions	_	
207-6	41890-41898	included	_	
207-7	41899-41906	frontal	_	
207-8	41906-41907	,	_	
207-9	41908-41915	central	_	
207-10	41915-41916	,	_	
207-11	41917-41925	parietal	_	
207-12	41925-41926	,	_	
207-13	41927-41936	occipital	_	
207-14	41936-41937	,	_	
207-15	41938-41946	anterior	_	
207-16	41946-41947	,	_	
207-17	41948-41951	and	_	
207-18	41952-41961	posterior	_	
207-19	41962-41970	temporal	_	
207-20	41971-41977	cortex	_	
207-21	41977-41978	.	_	

#Text=To create regional averages, data from 16 gradiometers were averaged.
208-1	41979-41981	To	_	
208-2	41982-41988	create	_	
208-3	41989-41997	regional	_	
208-4	41998-42006	averages	_	
208-5	42006-42007	,	_	
208-6	42008-42012	data	_	
208-7	42013-42017	from	_	
208-8	42018-42020	16	_	
208-9	42021-42033	gradiometers	_	
208-10	42034-42038	were	_	
208-11	42039-42047	averaged	_	
208-12	42047-42048	.	_	

#Text=Global ICCs.
209-1	42049-42055	Global	_	
209-2	42056-42060	ICCs	_	
209-3	42060-42061	.	_	

#Text=Global ICC estimates based on normalized power were calculated within each visit and across one week for each task.
210-1	42062-42068	Global	_	
210-2	42069-42072	ICC	_	
210-3	42073-42082	estimates	_	
210-4	42083-42088	based	_	
210-5	42089-42091	on	_	
210-6	42092-42102	normalized	_	
210-7	42103-42108	power	_	
210-8	42109-42113	were	_	
210-9	42114-42124	calculated	_	
210-10	42125-42131	within	_	
210-11	42132-42136	each	_	
210-12	42137-42142	visit	_	
210-13	42143-42146	and	_	
210-14	42147-42153	across	_	
210-15	42154-42157	one	_	
210-16	42158-42162	week	_	
210-17	42163-42166	for	_	
210-18	42167-42171	each	_	
210-19	42172-42176	task	_	
210-20	42176-42177	.	_	

#Text=Data represent mean with 95% confidence interval.
211-1	42178-42182	Data	_	
211-2	42183-42192	represent	_	
211-3	42193-42197	mean	_	
211-4	42198-42202	with	_	
211-5	42203-42206	95%	_	
211-6	42207-42217	confidence	_	
211-7	42218-42226	interval	_	
211-8	42226-42227	.	_	

#Text=Healthy controls had excellent to good reliability across one hour and one week in most bands (Sensor ICCs >0.85, Source ICCs >0.72), with the exception fair reliability across one week in delta (Sensor ICCs >0.55, Source ICCs >0.42).
212-1	42228-42235	Healthy	_	
212-2	42236-42244	controls	_	
212-3	42245-42248	had	_	
212-4	42249-42258	excellent	_	
212-5	42259-42261	to	_	
212-6	42262-42266	good	_	
212-7	42267-42278	reliability	_	
212-8	42279-42285	across	_	
212-9	42286-42289	one	_	
212-10	42290-42294	hour	_	
212-11	42295-42298	and	_	
212-12	42299-42302	one	_	
212-13	42303-42307	week	_	
212-14	42308-42310	in	_	
212-15	42311-42315	most	_	
212-16	42316-42321	bands	_	
212-17	42322-42323	(	_	
212-18	42323-42329	Sensor	_	
212-19	42330-42334	ICCs	_	
212-20	42335-42336	>	_	
212-21	42336-42340	0.85	_	
212-22	42340-42341	,	_	
212-23	42342-42348	Source	_	
212-24	42349-42353	ICCs	_	
212-25	42354-42355	>	_	
212-26	42355-42359	0.72	_	
212-27	42359-42360	)	_	
212-28	42360-42361	,	_	
212-29	42362-42366	with	_	
212-30	42367-42370	the	_	
212-31	42371-42380	exception	_	
212-32	42381-42385	fair	_	
212-33	42386-42397	reliability	_	
212-34	42398-42404	across	_	
212-35	42405-42408	one	_	
212-36	42409-42413	week	_	
212-37	42414-42416	in	_	
212-38	42417-42422	delta	_	
212-39	42423-42424	(	_	
212-40	42424-42430	Sensor	_	
212-41	42431-42435	ICCs	_	
212-42	42436-42437	>	_	
212-43	42437-42441	0.55	_	
212-44	42441-42442	,	_	
212-45	42443-42449	Source	_	
212-46	42450-42454	ICCs	_	
212-47	42455-42456	>	_	
212-48	42456-42460	0.42	_	
212-49	42460-42461	)	_	
212-50	42461-42462	.	_	

#Text=Participants with schizophrenia had excellent to fair reliability across one hour and one week (Sensor ICCs >0.80, Source ICCs >0.52), with slightly lower one week reliability in delta and theta bands (Sensor ICCs >0.71, Source ICCs >0.48).
213-1	42463-42475	Participants	_	
213-2	42476-42480	with	_	
213-3	42481-42494	schizophrenia	_	
213-4	42495-42498	had	_	
213-5	42499-42508	excellent	_	
213-6	42509-42511	to	_	
213-7	42512-42516	fair	_	
213-8	42517-42528	reliability	_	
213-9	42529-42535	across	_	
213-10	42536-42539	one	_	
213-11	42540-42544	hour	_	
213-12	42545-42548	and	_	
213-13	42549-42552	one	_	
213-14	42553-42557	week	_	
213-15	42558-42559	(	_	
213-16	42559-42565	Sensor	_	
213-17	42566-42570	ICCs	_	
213-18	42571-42572	>	_	
213-19	42572-42576	0.80	_	
213-20	42576-42577	,	_	
213-21	42578-42584	Source	_	
213-22	42585-42589	ICCs	_	
213-23	42590-42591	>	_	
213-24	42591-42595	0.52	_	
213-25	42595-42596	)	_	
213-26	42596-42597	,	_	
213-27	42598-42602	with	_	
213-28	42603-42611	slightly	_	
213-29	42612-42617	lower	_	
213-30	42618-42621	one	_	
213-31	42622-42626	week	_	
213-32	42627-42638	reliability	_	
213-33	42639-42641	in	_	
213-34	42642-42647	delta	_	
213-35	42648-42651	and	_	
213-36	42652-42657	theta	_	
213-37	42658-42663	bands	_	
213-38	42664-42665	(	_	
213-39	42665-42671	Sensor	_	
213-40	42672-42676	ICCs	_	
213-41	42677-42678	>	_	
213-42	42678-42682	0.71	_	
213-43	42682-42683	,	_	
213-44	42684-42690	Source	_	
213-45	42691-42695	ICCs	_	
213-46	42696-42697	>	_	
213-47	42697-42701	0.48	_	
213-48	42701-42702	)	_	
213-49	42702-42703	.	_	

#Text=Regional ICCs.
214-1	42704-42712	Regional	_	
214-2	42713-42717	ICCs	_	
214-3	42717-42718	.	_	

#Text=Regional ICC estimates from the Rest10 task were calculated across 1 week.
215-1	42719-42727	Regional	_	
215-2	42728-42731	ICC	_	
215-3	42732-42741	estimates	_	
215-4	42742-42746	from	_	
215-5	42747-42750	the	_	
215-6	42751-42757	Rest10	_	
215-7	42758-42762	task	_	
215-8	42763-42767	were	_	
215-9	42768-42778	calculated	_	
215-10	42779-42785	across	_	
215-11	42786-42787	1	_	
215-12	42788-42792	week	_	
215-13	42792-42793	.	_	

#Text=Healthy controls had excellent reliability across a week in most sensor regions and bands (ICCs >0.77), with exceptions in the delta band right orbital region during the eyes closed condition (ICCs >0.46) and right central regions during the eyes open condition (ICCs >0.62).
216-1	42794-42801	Healthy	_	
216-2	42802-42810	controls	_	
216-3	42811-42814	had	_	
216-4	42815-42824	excellent	_	
216-5	42825-42836	reliability	_	
216-6	42837-42843	across	_	
216-7	42844-42845	a	_	
216-8	42846-42850	week	_	
216-9	42851-42853	in	_	
216-10	42854-42858	most	_	
216-11	42859-42865	sensor	_	
216-12	42866-42873	regions	_	
216-13	42874-42877	and	_	
216-14	42878-42883	bands	_	
216-15	42884-42885	(	_	
216-16	42885-42889	ICCs	_	
216-17	42890-42891	>	_	
216-18	42891-42895	0.77	_	
216-19	42895-42896	)	_	
216-20	42896-42897	,	_	
216-21	42898-42902	with	_	
216-22	42903-42913	exceptions	_	
216-23	42914-42916	in	_	
216-24	42917-42920	the	_	
216-25	42921-42926	delta	_	
216-26	42927-42931	band	_	
216-27	42932-42937	right	_	
216-28	42938-42945	orbital	_	
216-29	42946-42952	region	_	
216-30	42953-42959	during	_	
216-31	42960-42963	the	_	
216-32	42964-42968	eyes	_	
216-33	42969-42975	closed	_	
216-34	42976-42985	condition	_	
216-35	42986-42987	(	_	
216-36	42987-42991	ICCs	_	
216-37	42992-42993	>	_	
216-38	42993-42997	0.46	_	
216-39	42997-42998	)	_	
216-40	42999-43002	and	_	
216-41	43003-43008	right	_	
216-42	43009-43016	central	_	
216-43	43017-43024	regions	_	
216-44	43025-43031	during	_	
216-45	43032-43035	the	_	
216-46	43036-43040	eyes	_	
216-47	43041-43045	open	_	
216-48	43046-43055	condition	_	
216-49	43056-43057	(	_	
216-50	43057-43061	ICCs	_	
216-51	43062-43063	>	_	
216-52	43063-43067	0.62	_	
216-53	43067-43068	)	_	
216-54	43068-43069	.	_	

#Text=Participants with schizophrenia had good reliability in many bands and regions (ICCs >0.65), with the lowest reliability in theta band during the eyes open condition (ICCs >0.57) and slightly lower reliability overall in several regions when compared to healthy controls.
217-1	43070-43082	Participants	_	
217-2	43083-43087	with	_	
217-3	43088-43101	schizophrenia	_	
217-4	43102-43105	had	_	
217-5	43106-43110	good	_	
217-6	43111-43122	reliability	_	
217-7	43123-43125	in	_	
217-8	43126-43130	many	_	
217-9	43131-43136	bands	_	
217-10	43137-43140	and	_	
217-11	43141-43148	regions	_	
217-12	43149-43150	(	_	
217-13	43150-43154	ICCs	_	
217-14	43155-43156	>	_	
217-15	43156-43160	0.65	_	
217-16	43160-43161	)	_	
217-17	43161-43162	,	_	
217-18	43163-43167	with	_	
217-19	43168-43171	the	_	
217-20	43172-43178	lowest	_	
217-21	43179-43190	reliability	_	
217-22	43191-43193	in	_	
217-23	43194-43199	theta	_	
217-24	43200-43204	band	_	
217-25	43205-43211	during	_	
217-26	43212-43215	the	_	
217-27	43216-43220	eyes	_	
217-28	43221-43225	open	_	
217-29	43226-43235	condition	_	
217-30	43236-43237	(	_	
217-31	43237-43241	ICCs	_	
217-32	43242-43243	>	_	
217-33	43243-43247	0.57	_	
217-34	43247-43248	)	_	
217-35	43249-43252	and	_	
217-36	43253-43261	slightly	_	
217-37	43262-43267	lower	_	
217-38	43268-43279	reliability	_	
217-39	43280-43287	overall	_	
217-40	43288-43290	in	_	
217-41	43291-43298	several	_	
217-42	43299-43306	regions	_	
217-43	43307-43311	when	_	
217-44	43312-43320	compared	_	
217-45	43321-43323	to	_	
217-46	43324-43331	healthy	_	
217-47	43332-43340	controls	_	
217-48	43340-43341	.	_	

#Text=Parietal Region ICCs.
218-1	43342-43350	Parietal	_	
218-2	43351-43357	Region	_	
218-3	43358-43362	ICCs	_	
218-4	43362-43363	.	_	

#Text=Parietal region ICC estimates based on normalized power were calculated within each visit and across one week for each task.
219-1	43364-43372	Parietal	_	
219-2	43373-43379	region	_	
219-3	43380-43383	ICC	_	
219-4	43384-43393	estimates	_	
219-5	43394-43399	based	_	
219-6	43400-43402	on	_	
219-7	43403-43413	normalized	_	
219-8	43414-43419	power	_	
219-9	43420-43424	were	_	
219-10	43425-43435	calculated	_	
219-11	43436-43442	within	_	
219-12	43443-43447	each	_	
219-13	43448-43453	visit	_	
219-14	43454-43457	and	_	
219-15	43458-43464	across	_	
219-16	43465-43468	one	_	
219-17	43469-43473	week	_	
219-18	43474-43477	for	_	
219-19	43478-43482	each	_	
219-20	43483-43487	task	_	
219-21	43487-43488	.	_	

#Text=Data represent mean with 95% confidence interval.
220-1	43489-43493	Data	_	
220-2	43494-43503	represent	_	
220-3	43504-43508	mean	_	
220-4	43509-43513	with	_	
220-5	43514-43517	95%	_	
220-6	43518-43528	confidence	_	
220-7	43529-43537	interval	_	
220-8	43537-43538	.	_	

#Text=Healthy controls had excellent to good parietal region reliability across the spectral measures of power, normalized power, half power, and Shannon spectral entropy (Sensor ICCs >0.82, Source ICCs >0.68), with the exception of fair reliability in alpha reactivity (Sensor ICCs >0.56, Source ICCs >0.55).
221-1	43539-43546	Healthy	_	
221-2	43547-43555	controls	_	
221-3	43556-43559	had	_	
221-4	43560-43569	excellent	_	
221-5	43570-43572	to	_	
221-6	43573-43577	good	_	
221-7	43578-43586	parietal	_	
221-8	43587-43593	region	_	
221-9	43594-43605	reliability	_	
221-10	43606-43612	across	_	
221-11	43613-43616	the	_	
221-12	43617-43625	spectral	_	
221-13	43626-43634	measures	_	
221-14	43635-43637	of	_	
221-15	43638-43643	power	_	
221-16	43643-43644	,	_	
221-17	43645-43655	normalized	_	
221-18	43656-43661	power	_	
221-19	43661-43662	,	_	
221-20	43663-43667	half	_	
221-21	43668-43673	power	_	
221-22	43673-43674	,	_	
221-23	43675-43678	and	_	
221-24	43679-43686	Shannon	_	
221-25	43687-43695	spectral	_	
221-26	43696-43703	entropy	_	
221-27	43704-43705	(	_	
221-28	43705-43711	Sensor	_	
221-29	43712-43716	ICCs	_	
221-30	43717-43718	>	_	
221-31	43718-43722	0.82	_	
221-32	43722-43723	,	_	
221-33	43724-43730	Source	_	
221-34	43731-43735	ICCs	_	
221-35	43736-43737	>	_	
221-36	43737-43741	0.68	_	
221-37	43741-43742	)	_	
221-38	43742-43743	,	_	
221-39	43744-43748	with	_	
221-40	43749-43752	the	_	
221-41	43753-43762	exception	_	
221-42	43763-43765	of	_	
221-43	43766-43770	fair	_	
221-44	43771-43782	reliability	_	
221-45	43783-43785	in	_	
221-46	43786-43791	alpha	_	
221-47	43792-43802	reactivity	_	
221-48	43803-43804	(	_	
221-49	43804-43810	Sensor	_	
221-50	43811-43815	ICCs	_	
221-51	43816-43817	>	_	
221-52	43817-43821	0.56	_	
221-53	43821-43822	,	_	
221-54	43823-43829	Source	_	
221-55	43830-43834	ICCs	_	
221-56	43835-43836	>	_	
221-57	43836-43840	0.55	_	
221-58	43840-43841	)	_	
221-59	43841-43842	.	_	

#Text=At the sensor level, participants with schizophrenia had excellent parietal region reliability across several spectral measures (Sensor ICCs >0.77), with the exception of good to poor reliability for SSE during Eyes Open (ICC= 0.69) and alpha reactivity (ICC =0.38).
222-1	43843-43845	At	_	
222-2	43846-43849	the	_	
222-3	43850-43856	sensor	_	
222-4	43857-43862	level	_	
222-5	43862-43863	,	_	
222-6	43864-43876	participants	_	
222-7	43877-43881	with	_	
222-8	43882-43895	schizophrenia	_	
222-9	43896-43899	had	_	
222-10	43900-43909	excellent	_	
222-11	43910-43918	parietal	_	
222-12	43919-43925	region	_	
222-13	43926-43937	reliability	_	
222-14	43938-43944	across	_	
222-15	43945-43952	several	_	
222-16	43953-43961	spectral	_	
222-17	43962-43970	measures	_	
222-18	43971-43972	(	_	
222-19	43972-43978	Sensor	_	
222-20	43979-43983	ICCs	_	
222-21	43984-43985	>	_	
222-22	43985-43989	0.77	_	
222-23	43989-43990	)	_	
222-24	43990-43991	,	_	
222-25	43992-43996	with	_	
222-26	43997-44000	the	_	
222-27	44001-44010	exception	_	
222-28	44011-44013	of	_	
222-29	44014-44018	good	_	
222-30	44019-44021	to	_	
222-31	44022-44026	poor	_	
222-32	44027-44038	reliability	_	
222-33	44039-44042	for	_	
222-34	44043-44046	SSE	_	
222-35	44047-44053	during	_	
222-36	44054-44058	Eyes	_	
222-37	44059-44063	Open	_	
222-38	44064-44065	(	_	
222-39	44065-44068	ICC	_	
222-40	44068-44069	=	_	
222-41	44070-44074	0.69	_	
222-42	44074-44075	)	_	
222-43	44076-44079	and	_	
222-44	44080-44085	alpha	_	
222-45	44086-44096	reactivity	_	
222-46	44097-44098	(	_	
222-47	44098-44101	ICC	_	
222-48	44102-44103	=	_	
222-49	44103-44107	0.38	_	
222-50	44107-44108	)	_	
222-51	44108-44109	.	_	

#Text=At the source level, there was fair reliability of normalized power (ICCs>0.57), power across one week (ICCs>0.69), and alpha reactivity (ICCs >0.43), but poor reliability of power within one hour (ICCs <0.16).
223-1	44110-44112	At	_	
223-2	44113-44116	the	_	
223-3	44117-44123	source	_	
223-4	44124-44129	level	_	
223-5	44129-44130	,	_	
223-6	44131-44136	there	_	
223-7	44137-44140	was	_	
223-8	44141-44145	fair	_	
223-9	44146-44157	reliability	_	
223-10	44158-44160	of	_	
223-11	44161-44171	normalized	_	
223-12	44172-44177	power	_	
223-13	44178-44179	(	_	
223-14	44179-44183	ICCs	_	
223-15	44183-44184	>	_	
223-16	44184-44188	0.57	_	
223-17	44188-44189	)	_	
223-18	44189-44190	,	_	
223-19	44191-44196	power	_	
223-20	44197-44203	across	_	
223-21	44204-44207	one	_	
223-22	44208-44212	week	_	
223-23	44213-44214	(	_	
223-24	44214-44218	ICCs	_	
223-25	44218-44219	>	_	
223-26	44219-44223	0.69	_	
223-27	44223-44224	)	_	
223-28	44224-44225	,	_	
223-29	44226-44229	and	_	
223-30	44230-44235	alpha	_	
223-31	44236-44246	reactivity	_	
223-32	44247-44248	(	_	
223-33	44248-44252	ICCs	_	
223-34	44253-44254	>	_	
223-35	44254-44258	0.43	_	
223-36	44258-44259	)	_	
223-37	44259-44260	,	_	
223-38	44261-44264	but	_	
223-39	44265-44269	poor	_	
223-40	44270-44281	reliability	_	
223-41	44282-44284	of	_	
223-42	44285-44290	power	_	
223-43	44291-44297	within	_	
223-44	44298-44301	one	_	
223-45	44302-44306	hour	_	
223-46	44307-44308	(	_	
223-47	44308-44312	ICCs	_	
223-48	44313-44314	<	_	
223-49	44314-44318	0.16	_	
223-50	44318-44319	)	_	
223-51	44319-44320	.	_	

#Text=Parietal Region Spectral Analysis.
224-1	44321-44329	Parietal	_	
224-2	44330-44336	Region	_	
224-3	44337-44345	Spectral	_	
224-4	44346-44354	Analysis	_	
224-5	44354-44355	.	_	

#Text=Data represent mean (±SEM), asterisks denote p<0.05.
225-1	44356-44360	Data	_	
225-2	44361-44370	represent	_	
225-3	44371-44375	mean	_	
225-4	44376-44377	(	_	
225-5	44377-44378	±	_	
225-6	44378-44381	SEM	_	
225-7	44381-44382	)	_	
225-8	44382-44383	,	_	
225-9	44384-44393	asterisks	_	
225-10	44394-44400	denote	_	
225-11	44401-44402	p	_	
225-12	44402-44403	<	_	
225-13	44403-44407	0.05	_	
225-14	44407-44408	.	_	

#Text=Patients with schizophrenia had reduced parietal alpha power during the eyes closed resting-state only (A).
226-1	44409-44417	Patients	_	
226-2	44418-44422	with	_	
226-3	44423-44436	schizophrenia	_	
226-4	44437-44440	had	_	
226-5	44441-44448	reduced	_	
226-6	44449-44457	parietal	_	
226-7	44458-44463	alpha	_	
226-8	44464-44469	power	_	
226-9	44470-44476	during	_	
226-10	44477-44480	the	_	
226-11	44481-44485	eyes	_	
226-12	44486-44492	closed	_	
226-13	44493-44506	resting-state	_	
226-14	44507-44511	only	_	
226-15	44512-44513	(	_	
226-16	44513-44514	A	_	
226-17	44514-44515	)	_	
226-18	44515-44516	.	_	

#Text=This reduction in sensor level alpha normalized power (B) and alpha reactivity (C) remained significantly reduced across runs and visits over a week.
227-1	44517-44521	This	_	
227-2	44522-44531	reduction	_	
227-3	44532-44534	in	_	
227-4	44535-44541	sensor	_	
227-5	44542-44547	level	_	
227-6	44548-44553	alpha	_	
227-7	44554-44564	normalized	_	
227-8	44565-44570	power	_	
227-9	44571-44572	(	_	
227-10	44572-44573	B	_	
227-11	44573-44574	)	_	
227-12	44575-44578	and	_	
227-13	44579-44584	alpha	_	
227-14	44585-44595	reactivity	_	
227-15	44596-44597	(	_	
227-16	44597-44598	C	_	
227-17	44598-44599	)	_	
227-18	44600-44608	remained	_	
227-19	44609-44622	significantly	_	
227-20	44623-44630	reduced	_	
227-21	44631-44637	across	_	
227-22	44638-44642	runs	_	
227-23	44643-44646	and	_	
227-24	44647-44653	visits	_	
227-25	44654-44658	over	_	
227-26	44659-44660	a	_	
227-27	44661-44665	week	_	
227-28	44665-44666	.	_	

#Text=At the source level, patients with schizophrenia had reduced alpha power in several parietal regions [Superior Parietal (SupPar, SP), Inferior Parietal (InfPar, IP), and Precuneus (PC)] during the eyes closed resting-state only (D).
228-1	44667-44669	At	_	
228-2	44670-44673	the	_	
228-3	44674-44680	source	_	
228-4	44681-44686	level	_	
228-5	44686-44687	,	_	
228-6	44688-44696	patients	_	
228-7	44697-44701	with	_	
228-8	44702-44715	schizophrenia	_	
228-9	44716-44719	had	_	
228-10	44720-44727	reduced	_	
228-11	44728-44733	alpha	_	
228-12	44734-44739	power	_	
228-13	44740-44742	in	_	
228-14	44743-44750	several	_	
228-15	44751-44759	parietal	_	
228-16	44760-44767	regions	_	
228-17	44768-44769	[	_	
228-18	44769-44777	Superior	_	
228-19	44778-44786	Parietal	_	
228-20	44787-44788	(	_	
228-21	44788-44794	SupPar	_	
228-22	44794-44795	,	_	
228-23	44796-44798	SP	_	
228-24	44798-44799	)	_	
228-25	44799-44800	,	_	
228-26	44801-44809	Inferior	_	
228-27	44810-44818	Parietal	_	
228-28	44819-44820	(	_	
228-29	44820-44826	InfPar	_	
228-30	44826-44827	,	_	
228-31	44828-44830	IP	_	
228-32	44830-44831	)	_	
228-33	44831-44832	,	_	
228-34	44833-44836	and	_	
228-35	44837-44846	Precuneus	_	
228-36	44847-44848	(	_	
228-37	44848-44850	PC	_	
228-38	44850-44851	)	_	
228-39	44851-44852	]	_	
228-40	44853-44859	during	_	
228-41	44860-44863	the	_	
228-42	44864-44868	eyes	_	
228-43	44869-44875	closed	_	
228-44	44876-44889	resting-state	_	
228-45	44890-44894	only	_	
228-46	44895-44896	(	_	
228-47	44896-44897	D	_	
228-48	44897-44898	)	_	
228-49	44898-44899	.	_	

#Text=This reduction in source level alpha normalized power (E) and alpha reactivity (F) remained significantly reduced across runs and visits over a week.
229-1	44900-44904	This	_	
229-2	44905-44914	reduction	_	
229-3	44915-44917	in	_	
229-4	44918-44924	source	_	
229-5	44925-44930	level	_	
229-6	44931-44936	alpha	_	
229-7	44937-44947	normalized	_	
229-8	44948-44953	power	_	
229-9	44954-44955	(	_	
229-10	44955-44956	E	_	
229-11	44956-44957	)	_	
229-12	44958-44961	and	_	
229-13	44962-44967	alpha	_	
229-14	44968-44978	reactivity	_	
229-15	44979-44980	(	_	
229-16	44980-44981	F	_	
229-17	44981-44982	)	_	
229-18	44983-44991	remained	_	
229-19	44992-45005	significantly	_	
229-20	45006-45013	reduced	_	
229-21	45014-45020	across	_	
229-22	45021-45025	runs	_	
229-23	45026-45029	and	_	
229-24	45030-45036	visits	_	
229-25	45037-45041	over	_	
229-26	45042-45043	a	_	
229-27	45044-45048	week	_	
229-28	45048-45049	.	_	

#Text=Source Functional Connectivity.
230-1	45050-45056	Source	_	
230-2	45057-45067	Functional	_	
230-3	45068-45080	Connectivity	_	
230-4	45080-45081	.	_	

#Text=Data represent mean (±SEM), asterisks denote p<0.05.
231-1	45082-45086	Data	_	
231-2	45087-45096	represent	_	
231-3	45097-45101	mean	_	
231-4	45102-45103	(	_	
231-5	45103-45104	±	_	
231-6	45104-45107	SEM	_	
231-7	45107-45108	)	_	
231-8	45108-45109	,	_	
231-9	45110-45119	asterisks	_	
231-10	45120-45126	denote	_	
231-11	45127-45128	p	_	
231-12	45128-45129	<	_	
231-13	45129-45133	0.05	_	
231-14	45133-45134	.	_	

#Text=Connectivity based on the weighted phase lag index measure for select region pairs was evaluated across runs.
232-1	45135-45147	Connectivity	_	
232-2	45148-45153	based	_	
232-3	45154-45156	on	_	
232-4	45157-45160	the	_	
232-5	45161-45169	weighted	_	
232-6	45170-45175	phase	_	
232-7	45176-45179	lag	_	
232-8	45180-45185	index	_	
232-9	45186-45193	measure	_	
232-10	45194-45197	for	_	
232-11	45198-45204	select	_	
232-12	45205-45211	region	_	
232-13	45212-45217	pairs	_	
232-14	45218-45221	was	_	
232-15	45222-45231	evaluated	_	
232-16	45232-45238	across	_	
232-17	45239-45243	runs	_	
232-18	45243-45244	.	_	

#Text=Patients with schizophrenia had increased connectivity in Superior Parietal to Lateral Occipital regions during the Rest10 task on Visit 2 (A) and in Superior Parietal to Entorhinal regions on Visit 1 (B).
233-1	45245-45253	Patients	_	
233-2	45254-45258	with	_	
233-3	45259-45272	schizophrenia	_	
233-4	45273-45276	had	_	
233-5	45277-45286	increased	_	
233-6	45287-45299	connectivity	_	
233-7	45300-45302	in	_	
233-8	45303-45311	Superior	_	
233-9	45312-45320	Parietal	_	
233-10	45321-45323	to	_	
233-11	45324-45331	Lateral	_	
233-12	45332-45341	Occipital	_	
233-13	45342-45349	regions	_	
233-14	45350-45356	during	_	
233-15	45357-45360	the	_	
233-16	45361-45367	Rest10	_	
233-17	45368-45372	task	_	
233-18	45373-45375	on	_	
233-19	45376-45381	Visit	_	
233-20	45382-45383	2	_	
233-21	45384-45385	(	_	
233-22	45385-45386	A	_	
233-23	45386-45387	)	_	
233-24	45388-45391	and	_	
233-25	45392-45394	in	_	
233-26	45395-45403	Superior	_	
233-27	45404-45412	Parietal	_	
233-28	45413-45415	to	_	
233-29	45416-45426	Entorhinal	_	
233-30	45427-45434	regions	_	
233-31	45435-45437	on	_	
233-32	45438-45443	Visit	_	
233-33	45444-45445	1	_	
233-34	45446-45447	(	_	
233-35	45447-45448	B	_	
233-36	45448-45449	)	_	
233-37	45449-45450	.	_	

#Text=However, the increase in connectivity did not persist between runs and was found to vary considerably in magnitude and direction between visits in both healthy controls and patients.
234-1	45451-45458	However	_	
234-2	45458-45459	,	_	
234-3	45460-45463	the	_	
234-4	45464-45472	increase	_	
234-5	45473-45475	in	_	
234-6	45476-45488	connectivity	_	
234-7	45489-45492	did	_	
234-8	45493-45496	not	_	
234-9	45497-45504	persist	_	
234-10	45505-45512	between	_	
234-11	45513-45517	runs	_	
234-12	45518-45521	and	_	
234-13	45522-45525	was	_	
234-14	45526-45531	found	_	
234-15	45532-45534	to	_	
234-16	45535-45539	vary	_	
234-17	45540-45552	considerably	_	
234-18	45553-45555	in	_	
234-19	45556-45565	magnitude	_	
234-20	45566-45569	and	_	
234-21	45570-45579	direction	_	
234-22	45580-45587	between	_	
234-23	45588-45594	visits	_	
234-24	45595-45597	in	_	
234-25	45598-45602	both	_	
234-26	45603-45610	healthy	_	
234-27	45611-45619	controls	_	
234-28	45620-45623	and	_	
234-29	45624-45632	patients	_	
234-30	45632-45633	.	_	

#Text=Correlation between MEG alpha power and PANSS scores.
235-1	45634-45645	Correlation	_	
235-2	45646-45653	between	_	
235-3	45654-45657	MEG	_	
235-4	45658-45663	alpha	_	
235-5	45664-45669	power	_	
235-6	45670-45673	and	_	
235-7	45674-45679	PANSS	_	
235-8	45680-45686	scores	_	
235-9	45686-45687	.	_	

#Text=Parietal region spectral analysis revealed patients with schizophrenia had reduced parietal alpha power and normalized power during the eyes closed resting-state compared to healthy controls.
236-1	45688-45696	Parietal	_	
236-2	45697-45703	region	_	
236-3	45704-45712	spectral	_	
236-4	45713-45721	analysis	_	
236-5	45722-45730	revealed	_	
236-6	45731-45739	patients	_	
236-7	45740-45744	with	_	
236-8	45745-45758	schizophrenia	_	
236-9	45759-45762	had	_	
236-10	45763-45770	reduced	_	
236-11	45771-45779	parietal	_	
236-12	45780-45785	alpha	_	
236-13	45786-45791	power	_	
236-14	45792-45795	and	_	
236-15	45796-45806	normalized	_	
236-16	45807-45812	power	_	
236-17	45813-45819	during	_	
236-18	45820-45823	the	_	
236-19	45824-45828	eyes	_	
236-20	45829-45835	closed	_	
236-21	45836-45849	resting-state	_	
236-22	45850-45858	compared	_	
236-23	45859-45861	to	_	
236-24	45862-45869	healthy	_	
236-25	45870-45878	controls	_	
236-26	45878-45879	.	_	

#Text=The eyes closed normalized power in patients negatively correlated with PANSS positive scores during both Visit 1 (A) and Visit 2 (B), indicating increased positive symptoms scores related to reduced parietal alpha power.
237-1	45880-45883	The	_	
237-2	45884-45888	eyes	_	
237-3	45889-45895	closed	_	
237-4	45896-45906	normalized	_	
237-5	45907-45912	power	_	
237-6	45913-45915	in	_	
237-7	45916-45924	patients	_	
237-8	45925-45935	negatively	_	
237-9	45936-45946	correlated	_	
237-10	45947-45951	with	_	
237-11	45952-45957	PANSS	_	
237-12	45958-45966	positive	_	
237-13	45967-45973	scores	_	
237-14	45974-45980	during	_	
237-15	45981-45985	both	_	
237-16	45986-45991	Visit	_	
237-17	45992-45993	1	_	
237-18	45994-45995	(	_	
237-19	45995-45996	A	_	
237-20	45996-45997	)	_	
237-21	45998-46001	and	_	
237-22	46002-46007	Visit	_	
237-23	46008-46009	2	_	
237-24	46010-46011	(	_	
237-25	46011-46012	B	_	
237-26	46012-46013	)	_	
237-27	46013-46014	,	_	
237-28	46015-46025	indicating	_	
237-29	46026-46035	increased	_	
237-30	46036-46044	positive	_	
237-31	46045-46053	symptoms	_	
237-32	46054-46060	scores	_	
237-33	46061-46068	related	_	
237-34	46069-46071	to	_	
237-35	46072-46079	reduced	_	
237-36	46080-46088	parietal	_	
237-37	46089-46094	alpha	_	
237-38	46095-46100	power	_	
237-39	46100-46101	.	_	

#Text=Participant Characteristics
#Text=\tHealthy Controls(Mean ±SEM)\tPatients with Schizophrenia(Mean ±SEM)\t \tDemoqraphics\t\t\t \tGender (M/F)\t8/5\t8/5\t \tAge (Males)\t32.65 ±3.14\t32.98 ±2.54\t \tAge (Females)\t37.95 ±2.91\t38.35 ±3.57\t \tEducation (yrs) **\t15.23 ±0.59\t13.00 ±0.39\t \tEthnicity (% Hisp/NonHisp)\t23% / 77%\t46% / 54%\t \tClinical:\t\t\t \tWTAR Standard IQ\t107.08 ±4.17\t99.38 ±4.69\t \tStandard Range\t(77–123)\t(77–124)\t \tWTAR Predicted IQ\t106.69 ±1.70\t103.31 ±1.34\t \tPredicted Range\t(98–116)\t(94–111)\t \tPANSS Scores\t\t\t \tPositive (Visiti)\t--\t11.38 ±1.16\t \tPositive (Visit2)\t--\t11.38 ±1.23\t \tNegative (Visiti)\t--\t11.85 ±0.96\t \tNegative (Visit2)\t--\t11.92 ±1.21\t \tGeneral (Visiti)\t--\t19.77 ±0.86\t \tGeneral (Visit2)\t--\t18.54 ±0.86\t \tMedications\t\t\t \tOLZ(mg/day)\t--\t16.79 ±4.11\t \tDuration of Illness (yrs)\t--\t15.00 ±2.59\t \t
#Text=Asterisks represent significant differences between groups (** p<0.05).
238-1	46102-46113	Participant	_	
238-2	46114-46129	Characteristics	_	
238-3	46131-46138	Healthy	_	
238-4	46139-46147	Controls	_	
238-5	46147-46148	(	_	
238-6	46148-46152	Mean	_	
238-7	46153-46154	±	_	
238-8	46154-46157	SEM	_	
238-9	46157-46158	)	_	
238-10	46159-46167	Patients	_	
238-11	46168-46172	with	_	
238-12	46173-46186	Schizophrenia	_	
238-13	46186-46187	(	_	
238-14	46187-46191	Mean	_	
238-15	46192-46193	±	_	
238-16	46193-46196	SEM	_	
238-17	46196-46197	)	_	
238-18	46200-46212	Demoqraphics	_	
238-19	46217-46223	Gender	_	
238-20	46224-46225	(	_	
238-21	46225-46226	M	_	
238-22	46226-46227	/	_	
238-23	46227-46228	F	_	
238-24	46228-46229	)	_	
238-25	46230-46231	8	_	
238-26	46231-46232	/	_	
238-27	46232-46233	5	_	
238-28	46234-46235	8	_	
238-29	46235-46236	/	_	
238-30	46236-46237	5	_	
238-31	46240-46243	Age	_	
238-32	46244-46245	(	_	
238-33	46245-46250	Males	_	
238-34	46250-46251	)	_	
238-35	46252-46257	32.65	_	
238-36	46258-46259	±	_	
238-37	46259-46263	3.14	_	
238-38	46264-46269	32.98	_	
238-39	46270-46271	±	_	
238-40	46271-46275	2.54	_	
238-41	46278-46281	Age	_	
238-42	46282-46283	(	_	
238-43	46283-46290	Females	_	
238-44	46290-46291	)	_	
238-45	46292-46297	37.95	_	
238-46	46298-46299	±	_	
238-47	46299-46303	2.91	_	
238-48	46304-46309	38.35	_	
238-49	46310-46311	±	_	
238-50	46311-46315	3.57	_	
238-51	46318-46327	Education	_	
238-52	46328-46329	(	_	
238-53	46329-46332	yrs	_	
238-54	46332-46333	)	_	
238-55	46334-46335	*	_	
238-56	46335-46336	*	_	
238-57	46337-46342	15.23	_	
238-58	46343-46344	±	_	
238-59	46344-46348	0.59	_	
238-60	46349-46354	13.00	_	
238-61	46355-46356	±	_	
238-62	46356-46360	0.39	_	
238-63	46363-46372	Ethnicity	_	
238-64	46373-46374	(	_	
238-65	46374-46375	%	_	
238-66	46376-46380	Hisp	_	
238-67	46380-46381	/	_	
238-68	46381-46388	NonHisp	_	
238-69	46388-46389	)	_	
238-70	46390-46393	23%	_	
238-71	46394-46395	/	_	
238-72	46396-46399	77%	_	
238-73	46400-46403	46%	_	
238-74	46404-46405	/	_	
238-75	46406-46409	54%	_	
238-76	46412-46420	Clinical	_	
238-77	46420-46421	:	_	
238-78	46426-46430	WTAR	_	
238-79	46431-46439	Standard	_	
238-80	46440-46442	IQ	_	
238-81	46443-46449	107.08	_	
238-82	46450-46451	±	_	
238-83	46451-46455	4.17	_	
238-84	46456-46461	99.38	_	
238-85	46462-46463	±	_	
238-86	46463-46467	4.69	_	
238-87	46470-46478	Standard	_	
238-88	46479-46484	Range	_	
238-89	46485-46486	(	_	
238-90	46486-46488	77	_	
238-91	46488-46489	–	_	
238-92	46489-46492	123	_	
238-93	46492-46493	)	_	
238-94	46494-46495	(	_	
238-95	46495-46497	77	_	
238-96	46497-46498	–	_	
238-97	46498-46501	124	_	
238-98	46501-46502	)	_	
238-99	46505-46509	WTAR	_	
238-100	46510-46519	Predicted	_	
238-101	46520-46522	IQ	_	
238-102	46523-46529	106.69	_	
238-103	46530-46531	±	_	
238-104	46531-46535	1.70	_	
238-105	46536-46542	103.31	_	
238-106	46543-46544	±	_	
238-107	46544-46548	1.34	_	
238-108	46551-46560	Predicted	_	
238-109	46561-46566	Range	_	
238-110	46567-46568	(	_	
238-111	46568-46570	98	_	
238-112	46570-46571	–	_	
238-113	46571-46574	116	_	
238-114	46574-46575	)	_	
238-115	46576-46577	(	_	
238-116	46577-46579	94	_	
238-117	46579-46580	–	_	
238-118	46580-46583	111	_	
238-119	46583-46584	)	_	
238-120	46587-46592	PANSS	_	
238-121	46593-46599	Scores	_	
238-122	46604-46612	Positive	_	
238-123	46613-46614	(	_	
238-124	46614-46620	Visiti	_	
238-125	46620-46621	)	_	
238-126	46622-46623	-	_	
238-127	46623-46624	-	_	
238-128	46625-46630	11.38	_	
238-129	46631-46632	±	_	
238-130	46632-46636	1.16	_	
238-131	46639-46647	Positive	_	
238-132	46648-46649	(	_	
238-133	46649-46655	Visit2	_	
238-134	46655-46656	)	_	
238-135	46657-46658	-	_	
238-136	46658-46659	-	_	
238-137	46660-46665	11.38	_	
238-138	46666-46667	±	_	
238-139	46667-46671	1.23	_	
238-140	46674-46682	Negative	_	
238-141	46683-46684	(	_	
238-142	46684-46690	Visiti	_	
238-143	46690-46691	)	_	
238-144	46692-46693	-	_	
238-145	46693-46694	-	_	
238-146	46695-46700	11.85	_	
238-147	46701-46702	±	_	
238-148	46702-46706	0.96	_	
238-149	46709-46717	Negative	_	
238-150	46718-46719	(	_	
238-151	46719-46725	Visit2	_	
238-152	46725-46726	)	_	
238-153	46727-46728	-	_	
238-154	46728-46729	-	_	
238-155	46730-46735	11.92	_	
238-156	46736-46737	±	_	
238-157	46737-46741	1.21	_	
238-158	46744-46751	General	_	
238-159	46752-46753	(	_	
238-160	46753-46759	Visiti	_	
238-161	46759-46760	)	_	
238-162	46761-46762	-	_	
238-163	46762-46763	-	_	
238-164	46764-46769	19.77	_	
238-165	46770-46771	±	_	
238-166	46771-46775	0.86	_	
238-167	46778-46785	General	_	
238-168	46786-46787	(	_	
238-169	46787-46793	Visit2	_	
238-170	46793-46794	)	_	
238-171	46795-46796	-	_	
238-172	46796-46797	-	_	
238-173	46798-46803	18.54	_	
238-174	46804-46805	±	_	
238-175	46805-46809	0.86	_	
238-176	46812-46823	Medications	_	
238-177	46828-46831	OLZ	_	
238-178	46831-46832	(	_	
238-179	46832-46834	mg	_	
238-180	46834-46835	/	_	
238-181	46835-46838	day	_	
238-182	46838-46839	)	_	
238-183	46840-46841	-	_	
238-184	46841-46842	-	_	
238-185	46843-46848	16.79	_	
238-186	46849-46850	±	_	
238-187	46850-46854	4.11	_	
238-188	46857-46865	Duration	_	
238-189	46866-46868	of	_	
238-190	46869-46876	Illness	_	
238-191	46877-46878	(	_	
238-192	46878-46881	yrs	_	
238-193	46881-46882	)	_	
238-194	46883-46884	-	_	
238-195	46884-46885	-	_	
238-196	46886-46891	15.00	_	
238-197	46892-46893	±	_	
238-198	46893-46897	2.59	_	
238-199	46901-46910	Asterisks	_	
238-200	46911-46920	represent	_	
238-201	46921-46932	significant	_	
238-202	46933-46944	differences	_	
238-203	46945-46952	between	_	
238-204	46953-46959	groups	_	
238-205	46960-46961	(	_	
238-206	46961-46962	*	_	
238-207	46962-46963	*	_	
238-208	46964-46965	p	_	
238-209	46965-46966	<	_	
238-210	46966-46970	0.05	_	
238-211	46970-46971	)	_	
238-212	46971-46972	.	_	

#Text=All other comparisons (p>0.05).
239-1	46973-46976	All	_	
239-2	46977-46982	other	_	
239-3	46983-46994	comparisons	_	
239-4	46995-46996	(	_	
239-5	46996-46997	p	_	
239-6	46997-46998	>	_	
239-7	46998-47002	0.05	_	
239-8	47002-47003	)	_	
239-9	47003-47004	.	_	
